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Chapter 1
General Introduction
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Platelets in the classical model of thrombus formation
Platelets play an essential role in the cessation of bleeding at sites of vascular injury (hemostasis) 
by aggregating into a thrombus to seal off the damaged area1. The adhered platelets release a 
plethora of bioactive substances from their dense and ɑ-granules, which stimulate the healing of 
the thrombus-containing vessel wall. Platelets furthermore contribute to pathological thrombosis 
particular in the arterial part of the circulation, where the wall shear rate is high. This occurs via 
a similar process of thrombus formation, triggered for instance by rupture of damage of an athe-
rosclerotic plaque in the artery2, 3. This rupture leads to cardiovascular disease, as in myocardial 
infarction or stroke, which are still major causes of death in the industrialized world4. 
 Based on the assumption that platelet interaction with the extracellular matrix protein colla-
gen is a primary event in arterial thrombosis, several research groups have developed molecular 
models of collagen-dependent thrombus formation2, 3, 5, 6. Support for such models comes from 
multiple in vivo studies, where arterial thrombosis is experimentally induced in mice, and from 
parallel in vitro studies where whole blood is flown at arterial wall shear rate over a collagen sur-
face 6-9.In the classical model of thrombus formation (Figure 1), fibrillar collagen together with von 
Willebrand factor (VWF), which binds to the collagen, are the primary triggers for platelet adhesion 
and subsequent activation and thrombus formation 1, 10.The bound VWF traps flowing platelets via 
the receptor glycoprotein Ib-V-IX and integrin αIIbβ3, while collagen establishes platelet adhesion 
via the receptors glycoprotein VI and integrin α2β1. Both in the mouse and human system, these 
platelet-adhesive receptors, in an orchestrated interplay, induce activation of nearby flowing plate-
lets so that a thrombus gradually is built up11, 12-14.
 Activation of integrin αIIbβ3 is essential for platelet-platelet interactions via the bridging pro-
tein fibrinogen. Continued activation of the integrin is required for maintenance of these interac-
tions and, hence, for thrombus stability15, 16. Another event in platelet activation is a rise in cytosolic 
free Ca2+ concentration, which leads to integrin activation, platelet shape change (pseudopod and 
lamellipod formation) and to secretion of platelet dense and α-granules1, 17, 18. The dense granules 
release nucleotides such as ADP and ATP, which support thrombus formation by potently stimula-
ting other platelets19, 20. The effects of released ADP are antagonized by purinergic receptor block-
ers that are in regular clinical use21. The ɑ-granules release a large number of proteins with dif-
ferent roles. These include VWF and fibrinogen, which in an autocrine way can support thrombus 
formation. However, also other granular proteins may contribute to thrombus formation, but this is 
unclear. One of the consequences of α-granule release is exposure of the proinflammatory glyco-
protein P-selectin (CD62P) at the platelet surface, which enforces platelet-leukocyte interactions2. 
Platelets furthermore produce the secondary mediator thromboxane A2, formed from its precursor 
arachidonic acid, a process that is irreversibly inhibited by the drug aspirin7. Together, all these 
autacoid effectors can contribute to the recruitment and capture of passing platelets into a growing 
thrombus.
 Recently, interest has been raised in heterogeneity of platelet responses during thrombus 
formation22. The majority of collagen-adhered platelets assemble into aggregates via activated 
integrins. These platelets display moderate rises in cytosolic Ca2+, sufficient for shape change, 
integrin αIIbβ3 activation, thromboxane formation and secretion of granule contents
18. However, 
a subpopulation of these platelets displays a continued high cytosolic Ca2+ concentration, which 
triggers membrane blebbing and exposure of phosphatidylserine at their outer membrane via the 
scramblase protein anoctamin 6 (TMEM16F)23. Exposure of phosphatidylserine by collagen-ad-
hered platelets is a known marker of glycoprotein VI activity11, 24, 25. This population of platelets is 
active in coagulation, in particular by supporting the formation of thrombin and fibrin at their sur-
face26. The major mechanism for Ca2+ influx into platelets is that of store-operated Ca2+ entry via 
the cation channel Orai127. Mutations in this channel are found in patients with severe combined 
immunodeficiency syndrome28. The consequences of such mutations for thrombus formation have 
not yet been investigated in detail.
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9 Thrombin, which is generated at the surface of procoagulant platelets from prothrombin by 
the coagulation factors Xa and Va stimulates other platelets via the G-coupled protease-activated 
receptors, PAR1 and PAR429, 30. Thrombin furthermore cleaves fibrinogen into fibrin monomers 
and activates several coagulation factors. Hence, thrombin plays a central role at the interface of 
platelet and coagulation activation31. Interestingly, another effect of thrombin secondary to fibrin 
formation is stimulation of platelet-dependent clot retraction via activated ɑIIbβ3. In flow assays a 
similar process is observed, namely contraction of a thrombus formed on collagen, a process that 
contributes to stabilization of the thrombus32, 33. The regulation of this process is not well under-
stood.
 In the present thesis, thrombus formation is defined as the overall result of platelet activa-
tion, aggregation and procoagulant activity during whole blood flow over a thrombogenic surface 
in vitro or in vivo, regardless of the presence or absence of fibrin.
Limitations and extensions of the classical model
The classical model of thrombus formation concentrates on the primary function of collagen/VWF 
to induce platelet activation under flow and, thereby, form a platelet aggregate. However, in recent 
years, it has become clear that this model may need to be extended or adapted, to better un-
derstand the roles of: unexplored granule-derived components from platelets, different molecular 
forms of VWF, and platelet-adhesive substrates other than collagen.
Roles of components in ɑ- granules and dense granules
Lack of platelet α-granules is associated with a mild to moderate bleeding tendency in patients 
with congenital gray platelet syndrome. Recently, this disease has been linked to mutations in the 
NBEAL2 gene, leading to defects in platelet activation properties34-36. Another bleeding disease that 
is characterized by few granules and giant platelets, is the May-Hegglin anomaly, likely caused 
by mutations in the MYH9 gene37, 38.  Consequences of these secretion defects for the process of 
thrombus formation are not well investigated. Likewise, it is not fully clear how components stored 
in the granules are involved in this process. One of the most highly expressed storage proteins in 
terms of copy numbers is thrombospondin-139. Given that it is a key ligand of the platelet receptor 
CD36, also present at high copy numbers40, the question raises if an inability of thrombospon-
din-CD36 interactions may contribute to the gray platelet syndrome.
 The platelet dense granules are packed with non-protein compounds like Ca2+, ADP, ATP, se-
rotonin and polyphosphates7. A bleeding diathesis linked to deficiencies in platelet dense granules 
is presented by patients with Hermansky-Pudlak syndrome37, 41. At least eight disease-rated genes 
have been identified (HPS1–HPS8), where mutations lead to a similar phenotype, for instance al-
binism37
Different forms of VWF
How different types of collagen support thrombus formation has been investigated in considerable 
detail42, 43. However, much less is clear of the contribution of different forms of VWF present in the 
blood plasma and deposited at the vessel wall. The importance of VWF as a bridging molecule, 
linking platelet adhesion and activation, may appear from the fact that quantitative or qualitative 
defects in this protein lead to the bleeding disorder, von Willebrand disease44, 45. The large gly-
coprotein VWF is synthesized in endothelial cells and megakaryocytes, where it concentrates in 
granules that – in endothelial cells – are either subjected to continuous secretion or to regulated 
exocytosis46, 47. VWF that is synthesized in megakaryocytes assembles in the platelet α-granules. In 
both endothelial cells and platelets, the VWF is stored as large multimers ranging in size from 500 
to 20,000 kDa, but in the blood VWF also circulates as smaller multimers48.
 The metalloproteinase ADAMTS-13, released from endothelial cells, is one of the predomi-
nant proteases cleaving large VWF multimers into smaller, less active multimers49. Hence, low le-
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Figure 1. The classical model of collagen-dependent thrombus formation. In this model, collagen that is ex-
posed after vessel wall damage is considered to be the main platelet-activating substance triggering the formation of an 
arterial thrombus. Exposed collagen fibers bind VWF, to which under high wall-shear conditions platelets (grey) bind via 
the glycoprotein Ib-V-IX complex (GPIb). Subsequent stable platelet-collagen interaction is achieved via the receptors 
GPVI and integrin α2β1, resulting in activation of platelets. Autocrine mediators such as ADP and thromboxane A2 acti-
vate other, flowing platelets and trap these into the thrombus. GPVI activation also leads to the formation of blebbing, 
phosphatidylserine-exposing platelets (brown), which provide a surface for the generation of thrombin. Arrow indicates 
the direction of flow. 
vels of ADAMTS-13 associate with increased VWF activity and, thereby, a higher thrombosis ten-
dency50. ADAMTS-13 cleaves VWF in the A2 domain, a process that is accelerated by high shear 
stress, factor VIII, and the platelet glycoprotein Ib-V-IX complex51, 52. Asymmetric cleavage of the 
A2 domain by ADAMTS-13, results in multimers with slower, intermediate or faster migrating triplet 
bands. 53, 54. The smaller and larger triplet bands either lack or contain one 140 kDa N-terminal 
peptide sequence compared to the intermediate VWF triplet band, respectively55. Because the 
N-terminal sequence contains binding sites for factor VIII and glycoprotein Ib, it can be expected 
that the smaller VWF forms with extra N-terminal sequences are more active in platelet binding. 
However, this has not been investigated.
Contributions of vascular components other than collagen
Platelets express adhesive receptors not only for collagen, but also for several other vascular and 
plasma proteins56. Limited flow adhesion studies have been performed on surfaces coated with 
fibrinogen57, fibronectin58, vitronectin59, 60, laminin61, or thrombospondin-162. In all cases thrombus 
formation could be observed. However, the adhesiveness of these surfaces has not been compared 
with that of collagens. A relevant receptor on platelets is the C-type lectin-like receptor CLEC-2, 
which lacks a physiological ligand in the vasculature, but is known to contribute to arterial throm-
bus formation in vivo as strongly as the collagen receptor, glycoprotein VI63, 64. In vitro, CLEC-2 can 
be stimulated with the snake venom rhodocytin, but this ligand has not been examined in flow 
adhesion studies.
 For the present thesis, we reasoned that direct comparison in flow adhesion experiments of 
all these platelet-adhesive proteins, alone or in combination, should give better insight into the rel-
ative roles of the different platelet adhesion receptors in thrombosis. Other authors have demon-
strated that precise measurement of the platelet Ca2+ response can predict the extent of thrombus 
formation on collagen65. We aimed to extend this work by comparing a large variety of adhesive 
surfaces and platelet activation parameters upon thrombus formation. The hypothesis is that a 
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direct comparison of multiple adhesive surfaces and of multiple activation parameters: (i) will give 
detailed insight into the multi-dynamics of thrombus formation and the most relevant variables of 
this process; and (ii) will lead to a high-throughput flow chamber assay to assess platelet function, 
for instance in a clinical setting.
Clinical testing of platelet function
Platelet activation tests are widely used in the clinic not only to identify platelet-related bleeding 
disorders, but also to determine the efficacy of antiplatelet medication. As reviewed elsewhere, a 
whole range of techniques is available for such testing66. Here only assays that are relevant for this 
thesis are mentioned.
 Several recently developed assays use whole blood samples or platelet-rich plasma to si-
multaneously detect platelet and coagulant activity. These include rotational thromboelastography 
(ROTEM) or thromboelastometry (TEM) and methods of calibrated automated thrombin generation 
(CAT). The ROTEM or TEM tests determine the kinetics of fibrin clot formation and platelet-depen-
dent clot retraction67-69. These tests are sensitive to the presence of platelets and fibrinogen under 
conditions of coagulation70. The CAT assay in its most popular form measures tissue factor-trig-
gered thrombin generation, in a way where the coagulant surface is provided by either activated 
platelets or phospholipids from other sources71, 72. Although these tests can use whole blood sam-
ples, their main focus is on coagulation activity rather than on platelet function.
 Light transmission aggregometry is regarded as the gold standard of platelet function tes- 
ting, and is as such frequently employed for the identification of platelet dysfunctions73. In cu-
vettes, samples of platelet-rich plasma or washed platelets are triggered with an agonist such as 
collagen or ADP, and the changes in light transmission are recorded74. Measured are light trans-
mission changes caused by platelet shape change and integrin αIIbβ3-dependent platelet aggrega-
tion75. Secretion of ATP from dense granules can be measured by luminescence aggregometry76, 77. 
Because it requires centrifugation steps to obtain a platelet preparation, these aggregometry tests 
are rather time-consuming.
 Specific functional assays, using whole blood or platelets in plasma, are often employed to 
check for the efficacy of antiplatelet medication73, 75. Regularly employed are the PlateletWorks, 
VerifyNow and VASP tests, which will not be discussed further. The PFA-100 system is the only 
validated test to assess platelet activation under high shear flow conditions. It measures capillary 
occlusion due to platelet aggregation onto a grid coated with collagen. However, its use is mostly 
limited to the detection of acquired or congenital von Willebrand disease (VWD) or αIIbβ3 deficien-
cies73.
 Several laboratories have been working on the development of platelet function tests for 
high-throughput screening purposes. Recently, the optical multichannel (Optimul) assay has been 
proposed as an easy-to-handle and cheap alternative for light transmission aggregometry78, 79. 
It uses a 96-well plate, containing lyophilized platelet agonists, and detects the changes in light 
absorbance upon aggregation of platelets in plasma. Other methods, not requiring centrifugation 
steps, use 96-well plates in combination with (diluted) whole blood samples. Platelet activation in 
response to the agonists is tested here with fluorescent-labeled antibodies against surface activa-
tion markers (activated integrins, P-selectin) and automated flow cytometry after fixation80, 81.
 A drawback of several of the tests mentioned above is that they are applicable for a limited 
number of disease states66. Thereby, they are not always critically validated in terms of checking 
for variation due to technical and pre-analytical factors, and for intra- and inter-subject factors82.
 For more than a decade, it has been argued that parallel-plate flow chambers can help in 
the clinically testing of platelet function, as they mimic the in vivo situation of blood flow83. Flow 
chamber based assays of thrombus formation measure platelet activation and aggregation as well 
as platelet procoagulant activity at the same time, and can use different platelet-adhesive surfaces
such as collagen, endothelial cells or atherosclerotic plaque material42, 84, 85. However, the flow 
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chamber technology lacks standardization in chamber construction, operating procedures and data 
analysis, which limitations unfortunately are not overcome by the use of small-size microfluidic flow 
devices86. With all the knowledge and expertise present at the Heemskerk/Cosemans lab, one of 
my intentions was to further develop and standardize this technology to a rapid multi-parameter 
and high-throughput test that can make its way to the hospital.
Systems biology and thrombus formation
Adequate handling of “big data” becomes more and more important in medical biology. High-through-
put technologies, for instance in genomics and proteomics, generate enormous amounts of data 
that require novel scientific approaches for capturing, handling, curating, systematic analysis and 
visualization87. Challenges are provided by not only the large size, but also the high complexity of 
new data arrays. Systems biology (systeomics) is a novel interdisciplinary field to study complex 
interactions in biological systems, using a holistic approach87, 88, 89. Originally, the system of omics 
studies was a given cell or organism. Systems biology techniques aimed to increase the ability: (i) 
to understand all components in the cell or organism up to the molecular level, (ii) to predict the 
future status of the cell or organism under normal conditions, (iii) to forecast responses to a given 
input stimulus, and (iv) to estimate the changes in system behaviour upon perturbation of one or 
more of the components89. However, in recent days, systems biology approaches are increasingly 
used to understand the component and molecular interactions in other types of biological systems.
 In platelet research, systems biology tools have been used only limitedly so far, for example 
by the Diamond group.65 Analysis of large-scale data of platelet proteomics has given insight into 
the quantitative molecular composition of over 4000 platelet proteins39, platelet mRNA species36 
and protein fragments secreted from platelets90. Such data appear to be crucial for increased un-
derstanding of the role of platelets in health and disease, as well as for identifying potentially new 
biomarkers or drug targets91. In the interpretation of these omics data, peer reviewed and curated 
functional protein databases such as the PlateletWeb92 and the Reactome93 have appeared to be 
highly valuable. While the PlateletWeb contains information from human platelet studies only, the 
Reactome is cross-referenced with other bioinformatics databases. In this context, the Gene Onto-
logy Consortium database is mentioned, aiming to integrate data on the functions of gene products 
across a range of organisms94. Most of these databases are accessible via open online sources, 
which provide support in network visualization, interpretation, analysis and clustering of complex 
pathways.
 In small size scientific studies, the curating and analysis of data is usually performed in a 
supervised way. However, in case of high-throughput studies, analysis can be less straightforward 
so that methods have been developed to handle the more complex datasets. A usual first step is 
scaling, for instance by normalizing multivariate data on a fixed scoring scale. This is followed by 
the construction of algorithms aimed to understand the normalized data, for instance by dimension 
reduction, classification or regression analysis89. Cluster analysis of data can be performed in a 
supervised or an unsupervised (hypothesis-free) hierarchical way95.
 Network analysis of genomic or proteomic data can be done with programs like Cytoscape. 
This tool allows visualization of the interactions between the proteins or genes of interest, which 
can be obtained from the IntAct database. In the network, the proteins or genes are represented in 
so-called nodes and the interactions are symbolized by edges96. Furthermore, new datasets can be 
combined with already available datasets. These systems biology techniques are emerging in the 
field of thrombosis and hemostasis, and may be of great value in the high-throughput approaches 
described in this thesis.
Thrombus formation and translational research
In the fight against cardiovascular disease, there is a continued search for new targets for an-
tiplatelet and anticoagulant drugs that reduce thrombosis but not increase the bleeding risk. In 
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order to understand the contribution of platelet and coagulation proteins in thrombosis, genetically 
modified mice deficient in specific genes have been generated, and used for in vivo determination 
of arterial thrombosis and tail bleeding time. Current understanding is that such experimental 
thrombosis studies are relevant for the human situation, although it should be realized that there 
are significant differences at the molecular and structural level with varying degrees of homology 
between mouse and human proteins. So far, more than thousand mouse studies with more than 
hundred knockouts have been carried out, providing insight into key molecular processes of murine 
thrombosis and hemostasis. However, reviews attempting to relate these mouse studies are mostly 
limited to qualitative descriptions of the effects of genetic modification, which makes quantitative 
comparison a difficult task97-99. One important reason for this is the great variation in methods and 
procedures employed for the in vivo measurements, thus pointing for a need of future standardiza-
tion of these methods100. On the other hand, in vitro flow chamber studies performed in the same 
mice often give similar results as in vivo studies of arterial thrombus formation83. We hypothesized 
that, in spite of the methodological variation, systems biology approaches can be helpful in per-
forming a systematic meta-analysis combining the results of the majority of in vivo and in vitro 
mouse studies. 
Aims and outline of this thesis
In this thesis, the process of thrombus formation is studied in a translational and preclinical per-
spective by means of a systems biology approach. Following chapter 1 as a general introduction, 
chapter 2 provides an overview of the currently available microfluidic devices for applications in 
the field of thrombosis and hemostasis. Sketched are possibilities for use of such microfluidic de-
vices in the preclinical testing of high-throughput analysis of platelet function in the environment 
of flowing whole-blood on a variety of platelet-adhesive substrates.
 Chapter 3 describes standard protocols for multi-parameter measurement of the roles of 
platelets in thrombus formation, as assessed with various fluorescence microscopic systems. De-
tailed information is provided on the multispot technique, the blood drawing, the flow perfusion 
protocol, the microscopy, and the methods of image analysis. The aim of this chapter is to provide 
guidance through all steps in the preparation and performance of a successful whole-blood perfu-
sion experiment. In the subsequent experimental chapter 4, a large number of platelet-adhesive 
surfaces is compared for their efficacy to support platelet adhesion and thrombus formation at 
various wall shear rates. This work is aimed at assessing the relative roles in these processes of the 
major adhesive receptors, glycoproteins Ib, and VI, CLEC-2, CD36, and the integrins αIIbβ3, αvβ3, 
α2β1, α5β1 and α6β1. Also compared are the various platelet responses during thrombus formation, 
i.e. integrin activation, granule secretion and phosphatidylserine exposure. Another aim of this 
systematic analysis is to determine which surfaces/receptors and activation parameters are most 
suited for a screening assay to determine platelet function deficiencies in patients with bleeding 
disorders.
 In chapter 5, the role of VWF multimers in supporting thrombus formation is re-examined in 
greater detail. Therefore, plasma-derived VWF was separated into fractions with similar multimeric 
composition, but different triplet band patterns. Studied was the ability of these fractions to bind to 
glycoprotein Ib, and to support glycoprotein Ib-dependent platelet adhesion. Chapter 6 focusses 
on the role of thrombospondin-1, as a major component released from the platelet α-granules, 
in the support of thrombus formation on a collagen surface. Since earlier studies had identified 
the glycoprotein CD36 as a major platelet receptor for thrombospondin-1, the role of CD36 in 
thrombospondin-1-dependent platelet adhesion and thrombus formation was examined as well. 
Mice deficient in either thrombospondin-1 or CD36 were used for these studies, carried out in vivo 
and in vitro.
 During the process of thrombus formation, platelets interact with the coagulation system in 
several ways, i.e. by exposure of procoagulant phosphatidylserine, by supporting thrombin and 
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fibrin generation, and by regulating the contraction of a fibrin clot. In chapter 7, an inventory 
based on the published literature is made, in order to categorize which genetic deficiencies (in 
mouse) and which pharmacological interventions (in man) result in alterations in these different 
procoagulant roles of platelets. Particular attention was paid to the modulation - by genetic mod-
ification or pharmaca - of these roles via changes in platelet Ca2+ signaling and homotypic plate-
let-platelet interactions. Chapter 8 presents a meta-analysis, also based on the literature, in which 
a quantitative scoring scale was developed to systematically examine the effects of genetic defi-
ciency in mouse on experimental arterial thrombosis in vivo as well as on thrombus formation with 
flow chambers in vitro. In addition, a comparison was made with the effect of genetic deficiency 
on tail bleeding time. Online available systems biology tools were used to translate this ‘scoring of 
mouse genes’ to the human situation, for instance by integrating the mouse data into networks of 
human genes implicated in platelet function. This systematic approach may lead to new possible 
targets for antithrombotic therapies. Finally, in chapter 9 the the principle findings of this thesis 
are discussed in a broader perspective.
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Abstract
Cardiovascular disease is a major cause of mortality globally and is subject to ongoing research to 
improve clinical treatment. It is established that activation of platelets and coagulation are central 
to thrombosis, yet at different extents in the arterial and venous system. In vitro perfusion cham-
ber technology has contributed significant knowledge on the function of platelets in the thrombotic 
process under shear conditions. Recent efforts to downscale this technique with a variety of mi-
crofluidic devices has opened new possibilities to study this process under precisely controlled flow 
conditions. Such microfluidic devices possess the capability to execute platelet function tests more 
quickly than current assays, while using small blood samples. Gradually becoming available to the 
clinic now, they may provide a new means to manage the treatment of cardiovascular diseases, 
although accurate validation studies still are missing. This review highlights the progress that has 
been made in monitoring aspects of thrombus formation using microfluidic devices.
First generation fluidic devices to assess platelet function under flow
Given the established role of platelets in normal hemostasis and in pathological thrombosis, many 
assay systems have been developed to determine mechanisms underlying platelet (dys)function. 
The origin of platelet testing can be traced back to the early 1900s, when Duke established the in 
vivo bleeding time as a measure of platelet function 1. Nowadays, less invasive platelet function 
tests are routinely used for the diagnosis and management of patients with platelet dysfunctions 
as well as for monitoring the efficacy of antiplatelet therapies, such as with aspirin and purinergic 
receptor antagonists. Of more recent interest is the use of platelet function testing as a tool to 
aid the prediction of bleeding complications during surgery and to guide postsurgical haemostatic 
therapies.
 A general limitation of the most platelet function assays is that they do not well correlate with 
the clinical outcome in terms of bleeding or thrombosis. As described in recent overviews, the use 
of flow chamber technology has promising potential to overcome this limitation 2, 3. Conventional 
platelet function assays mostly exclude coagulation and only few assays introduce shear stress as 
an additional parameter (e.g. PFA-100). On the other hand, flow perfusion chambers allow the 
incorporation of platelet function, coagulation and shear stress at the same time. In addition, they 
allow the use of various platelet-adhesive substrates as a surface, most typically collagen type I/
III, von Willebrand factor (VWF), fibrinogen, tissue factor, fibronectin, extracellular matrix from 
endothelium, and human atherosclerotic plaque 4, 5, 6. Baumgartner pioneered the first successful in 
vitro flow device, the annular perfusion chamber in which denuded and inverted arterial segments 
were used as an adhesive surface 7. Later, Sakariassen et al. developed a parallel-plate perfusion 
chamber model in which a glass coverslip is coated with an adhesive substrate or endothelial cells 
and thrombus formation can be evaluated at shear rates of 50 to 10,500 s-1 8. This model has 
also been used in the study of interactions of leukocytes with endothelium. To date, the majority 
of perfusion chambers still use the same parallel-plate principle to study mechanisms of platelet 
adhesion and aggregation over a large range of shear rates 9. These systems have uncovered a 
multitude of pathways leading to Ca2+ signaling, integrin activation and secretion which contribute 
to thrombus formation and are tightly regulated by the hemodynamic environment 10, 11, 12.
 Although flow chamber technology with parallel-plate flow chambers is a proven tool to test 
platelet function and anti-thrombotic therapies, it is yet to be introduced into mainstream clinical 
diagnostic practise, mainly due to a lack of standardization in chamber construction and the use 
of this method 13. Further limitations are that these assays mostly rely on complex microscopic 
imaging analysis and require highly trained personnel. In addition, the volume of blood needed to 
perform multiple perfusions can be quite large; typically 5 mL or more, depending on the dimen-
sions of the perfusion chamber and the required wall shear rate 14. Nowadays, these limitations of 
in vitro perfusion chambers are being addressed with the use of microfluidic technology.
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New types of microfluidic devices for blood flow perfusion
As indicated below, the use of microfluidic technology provides new in depth knowledge of specific 
processes that regulate platelet activation under flow because of the unique and flexible design 
of such devices and their capability to high-throughput and small-dimension investigations into 
thrombus formation.
Manufacturing of polydimethylsiloxane microfluidic devices
Microfluidic technology comprises the design and manufacturing of devices for manipulation of 
fluids on a micrometer scale. Typically, this technique uses flow channel dimensions of 2-100 µm 
with fluid volumes inside these devices being in the lower microliter range. Although microfluidic 
devices can be fabricated with metal, glass or plastics, most devices that are currently used in cell 
biological research are made from the polymer, polydimethylsiloxane (PDMS). This silicone rubber 
is easy-to-use, inexpensive, biocompatible and transparent, which make PDMS chambers a cost 
effective and disposable device to investigate thrombus formation with high optical resolution. As 
a direct result of this, many different types of PDMS devices are reported, often with increased 
throughput over single channel devices. An overview of the current use of PMDS and other micro-
fluidics is given in Table 1.
 In general, for the construction of PDMS chambers, a photoresist layer, consisting of the 
epoxy-based, photo-cross-linkable polymer SU-8 is deposited on a silicon substrate and patterned 
as desired by using conventional lithography 15. This process involves the placement of an optically 
dense mask with a pattern of channels, followed by exposure to ultraviolet radiation to harden the 
SU-8 polymer. After extensive washing, the silicon master plate with a negative of the patterned 
channels serves as a stiff, reusable mold. A mixture of PDMS oligomers is then poured on this mold, 
allowed to solidify by cross-linking and then peeled off from the mold. Holes are punctured in the 
PDMS block to reach the closed channel structure, and tubing is connected to the channels for fluid 
inlet. The PDMS cast is usually used in combination with a glass coverslip which can be coated with 
platelet adhesive ligands as desired. The PDMS cast is bonded to the glass either by hydrophobic 
interaction or by plasma bonding. The result is a flow device with single or multiple channels, as 
desired (Table 1).
Precisely manipulating the flow conditions
The ability to computationally predict and accurately control the fluid dynamics in microfluidic de-
vices makes these ideal tools to mimic and study vascular processes that occur at predicted hemo-
dynamic shear conditions 9. It has been demonstrated that a channel ratio of width to height larger 
than 10 is desirable for uniform shear stress distribution across the microchannel, thereby yielding 
similar degrees of platelet adhesion to collagen type I compared to conventional parallel-plate 
devices 16. Nevertheless, microfluidic chips are reported with a much larger range of channel di-
mension ratios. A key characteristic for channels with a low width-height ratio is the appearance of 
considerable hydrodynamic effects stemming from the sidewalls, which typically lead to increased 
platelet adhesion in areas near the sidewalls 16. The impact of sidewall hemodynamics was exploit-
ed by Neeves and colleagues, who monitored platelet adhesion in various areas of the flow channel 
and found a proportional increase in platelet deposition near the sidewalls relative to the centre of 
the channel that was dependent on the applied input shear rate 17.
 An innovative microfluidic design was recently reported that completely eliminated effects of 
the channel sidewalls 18. In this method, the blood sample is hydrodynamically focussed between 
two layers of buffer, such that it is transported as a cylindrically sheathed stream, which does not 
interact with the channel side walls (Figure 1A). Due to the presence of laminar flow conditions, 
dilutional effects are eliminated in this setup, thereby preventing the blood to mix with the adja-
cent buffer streams. The design is such that the sample volume could be reduced to less than 50 
µL. Proof of concept of this system was demonstrated in that it showed a 50% inhibitory effect on 
Monitoring in vitro thrombus formation with novel microfluidic devices
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platelet surface adhesion to VWF with the integrin αIIbβ3 inhibitor, abciximab.
 Microfluidics have also been used to study effects of vessel stenosis on the thrombotic pro-
cess. Nesbitt and Westein employed a microfluidics system with protruding sidewall features to 
induce platelet aggregation at the apex of the stenosis 19. It was demonstrated that platelet ag-
gregation under conditions of micro-shear gradients can occur independently of autocrine platelet 
stimulation by ADP or thromboxane A2. The same group characterized the exact fluid dynamics 
patterns in microfluidic stenosis channels and showed that the magnitude of micro-shear gradients 
correlated with the platelet aggregation response 20.
 Microfluidic devices have furthermore been fabricated with circular cross-sections by intro-
ducing a coaxial stream of a gas and a solution of silicone oligomer in an organic solvent 21. The 
oligomer polymerizes outside the gas stream and leaves a circular cross section after removal of 
the solvent. This method is designed to mimic vascular conditions, and uses confluently grown en-
dothelial cells, thus replicating a round blood vessel with relevant circular blood flow hemodynam-
ics. Blood perfusion studies using this device have not been reported yet, but will be of significant 
interest.
Up-scaling the throughput of blood samples
Perhaps the most promising aspect of microfluidic technology to investigate thrombus formation 
is the ease and flexibility with which special PDMS microfluidic channel configurations can be 
designed. This makes the microfluidics technology ideally suited to up-scaling of the throughput 
by incorporating multiple flow channels into a single perfusion round, while keeping the required 
blood volume to a minimum. This aspect is a clear advantage of microfluidics over standard par-
allel-plate flow devices. Hosokawa et al. studied collagen-dependent thrombus formation in 25 
parallel capillary channels, which were fed from a single blood sample reservoir (Figure 1B). Using 
this approach, the efficacy of several antiplatelet drugs (aspirin, ADP receptor antagonists, abcix-
imab) could be evaluated under physiological flow conditions by monitoring flow pressure and by 
microscopic imaging 22. In this system dual platelet inhibition with aspirin and P2Y12 antagonist 
was more effective in thrombus inhibition than either drug alone. Although the method purposely 
averaged the flow pressure drop over all 25 channels, it must be noted that fluid flow in individual 
parallel channels fed from a common inlet reservoir is affected by the flow in other channels, when 
extensive thrombus formation occurs. This limitation is overcome by restraining the thrombus 
build-up. In this manner, Maloney et al. investigated the effects of P2Y1 and P2Y12 antagonists 
on collagen-induced platelet aggregation in a device with 8 parallel channels (Figure 1C) 23. In a 
single perfusion with less than 100 mL of blood, the IC50 values of both types of antagonists were 
determined.
 Upscaling of sample throughput has also been done with particular emphasis on the shear 
dependency of thrombus formation. PDMS devices were developed, allowing blood flow at diffe- 
rent shear rates with one sample, reducing inter-assay variability. Figure 1D shows an example of 
a parallel 8-channel design with different shear rate conditions by varying the lengths, and hence 
the fluid resistance, of the channel outlets. With this device the shear-dependent contributions of 
intracellular and extracellular domains of platelet αIIbβ3 were determined 
24.
Down-scaling the size of platelet adhesive surfaces
Another aspect of thrombus formation that can be studied using microfluidics is the effect of 
changing the adhesive surface, for instance by discontinuous coating procedures of small patches 
of adhesive ligands. The rationale for this is that endothelial damage in thrombosis is often fo-
cussed on in nature, a situation that can be mimicked by discontinuous ligand coating. A practical 
benefit of such coating is that excessive aggregate growth leading to channel occlusion can be 
prevented. Various techniques are reported to create local microspots of platelet-adhesive ligands.
Photolithography technology is used to create arrays of adhesive microspots surrounded by non-
Monitoring in vitro thrombus formation with novel microfluidic devices
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Figure 1. Microfluidic flow devices with special design. (A) Microfluidic device from polymethyl methacrylate 
(PMMA), consisting of a top plate, a channel of two laser-patterned PSA gaskets for buffer and sample and a coated 
coverslip. The buffer gasket allows two streams of buffer flowing parallel with the blood sample, resulting in three par-
allel streams in the main channel. Adapted from 18. (B) Microchip device (width 40 μm, height 40 µm) containing 25 
micro-capillaries, which is placed on a surface with immobilized collagen. Adapted from 22. (C) Multi-inlet single outlet 
flow device with 8 parallel perfusion channels in combination with a common collagen coating. Adapted from 23. (D) Mi-
crofluidic networks containing 24 μm deep flow channels. Additional resistance channels vary in length to create different 
flow rates per flow channel. Channels are connected to a common sample inlet at controlled pressure. Adapted from 24. 
(E) Device of parallel microfluidic flow channels (100 μm width) connected to a functionalized coverslip, coated with a 
perpendicular strip of collagen. Adapted from 17. (F) Microfluidic device consisting of a top channel with flowing blood, a 
track-etched polycarbonate membrane and a bottom channel that contains agonists, mounted to a vacuum holder. The 
cross-section area is 100 x 100 µm, where the flux of the agonist molecules is controlled by the membrane. Adapted 
from 36. (G) Caliper Technologies FS-417 four-sipper cell chip designed and used to detect agonist-induced calcium flux. 
Samples are drawn from the four “cell wells” and streamed through the chip. Agonist mixing is performed by diffusion 
while sample is continuously flown through the chip past the fluorescence detection zone. Flow rate is dependent on the 
combination of applied vacuum and the viscosity of the sample. Adapted from 37. (H) Microfluidic system designed to 
induce platelet aggregation at four distinct shear rates in whole blood within a high shear stenotic region (single inlet, 
multi-outlet). An optical system measures light transmission in the stenotic region. Adapted from 23.
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adhesive proteins or a lipid bilayer 25, 26, 27. The size and shape of the spots is controlled by photo-
lithography etching after placing a photomask with desired features and by irradiation with deep 
ultraviolet light. This method has been used to create circular microspots of phospholipids contai- 
ning tissue factor 28. It was elegantly demonstrated that, in addition to the absolute protein density, 
the size and the spatial arrangement of the microspots are critical in the ability of tissue factor to 
support coagulation 29, 30. Using a similar technique, a 200 mm patch of phospholipids containing 
tissue factor was immobilized in a circular glass capillary tube and characterized for coagulation 
under flow conditions 31. Phospholipid containing TF has recently been used in combination with 
immobilized collagen type I to study the stabilizing effects of fibrinformation on platelet aggregates 
32. By monitoring embolization events in the microfluidic channels it was found that fibrin increased 
clot strength by 12- to 28-fold.
 PDMS-based devices can also be used for micro-contact printing, which presents another 
method to deliver discrete patches of adhesive ligands to a glass surface 25. This method makes 
use of the high protein adsorption properties of PDMS. Ligands like collagen are incubated on a 
PDMS stamp with desired feature and are then transferred to glass by briefly stamping the PDMS 
block onto the glass surface. After blood perfusion, this results in thrombus formation precisely at 
the stamped areas (Figure 2A).
 Alternatively, immobilizing discrete ligand patches can be achieved with microarray printing. 
Diamond and co-workers describe that microarray printing of collagen and VWF, using 176 µm 
wide microspots in which multiple ligand combinations were studied in a single blood perfusion run 
33. This same technology was also employed to print microarray spots of collagen containing va 
rious amounts of tissue factor to determine threshold concentrations of triggers for coagulation in 
whole blood 34. Calculations learned that about 10 molecules tissue factor per mm2 are sufficient to 
initiate fibrin formation at 1000 s-1 shear rate. Although microarray printing has clear advantages, 
the relatively large diameter of the microspots commonly used (100-1000 mm) limits its application 
with small microfluidic systems. Hence, micro-spotting is usually performed in combination with 
conventional parallel plate flow devices.
 Discrete ligand patches can also be immobilized in microfluidic devices by infusing the ligand 
solution through separate microfluidic “coating” channels with defined width and allow the ligand 
to adsorb to the glass surface. Following removal of these channels, a second set of microfluidic 
channels is placed perpendicular to the direction of the first channel (Figure 2B). After blood per-
fusion, this results in thrombus formation selectively at the discrete coating strips. Using a similar 
setup it was demonstrated that PAR4 agonists stimulate platelet aggregation at the collagen sur-
face (Figure 1E) 17. This approach has also been used by others, who made immobilized strips of 
P-selectin, E-selectin and VWF, perpendicular or parallel to the direction of blood flow, to study the 
rolling velocity of neutrophils and platelets 35.
Novel applications of microfluidic devices for platelet and vascular research
Novel microfluidic techniques have been used to elucidate platelet and endothelial cell functions 
under flow conditions.
Platelet activation under flow
Using sophisticated PDMS microfluidics, the spatio-temporal role of ADP activation during throm-
bus formation under flow was investigated 36. Via two perpendicular channels, separated by 
a porous membrane, ADP was allowed to flux in a controlled way from the bottom channel into 
the upper perfusion channel (Figure 1F). It was demonstrated that the density of platelets within 
an aggregate increased with increasing ADP flux. In other work, a multi-channel system was used 
to simultaneously measure multiple concentrations of inhibitors of ADP-dependent platelet aggre-
gation on a collagen surface, demonstrating that apyrase lacks inhibitory function under high shear 
conditions 23.
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 Microfluidics can also monitor the activation of single platelets in suspension, e.g. by de-
tecting Ca2+ responses following on-chip mixing with agonists. By constructing a channel with a 
narrowing in the detection zone, individual responding platelets could be detected while passing 
through the channel (Figure 1G). This method demonstrated increases in intracellular Ca2+ levels 
following stimulation by the PAR-1 agonist SFLLRN, or ADP 37. An innovative microfluidic method to 
measure label-free platelet activation is based on the principle of deterministic lateral displacement 
to separate platelets on-chip from other cell types based on their size 38. This method exploits the
fact that small particles have a stronger lateral displacement than larger particles in a fluid flow.
The degree of displacement was measured separating the fluid flow into multiple parallel streams 
and counting platelet density in each parallel channel. This method proved to be accurate enough 
to detect the increased platelet size associated with thrombin activation.
Endothelial cell functions under flow
The endothelium has well characterized inhibitory mechanisms to prevent platelet activation through 
the production of nitric oxide and prostacyclin. On the other hand, VWF and P-selectin, stored in 
and secreted from the endothelial Weibel-Palade bodies, are potent ligands to recruit platelets and 
leukocytes. This places endothelial cells in a central position to regulate platelet function 
Figure 2. High-throughput flow microfluidics with discontinuously immobilized ligands. (A) Step 1: Mi-
cro-contact printing of collagen type III onto a glass coverslip, giving spot sizes of 20 mm. Step 2: A PDMS flow channel 
is placed over the microspot pattern and whole blood perfusion is done at 1600 s-1. The result is platelet adhesion speci- 
fically on the collagen-coated microspots. Scalebar, 20 mm. (B) Step 1: 4 PDMS coating channels with dual configuration 
(175 µm width) are used to immobilize up to 4 ligands on the glass resulting in 4×2 coated strips. Step 2: A second PDMS 
device with 4 independent flow channels (I to IV) is placed perpendicular over the coated strips, allowing thrombus 
formation in a multi-ligand perfusion. Right panels: Platelet adhesion to collagen type I (top), fibrinogen (middle) and 
collagen type III (bottom). Platelets and phosphatidyl serine exposure are visualized with brightfield and fluorescence 
microscopy respectively. Insets: zoomed area. Scale bar, 50 µm.
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and justifies their use in microfluidics to more closely mimic the physiological environment in which 
platelets can adhere.
 Several flow assays focus on shear stress effects in relation to endothelial cell function, such 
as tests for cytoskeletal remodelling and protein secretion mechanisms 39, 40, 41. Chau and colleagues 
demonstrated that shear stress triggers secretion of VWF from human umbilical vein endothelial 
cells cultured in a multichannel microfluidic device 42. Similar systems have been used to study 
the endothelial migration response through a chemo-attractant gradient. Microfluidic devices have 
the exclusive possibility to create a fluid gradient due to their laminar flow characteristics, which 
prevent mixing of two adjacent fluid streams. This property has been exploited by some groups to 
study the migration effects of endothelial cells through an immobilized chemo-attractant gradient 
that was accomplished by introducing parallel streams of different chemotactic agents 43, 44.
 The use of endothelial cells in microfluidic systems in combination with blood perfusion is 
only just emerging. A first paper, focussing on direct interactions of platelets with endothelial cells, 
demonstrated a role for ADP in platelet adhesion to endothelial cells, particularly after inhibition of 
endothelial nitric oxide production 45. However, this study was performed under static conditions, 
and the translation to flow conditions has not been made. The feasibility of microfluidics with 
seeded endothelial cells to monitor results of blood flow was demonstrated by Conant et al. 46, 
who showed stable platelet adhesion and thrombus formation after endothelial stimulation with 
TNF-ɑ. PDMS microfluidics using multiple parallel microchannels, lined with endothelial cells, could 
also model the pathophysiological processes of sickle cell disease and haemolytic uremic syndrome 
under blood flow conditions 47.
New detection technologies in combination with microfluidic devices
Detection methods in microfluidic devices are typically dedicated to monitor platelet adhesion and 
aggregation events, similarly to techniques used with parallel-plate flow chambers 14. The most 
common applied technique is brightfield, contrast-enhanced microscopy, visualizing flow-adhered 
platelets in real time at high optical resolution. Microscopy readouts of microfluidic flow assays 
report on platelet density, ranging from individual platelet behaviour to large scale thrombus for-
mation (Table 1). Alternative approaches are the detection of platelets by labeling with DiOC6 or 
fluorescently labeled antibodies. Tracking software has been used to monitor the translocation of 
platelets on a VWF surface 48. However, robust automated image analysis procedures for real-time 
quantification of thrombus formation still need to be developed.
 Alternative detection techniques are being explored to characterize platelet adhesion and 
aggregation by measuring light absorbance. Transmitted light can quantify platelet-rich thrombi 
due to the displacement of red blood cells leading to an increase in transmittance 49. However, this 
detection method cannot inform on platelet activation levels or thrombus density. Another method 
to detect platelet deposition with high sensitivity uses a quartz crystal microbalance 50. This method 
relies on the resonance frequency of a crystal in an alternating electric field, which is modulated by 
mass deposition at the detector surface. This detection modality could monitor effects of ADP sti-
mulation and integrin ɑIIbβ3 inhibition of platelets on a fibrinogen surface. Also this detection does 
not provide qualitative information on thrombus composition. Nevertheless, it is to be expected 
that microfluidic platelet function tests will benefit from current developments in sensitive detec-
tion methods.
Microfluidic device development towards preclinical testing
Microfluidic technology is regularly used in clinical routines, but this is limited to biochemical mea-
surements of specific blood components. Platforms such as Spinit, Asklepios, Kumetrix, Fluidics 
-on-Flex and Piccolo Xpress have been developed for point-of-care diagnostics detecting a large 
range of proteins, lipids and electrolytes in the nano- to micromolar range. However, the use of 
microfluidic devices for monitoring platelet aggregation and thrombus formation is still limited to 
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the academic setting, in the majority of cases for proof-of-principle experiments. An attempt to 
use PDMS microfluidics devices for whole-blood testing of thrombus formation in a point-of-care 
setting has been presented by Li et al. 49. These authors used a chip with 4 parallel microchannels 
with stenotic region (shear rates 500-13,000 s-1) to measure label-free thrombus formation by light 
absorption (Figure 1H). This method consumes blood without labeling, is fast and is relatively easy 
to perform. However, the assay is not yet validated for clinical applications, and its sensitivity to 
detect platelet hypo- or hyper-function is unknown. Limitations of this flow test are the relatively 
large blood sample volumes (2-8 mL), the inability to check for platelet activation markers and the 
use of only one adhesive substrate. The challenge will be to correctly integrate aspects from this 
and other microfluidics protocols to a test that is robust and sensitive enough to detect aberrant 
platelet function in a clinical setting.
 An important reason for further development of microfluidic devices for pre-clinical research 
and patient diagnosis is that they can provide another approach in comparison to the current as-
says that target platelet activation in a point-of-care setting (Multiplate aggregometry, VerifyNow, 
Impact, PlateletWorks, PFA-100, Cone-and-Plate Analyzer). As reviewed elsewhere, the diagnostic 
and prognostic value of these assays is only moderate (Review Harisson; this issue of Platelets). 
This is in part due to the multiplicity of platelet activation and regulatory pathways, which are diffi-
cult to capture in a single function test. For example, light transmittance aggregometry, VerifyNow, 
PlateletWorks, and PFA provided only limited prognostic information to identify patients at higher 
risk of bleeding following stent implantation 51. The clear advantage of PDMS microfluidic devices 
is that, using a small amount of blood, they can provide a means for high-throughput analysis of 
platelet function in the natural environment of flowing blood, at a range of shear rates and a vari-
ety of platelet-adhesive substrates. Especially in combination with multiple ligand micro-spotting, 
microfluidics have the potential to be developed as a clinical diagnostic tool for platelet function 
that may compete with other point-of-care tests.
Conclusions
Platelet activation in the in vivo environment is regulated by differentially exposed extracellular ma-
trix components, complex rheological flow conditions and release or generation of soluble platelet 
agonists. Microfluidics have made it possible to investigate thrombus formation in a multi-variable 
manner with accurate control of wall shear rate conditions with small blood samples, while using 
multichannel perfusion and microspot ligand coating. Another important possibility is the use of 
multiple ligands in a single perfusion, allowing increased throughput and determination of ligand 
interactions. In comparison to current point-of-care function tests, microfluidic assays may take the 
complex hemodynamic and biochemical environments present in vivo better into account. Integra-
tion of all these parameters into a user friendly device will aid in the management of cardiovascular 
diseases by improving current platelet function tests.
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Abstract
Thrombus formation by adhering and aggregating blood platelets is fundamental to hemostasis 
and is a prerequisite for vascular occlusion in pathological thrombosis. The parallel-plate flow 
chamber technique has been extensively used to measure platelet adhesion and activation in vitro 
at arterial or venous flow conditions. Here, we describe the use of brightfield and confocal fluores-
cence microscopy to record the various platelet activation processes contributing to thrombus for-
mation on microspotted arrays of thrombogenic surfaces; and we give procedures to analyze the 
acquired microscopic images. Furthermore, we describe technical problems that can be expected 
using the microspot technique. Content: (A) Flow chamber preparation and whole blood perfusion. 
(B) Brightfield and fluorescence microscopic imaging of thrombi. (C) Analysis of brightfield and 
fluorescence images.
Introduction
Thrombus formation by adhering and aggregating blood platelets is fundamental to hemostasis 
and is a prerequisite for vascular occlusion in pathological thrombosis 1.The parallel-plate flow 
chamber technique has been extensively used to measure platelet adhesion and activation in vitro 
at arterial or venous flow conditions 2-4. However, current tests use collagen as the only plate-
let-adhesive surface, thereby disregarding the contribution of other platelet-adhesive components 
in the vascular matrix. This is a relevant issue, since multiple platelet adhesive receptors need to 
interact and signal to form a stable platelet thrombus 5-6. On type I collagen fibers, the two collagen 
receptors, glycoprotein VI (GPVI) and integrin ɑ2β1 (GPIa/IIa) interact with the receptors for von 
Willebrand factor (VWF), a plasma protein that avidly binds to collagen, i.e. GPIb-V-IX and integrin 
ɑIIbβ3 (GPIIb/IIIa) 
6-8. It is hence relevant to compare the roles of these receptors with other ones, 
such as CLEC-2, CD36 (GPIV), and the integrins ɑ5β1, ɑ6β1 and ɑvβ3. In the accompanying paper, 
we have described a microspot technology, in which various platelet-adhesive compounds can 
be coated simultaneously in a flow chamber, and directly compared for their potential to support 
thrombus formation using small blood samples 9.
 When forming a thrombus, platelets show different types of responses, all of which may con-
tribute to effective hemostasis and pathological thrombosis. These include shape change (pseu-
dopod and lamellipod formation), integrin activation, secretion of the contents of dense granules 
and a-granules (P-selectin exposure), and actin-dependent contraction of the formed thrombus.1,5 
In addition, a subpopulation of the platelets – with high cytosolic Ca2+ – assumes a balloon-type 
of morphology and exposes the procoagulant phospholipid phosphatidylserine (PS) at their outer 
surface, at which coagulation factors bind and thrombin can be formed 10.
 Since it is unclear how these different platelet responses relate during thrombus formation, 
we developed procedures to measure these in a systematic way in combination with the microspot 
technology.9 In this protocol paper, we describe the use of brightfield and confocal fluorescence 
microscopy to record the various platelet activation processes contributing to thrombus formation; 
and we give procedures to analyze the acquired microscopic images. We note that all assays are 
performed in the absence of coagulation. Furthermore, we stress that: due to space restrictions 
not all details could be given; specific procedures may need adaptation in different laboratories; 
and that expert knowledge will be required for successful completion of the flow assays. We wel-
come comments on errors and suggestions for improvement. Content:
 
 A. Flow chamber preparation and whole blood perfusion.
 B. Brightfield and fluorescence microscopic imaging of thrombi.
 C. Analysis of brightfield and fluorescence images.
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Procedures A. Flow chamber preparation and whole blood perfusion
Reagents
 • Annexin A5 labeled with Alexa Fluor (AF)647 (Molecular Probes, A23204)
 •  Bovine serum albumin (BSA) (Sigma Aldrich, A6003)
 •  CaCl2 (Sigma Aldrich, C1016)
 • 3,3’ Dihexyloxacarbocyanine iodide (DiOC6) (Anaspec, 8984715)
 • Ethanol (VWR)
 • FITC-labeled anti-CD62P (P-selectin) mAb (Immunotech, A07790)
 • Fragmin (Pfizer, 5T1532)
 • D -Glucose (ACS Reagent)
 • HCl (Sigma Aldrich, H1758)
 • 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (Sigma Aldrich, H3375)
 • KCl (Sigma Aldrich, P9541)
 • MgCl2 (Sigma Aldrich, M8266)
 • D -Phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK) (BioConnect, A58SC-   
  201291A)
 • NaCl (Sigma Aldrich)
 • Unfractionated heparin (Sigma Aldrich, H3393-1)
 • FITC-labeled anti-fibrinogen mAb (WAK Chemie Medical, 64162)
Solutions
 • Blocking buffer: 136 mM NaCl, 10 mM HEPES, 2.7 mM KCl, 2 mM MgCl2, 1% BSA in milliQ 
  water (pH 7.45).
 • Coverslip cleaning solution: 2 M HCl in 50% ethanol.
 • DiOC6 in 1% DMSO in buffer
 • Flow buffer: 136 mM NaCl, 10 mM HEPES, 2.7 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 0.1% 
  glucose, 0.1% BSA, 1 U/mL heparin in milliQ water (pH 7.45 with NaOH).
 • Platelet-adhesive substances for coating are described elsewhere.9 For coating collagen 
  peptides, also see previous papers.11,12 Note that collagens and collagen solutions require 
  storage in acid milieu.8,12
 • PPACK in 10 mM HCl
 • Saline: 0.9% NaCl in milliQ water (sterilized).
Materials & equipment
 • Glass coverslips (24 x 60 mm, thickness 0.18 mm) (Menzel BB024060A1)
 • Precision mall with template for one or two rows of three microspots (3 mm centre-to-
  centre distance) for placement on glass coverslip. Note: apply either 1 x 3 or 2 x 3 
  microspots, depending on the possibility to observe these by the microscope.
 • Humid chamber for storing coated coverslips.
 • Open parallel-plate flow chamber: transparent polycarbonate block with engraved flow 
  channel (50 mm depth, 3 mm width, 30 cm length, inlet/outlet tubes at an angle of 11°). 
  The Maastricht chamber has been described before. It needs to be fixed in an aluminium 
  holder with screws.4
 • Silicon tubing (0.28 mm ID, 0.61 mm OD; Rubber BV Hilversum).
 • Blunt syringe needles (18 gauge) to connect with tubing.
 • Surgical tweezers to clamp tubing.
 • Pulse-free syringe perfusion pump Type 100 (Harvard Instruments).
 • Needle or system for blood drawing (e.g., 23 gauge).
 • Plastic syringes 1 mL (Becton-Dickinson).
 • 5 mL polystyrene tube (Greiner Bio-One).
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A1. Preparation of coverslips
CRITICAL: Wash cleaned coverslips thoroughly with water.
 Degrease new coverslips (use tweezers) with 2 M HCl in 50% ethanol.
  1. Wash coverslips twice with milliQ water to remove residual HCl.
  2. Leave coverslips to dry on drying rack.
A2. Coating of coverslips
CRITICAL: Prevent drying of biological material on coverslip by storing in humid environment.
 3. Prepare coating material (collagen, collagen peptide, decorin, fibrinogen, fibronec-
  tin, laminin, osteopontin, rhodocytin, thrombospondin, vitronectin, VWF), at 50-250 
  mg/mL, as described.9 
 4. Mount coverslip onto precision mall for coating.
 5. Apply 0.5 µL of coating solution(s) in the assigned place(s), and remove from 
  the mall.
 6. Store coverslip in humid environment to prevent drying out of microspots. Allow 
  coating material to bind for 60 minutes at room temperature.
 7. Block uncoated glass with blocking buffer, and leave in humid environment for 30   
  minutes.
 8. Wash blocked coverslip with saline. If not immediately used, leave coverslip in 
  humid environment to prevent drying.
A3. Assembly of coverslip and flow chamber 
CRITICAL: Check for leakage of the mounted flow chamber. Also check rigorously for absence of 
air bubbles before starting the experiment. Note that temperature changes can lead to appearance 
of air bubbles. Keep inlet tubing as short as possible.
 9. Connect tubing to inlet and outlet of the flow chamber.
 10. Rinse chamber and tubing with flow buffer, check for absence of air bubbles, and mount 
  coated coverslip on top of chamber.
 11. Place chamber with coverslip in aluminium holder and tighten screws.
 12. Check that flow chamber system is leak-tight by perfusion with flow buffer, flush out any 
  bubbles in chamber.
A4. Drawing of human blood by venipuncture  
CRITICAL: Before drawing human blood, obtain permission from your Medical Ethical Committee, 
according to the local and national regulations, and get full informed consent from donor. Coagu-
lation (traces of thrombin) need to be rigorously prevented by drawing without constraints, mixing 
well with anticoagulant, and incubation at 37oC. Note that PPACK is only shortly active as an anti-
coagulant at neutral pH. Other possible errors are described elsewhere.4
 13. Add 0.5 mL saline into a 5 mL polystyrene blood collection tube. Add 40 U/mL (f.c.) 
  fragmin, and add 40 µM PPACK (f.c.) just before venipuncture.
 14. Draw blood according to local protocols, and let smoothly flow into collection tube. 
  Directly mix blood with anticoagulant solution. We prefer an open system using a 23  
  gauge needle, to ensure undisturbed flow. Discard first 1 mL of blood before filling blood 
  collection tube.
 15. Incubate the collected blood at 37°C for 10-15 minutes to allow platelets to resensitize.
 16. Preferably, determine platelet and red cell counts. A decrease in platelet count points to 
  aggregation of platelets, e.g. by traces of thrombin.
 17. Add additional 20 µM PPACK (f.c.) once per hour.
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A5. Blood perfusion through flow chamber
CRITICAL: Check for correct pump settings to obtain the requested shear rate. Check for absence 
of air bubbles and fibrin clots during the whole experiment. Preferably use an inverted microscope. 
Several possible errors are described elsewhere.4 
 18. Only for experiments to determine stable platelet adhesion or thrombus volume, add 0.5 
  µg/mL DiOC6 (f.c.) to 0.5 mL blood sample. Allow staining of the blood cells for 5 
  minutes.
 19. Draw 0.5 mL blood sample into 1 mL syringe equipped with blunt needle. Make sure that 
  no air is present in top of needle.
 20. Connect syringe with blood sample to inlet tubing of prepared flow chamber. Carefully 
  avoid air bubbles (fluid-fluid contact).
 21. Prepare 1 mL syringe with flow buffer with required fluorescent labels. The following 
  labels are suitable for post-staining: FITC-labeled anti-CD62P mAb (1.25 µg/mL) or 
  FITC-labeled anti-fibrinogen mAb (1:100) and/or AF647-labeled annexin A5 (0.25 µg/  
  mL) (all f.c.).
 22. Mount flow chamber and holder on stage of the microscope, and identify position of 
  microspots with camera. Focus on optical plane of one microspot.
 23. Place syringe filled with whole blood on perfusion pump (push mode). Ensure proper 
  pump settings (arterial wall shear rate: 1600 s-1 for 3.5 minutes or 1000 s-1 for 4 minutes; 
  venous wall shear rate 150 s-1 for 6 minutes). Note that the wall shear rate depends on 
  the flow rate and the dimensions of the flow chamber. For calculation, see elsewhere.4
 24. Switch pump on. The experiment starts when the blood has reached the site of the mi
  crospots.
A6. Recording of stable adhesion and thrombus volume using DiOC6-labeled platelets
CRITICAL: Rinse shortly to prevent disaggregation of thrombi. 
 25. During the first 2 minutes of whole blood perfusion, record DiOC6 fluorescence micro-  
  scopic images at 2-seconds intervals (real-time recording of stable platelet adhesion).
 26. After 3.5, 4 or 6 minutes of perfusion (depending on shear rate), change syringe with 
  blood by syringe with flow buffer; set pump rate at 1000 s-1.
 27. For 2 minutes, rinse chamber with flow buffer.
 28. Take confocal z-stacks from thrombi during stasis; 2 to 3 stacks per microspot (recording 
  of thrombus volume).
A7. Recording of brightfield images and post-staining with fluorescent labels
CRITICAL: Rinse shortly to prevent disaggregation of thrombi. Prevent air bubbles in flow chamber 
during syringe replacements.
 29. Starting from point 25.
 30. At the end of the whole-blood perfusion, change syringe with blood by syringe with 
  fluorescent labels; set pump rate at 1000 s-1.
 31. For 2 minutes, perfuse buffer with labels through flow chamber; leave 1 minute for 
  staining.
 32. During the perfusion, take brightfield microscopic images (5 per microspot) under flow.
 33. Change syringe with labels by syringe with flow buffer; and perfuse for 2 minutes to 
  remove unbound label.
 34. Take fluorescence images during stasis (5 images per microspot).
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Procedures B. Brightfield and fluorescence microscopic imaging of thrombi
B1. Use of LSM 7 LIVE line-scanning confocal fluorescence microscope
SPECIFICATION: Recording of stable platelet adhesion and thrombus volume (DiOC6-labeled plate-
lets). Use in confocal mode for rapid real-time scanning of platelet adhesion, and of z-stacks to 
determine thrombus volume (see also Ref.12). Collect only sharp, high-quality images! Three color 
staining is possible (excitations 485, 530, 640 nm).
 1. Microscope: inverted confocal fluorescence microscope: Axio Observer Z1 (Carl Zeiss)  
  with differential interference contrast (DIC) optics. Camera: AxioCam HRm (Zeiss). 
  Scanning stage with insert for flow chamber holder.
 2. Laser head: LSM 7 Live (Zeiss). Lasers: DOPP 488 nm (100 mW), DPSS 532 nm (75   
  mW), Laser 635 nm (30 mW).
 3. Objective: 63x oil immersion (Zeiss, PlanApo, NA 1.40; DIC M27, WD 0.19 mm).
 4. Settings: [configuration 488 laser line]
   a. Excitation 488 nm, emission filter 495-555 nm, pinhole 1 AU.
   b. For time series: 1 cycle of 2 minutes with 2-seconds interval, laser power 5%,  
    gain 5, zoom 0.5x, scan speed 3-4 Lps.
   c. For z-stack: 0.5 µm between optical planes (70 slices), laser power 5%, gain 5,  
    zoom 1x, scan speed 1 Lps.
 5. Controlling software: ZEN 2010 (Zeiss).
 6. Output images: LSM file (512 x 512 pixels, 107 x 107 µm or 213 x 213 µm (depending
  on zoom), 8-bit).
B2. Use of BioRad/Zeiss Radiance 2100 laser scanning confocal microscope
SPECIFICATION: Imaging of thrombi post-labeled with FITC (OG488) and AF647 probes. Flow 
chamber with labeled thrombi is placed on stage up-side down. Scan with large pin holes to collect 
fluorescence from all optical planes. Collect only sharp, high-quality images! Three color staining is 
possible (excitations 485, 530, 640 nm).
 7. Microscope: right-up fluorescence microscope E600FN (Nikon, Japan). Scanning stage 
  with insert for flow chamber holder.
 8. Laser head: BioRad/Zeiss scan head. Lasers: Argon 488 nm (40 mW), Green He/Ne 543 
  nm (1.5 mW), Red diode 638 nm (5 mW).
 9. Objective: 60x oil immersion (Nikon, PlanApo SFluor, NA 1.30, WD 0.22 mm).
 10. Settings: Two-color fluorescence:
   a. PMT1: excitation 488 nm, laser power 20%, iris 1.5, emission filter 508-523 nm
   b. PMT2: excitation 637 nm, laser power 50%, iris 3.5, emission filter >660 nm
   c. zoom 1, Kalman averaging 2, scan speed 160 Lps.
 11. Recording software: LaserSharp 2000 software (Carl Zeiss).
 12. Output images: PIC file (512 x 512 pixels, 200 x 200 µm, 8-bit).
B3. Use of camera-based non-confocal fluorescence microscope system
SPECIFICATION: Imaging of thrombi post-labeled with FITC (OG488) and AF647 probes. Further-
more, recording of brightfield phase-contrast images to determine platelet deposition. Collect only 
sharp, high-quality images!
 13. Microscope: inverted fluorescence microscope Diaphot 200 (Nikon) with phase-   
  contrast. Two cameras connected with beam splitter, post-magnification and removable 
  infrared filter. Vista brightfield CCD camera; Hamamatsu EM-CCD C9100-12 fluorescence 
  camera. Scanning stage with insert for flow chamber holder.
 14. Fluorescence: Xenon lamp (100 W). Filter cube: FITC (OG488): exciter 485 ± 11 nm,  
  dichroic 400 nm, emitter 530 ± 15 nm. Brightfield trans-illumination (white light).
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 15. Objective: 40x oil-immersion (Nikon, Fluor/100, NA 1.30. Ph4DL, WD 0.20 mm).
 16. Settings: 
   a. Brightfield phase-contrast (empty filter cube). Post-magnification: 1x
   b. Fluorescence: excitation 485 nm, emission 530 nm. Post-magnification: 1.5x.
 17. Recording software: Axiovision 4.8 (Zeiss).
 18. Output images: TIFF file (512 x 512 pixels, 200 x 200 µm, 8-12 bit).
B4. Use of EVOS table fluorescence microscope
SPECIFICATION: Imaging of thrombi post-labeled with FITC (OG488) and AF647 probes. Further-
more, recording of brightfield images to determine platelet deposition (overlays can be made). 
Collect only sharp, high-quality images! Three color staining is possible (excitations 485, 530, 640 
nm).
 19. Microscope: EVOS-FL, inverted microscope, infinity-corrected fluorescence optical 
  system.
 20. LED diodes: DAPI 357 nm (emission 447 nm), GFP 470 nm (emission 510 nm), RFP 531 
  nm (emission 593 nm), Cy5 626 nm (emission 692 nm). Brightfield trans-illumination   
  (white light).
 21. Objective: 60x oil immersion (Olympus, UPlanSApo, NA 1.35, WD 0.15 mm).
 22. Settings: adjustable intensity of LEDs:
   a. Brightfield: transmitted light at intensity of 50%.
   b. GFP cube: excitation 470 nm, emission 510 nm, intensity 40%.
   c. Cy5 cube: excitation 626 nm, emission 692 nm, intensity 20%.
 23. Recording software: integrated in EVOS system. Make sure to save images of 
  individual colors.
 24. Output images: TIFF file (1360 x 1024 pixels, 142 x 107 µm, 8-bit).
Procedures C. Analysis of brightfield and fluorescence images
C1. Image analysis for morphological score
CRITICAL: Analysis of images blinded for the experimental condition.
 1. Determine morphological score of thrombi on coverslip based on recorded brightfield    
  phase-contrast or DIC images.
 2. Score at a 5-point scale (see Figure 1)
Figure 1. Assessment of morphological score of thrombi on 0-5 point scale. 
Representative images are given with description of  scores.
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C2. Image analysis with package Metamorph (Molecular Devices)
CRITICAL: Measurement of surface area coverage of brightfield and fluorescence images. 
The following procedures apply to 8-bit TIFF and PIC images. Conversion to 8-bit images can be 
done using ImageJ software (Open access). Image analysis can also be performed with ImageJ. 
Output data are given as numbers of pixels per region. To determine surface area coverage, use 
total pixel number of images. Note that the outcome of the analyses depends on the quality of the 
recorded images.
 1. Protocol for stable platelet adhesion (see Figure 2)
   a. Threshold every image within one time series with the same threshold > binary 
    image.
   b. In “process” and “arithmic”, choose the first binary image as “source image 1”  
    and the second binary image as “source image 2”.
   c. Click “subtract” with constant values at “0”.
   d. Choose apply.
   e. Repeat steps a-d for the next images.
   f. Choose “measure” > “integrated morphometry analysis”. Measure all binary im 
    ages and subtracted images.
   g. Export all values to Excel spreadsheet, and calculate % of change between con 
    secutive images.
 2. Protocol for surface area coverage of aggregated platelets (see Figure 3A)
   a. For each image, use edge detection in both horizontal (150) and vertical (150)  
    direction.
   b. Use the horizontally filtered image for threshold setting > binary image.
   c. Use morphological close filter (diamond, width = 12) and open filter (circle, 
    diameter = 5).
   d. Transfer regions to brightfield/fluorescence image, and check if region 
    detection is right.
   e. Export data to Excel file, and convert pixel numbers to % surface-area-coverage.
Figure 2. Intermediate processed images for determination of stable platelet adhesion, as described in the protocol. 
Time is in seconds.
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 3. Protocol for surface area coverage of platelet monolayers (see Figure 3B)
   a. Filter images using morphological bottom hat filter (diamond, width = 15), then 
    close filter (diamond, width = 4).
   b. Threshold closed image > binary image.
   c. Apply morphological dilate filter (square, width = 2).
   d. Transfer regions to original image, and check if region detection is right.
   e. Export data to Excel file, and convert pixel numbers to % surface area coverage.
 
 4. Protocol for integrated feature size
   a. The integrated feature size (IFS) is a value taking into account the proportional  
    contribution of large and small thrombi on microspots. It represents the 
    cumulative contribution of squared features, ranked from small to large indivi-
    dual features, with (f) from small to large are numbered 1-N. The IFS is calcu-
    lated as:
   b. First, from an analyzed image, rank the individual features (pixels per region)   
    from small to large (one image = one column with features) in an Excel file.
   c. Determine the pixel size of one single platelet. Exclude all features smaller than 
    this size (≈ 100 pixels).
   d. Integrate the values of the features (accumulated sum of pixels).
   e. Convert pixel size into µm2.
   f. Divide the accumulated feature size by the accumulated sum of all feature sizes, 
    and express as percentage.
   g. Calculate the area above the percentage curve in µm2.
   h. Express results on a logarithmic scale.
Figure 3. Results of automated image analysis, as described in the protocols. Sequences to determine surface 
area coverage of aggregated platelets (A) and of platelet monolayers (B), starting from phase-contrast images. Se-
quence to determine thrombus volume from stacks of fluorescence images (C).
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C3. Image analysis with package Axiovision 4.8 (Zeiss) for thrombus volume
CRITICAL: This program uses LSM files, and allows writing of scripts for automated image analy-
sis. Common output is: ID region, volume unscaled (pixel3), surface (µm2) and volume (µm3) per 
region. Summative data can be calculated per region. 
 1. Use scrap filter with minArea: 1 and maxArea: 100 (see Figure 3C).
 2. Use separation filter with count: 3 and in Morphology mode.
 3. Transfer regions to original image, and check if region detection is right.
 4. Export data to Excel file, and convert pixel numbers to µm3.
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Abstract
Assays measuring platelet aggregation (thrombus formation) at arterial shear rate mostly use col-
lagen as only platelet-adhesive surface. Here we report about a multi-surface and multi-parameter 
flow assay to characterize thrombus formation in whole blood from healthy subjects and patients 
with platelet function deficiencies. A systematic comparison is made of 52 adhesive surfaces with 
components activating the main platelet adhesive receptors, and of 8 output parameters reflecting 
distinct stages of thrombus formation. Three types of thrombus formation can be identified with 
a predicted hierarchy of the following receptors: glycoprotein (GP)VI, C-type lectin-like receptor-2 
(CLEC-2) > GPIb > α6β1, αIIbβ3 > α2β1 > CD36, α5β1, αvβ3. Application with patient blood reveals 
distinct abnormalities in thrombus formation in patients of severe combined immune deficiency, 
Glanzmann’s thrombasthenia, Hermansky-Pudlak syndrome, May-Hegglin anomaly or gray platelet 
syndrome. We suggest this test may be useful for the diagnosis of patients with suspected bleeding 
disorders or a pro-thrombotic tendency.
Introduction
The fundamental role of platelets in hemostasis and thrombosis relies on their capability of adhe-
sion to specific locations of the perturbed vessel wall upon injury, damage or inflammation. Contin-
ued adhesion of flowing platelets leads to buildup of a platelet plug or thrombus and is required to 
stop bleeding or, under pathological conditions, to induce thrombosis, for instance after rupture o 
an atherosclerotic plaque1. Many experimental studies with genetically modified mice or with blood 
from patients with hemostatic deficiencies, performed at either arterial (high shear rate) or venous 
(low shear rate) flow conditions, have emphasized that thrombus formation is a complex process 
encompassing multiple platelet receptors and signaling mechanisms2-4.
 For over two decades, parallel-plate flow chambers have been used to measure platelet ad-
hesion and activation under arterial or venous flow conditions, in particular using surfaces such as 
extracellular matrix or collagen5,6. Currently, this process of platelet adhesion and aggregation in 
flow devices is described as flow-dependent thrombus formation, regardless of the presence or ab-
sence of anticoagulants.4 Whole blood flow chamber tests with blood from many strains of geneti-
cally modified mice have revealed platelet function defects under flow in vitro that often associate 
with a reduced arterial thrombosis tendency in vivo1,7,8. These outcomes have boosted the use of 
commercial and home-made flow devices, in particular for the assessment of human platelet ac-
tivity in preclinical settings, in spite of the fact that international recommendations stress the need 
for further standardization of devices, protocols and measurement parameters9. In recent years, 
various types of microfluidic devices have been developed requiring only small volumes of human 
blood10,11, including devices containing endothelium, for instance to study blood from patients with 
sickle cell disease12. Unfortunately however, the great variation in design and use of the microfluidic 
chips hinders the process of standardization13. On the other hand, relatively simple, one-parameter 
microfluidics tests using collagen surfaces have already been employed to determine inter-subject 
variability and the efficacy of antiplatelet therapy in cardiac patients14-17.
 Clinically, the PFA-100 is the only device currently validated that assesses platelet function 
under high-shear flow conditions, by measuring the occlusion time due to platelet aggregation on 
a collagen matrix. The PFA-100 is frequently utilized to evaluate deficiencies in platelet function 
or von Willebrand factor (VWF) activity, but it only provides a single end-stage parameter. Current 
guidelines for laboratory investigations to check for heritable disorders of platelet function recom-
mend the PFA-100 as an optional screening test, but also stipulate that this test is not diagnostic 
and is insensitive to mild platelet disorders18. Taken together, there are promising possibilities for 
clinical employment of flow assays to test platelet adhesion and aggregation, but current methods 
often are incompletely developed and insufficiently standardized.
 The classic concept of flow-dependent thrombus formation is based on collagen-depen-
dent models of platelet aggregation, both in vivo in damaged mouse vessels and in vitro using 
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collagen-coated flow devices. Fibrillar collagen (collagen I or III) is considered as the primary 
platelet-activating substance in the damaged vessel wall controlling the thrombotic process2,4,8,19,20. 
The concept, in brief, is that at high arterial wall shear rate, initial platelet rolling is regulated by 
the interaction of platelet glycoprotein Ib-V-IX (GPIb) to VWF which is bound to collagen. Platelet 
adhesion and activation by VWF/collagen then is enforced by interplay of the collagen receptors, 
glycoprotein VI (GPVI) and integrin α2β1, and the fibrinogen receptor, integrin αIIbβ3
21,22. Platelets 
may first adhere via integrins and then become activated via GPVI, or first interact with GPVI23. 
Collagen-induced activation of platelets includes rises in cytosolic Ca2+, secretion of dense and 
ɑ-granules (monitored as P-selectin expression) and release of autacoids such as ADP, ATP and 
thromboxane A2, thus resulting in a plethora of paracrine substances able of recruiting and capture 
other passing platelets. Together with GPVI, these mediators induce affinity changes in integrins 
α2β1 and αIIbβ3, which are required for thrombus stability
24,25. Additionally, GPVI signaling stimulates 
platelet procoagulant activity and thrombin generation via phosphatidylserine exposure26.
 However, in the perturbed vessel wall, platelets will be in contact with many other adhesive 
ligands than only collagen and VWF. Platelets indeed express adhesive receptors for a large num-
ber of vascular and plasma proteins2. So far, adhesion of platelets under flow conditions has been 
studied on surfaces coated with fibrinogen27, fibronectin28, vitronectin29,30, osteopontin, laminin31,32, 
and thrombospondin-133. Another relevant receptor is the C-type lectin-like receptor-2 (CLEC-2), 
which still lacks a clear physiological ligand, but supports in murine studies thrombus formation in a 
similar way to the collagen receptor, GPVI34-36. Precisely how these adhesive proteins and receptors 
support thrombus formation under flow conditions in comparison to collagen and GPVI remains 
poorly understood.
 In this paper, we show a first systematic study to compare key physiological platelet-ad-
hesive proteins for all major adhesive receptors, alone and in combination, to support whole 
blood thrombus formation at specified wall shear rates. Based on this inventory, we developed 
a multi-microspot test using nine different surfaces, which is validated using blood samples from 
patients with distinct platelet function deficiencies. Using systems biology approaches, we use the 
test outcomes for a model predicting the roles of various receptors in thrombus formation at high 
and low wall-shear rate, and for a template determining aberrations in this process in patients with 
platelet dysfunctions.
Materials and Methods
Materials
Sources of proteins for microspot coatings are indicated in Suppl. Table 5. VWF purified from 
human plasma was obtained from University Medical Center Utrecht 45. Rhodocytin was purified 
by gel filtration and ion exchange chromatography from venom of the Malayan pit viper, Callose-
lasma rhodostoma46.  The following triple-helical peptides were synthesized as C-terminal amides 
and were purified by reverse phase high performance liquid chromatography47: H-GPC(GPO)3GFO-
GERGPO)3GPC-NH2 [GFOGER-(GPO)n]; H-GPC(GPP)5GFOGER(GPP)5GPC-NH2 [GFOGER-(GPP)n] and 
cross-linked collagen-related peptide, (GPO)n (Ref. 48); H-GPC(GPP)5GPRGQOGVMGFO(GPP)5G-
PC-NH2, collagen type-III derived VWF-binding peptide (VWF-BP), also called VWF-III (Ref. 44). 
BSA was obtained from Sigma; D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK) 
from Calbiochem; 3,3’dihexyloxacarbocyanine iodide (DiOC6) from AnaSpec; corn trypsin inhibitor 
from Haematologic Technology Inc.; recombinant human tissue factor from Dade-Behring; Gly-
Pro-Arg-Pro (GPRP) from Stago.
 Anti-fibrinogen antibody labelled with fluorescein isothiocyanate (FITC) was from WAK Che-
mie; FITC-labelled anti-CD62P (P-selectin) mAb from Immunotech; annexin A5 labelled with Alexa 
fluor (AF)647 from Molecular Probes. Blocking mAbs against specific receptors came from the 
following sources: mAb-1950 against integrin α2, mAb-1976 against integrin αvβ3 and mAb-1969 
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against α5β1 from Merck-Millipore; Fab-152 against CD36 from Santa Cruz; chimeric mAb abcix-
imab, directed against integrins αIIbβ3 and αvβ3 from Centocor. Sources of single-chain Ab 10B12 
against GPVI,48 mAb 15D7 against integrin α2β1 (ref. 48) and of 6B4 Fab2 fragment against the 
VWF-binding site on GPIbα49.
Microspotting of proteins and peptides
Glass coverslips (24 × 60 mm, Menzel) were degreased with 2 M HCl in 50% ethanol, and rinsed 
with water and saline. Using a precision mall, arrays of three consecutive microspots (3 mm cen-
ter-to-center distance) were applied on coverslips as 0.5 μL volumes of coating proteins or pep-
tides. Coating concentrations were optimized to give maximal static platelet adhesion, previously 
established in the range of 50-250 µg/mL (Ref. 24,37,45). Osteopontin, vitronectin and VWF were 
applied at 50 μg/mL; collagens, VWF-BP, laminin and thrombospondin-1 at 100 μg/mL; and other 
proteins and collagen-related peptides at 250 μg/mL. Coated podoplanin did not support platelet 
adhesion, and was not used for further experiments. Sources of coated proteins and peptides are 
given in Suppl. Table 5. Microspots with double or triple coatings were prepared by mixing the 
desired proteins or peptides at the concentrations above.
 Microspot-coated coverslips were incubated for 1 h in a humid atmosphere, and washed 
twice with saline. Coatings were verified by staining with Coomassie brilliant blue G, showing cir-
cular stained spots of ~1000 μm in diameter for most coated proteins; only laminin and collagen I 
gave smaller (800 μm) and larger (1200 μm) spots, respectively. Before flow perfusion, coverslips 
were blocked with HEPES buffer pH 7.45 (136 mM NaCl, 10 mM HEPES, 2.7 mM KCl, 2 mM MgCl2, 
0.1% glucose, 1 U/mL heparin) supplemented with 1% BSA.
 
Healthy control subjects and patients 
Studies were approved by the local Medical Ethics Committee (Maastricht University Medical Cen-
tre, NL31480.068.10). Blood samples (10 mL) were taken from healthy control subjects and pa-
tients, who had not used antiplatelet or anti-inflammatory medication for two weeks. All donors 
gave informed consent in accordance to the Declaration of Helsinki. Healthy controls (both sexes, 
age 23-58 years) were not under medical care, had not experienced bleeding problems, and had 
normal platelet counts (200-300 × 109/l) and haematocrit values (32-42%). For determination of 
intra-subject variability, blood samples from six healthy donors were taken on four different days, 
perfused and analysed.
 Patients all had a well-defined platelet deficiency and mild bleeding tendency, as reported by 
the examining physicians: a patient with Glanzmann’s thrombasthenia with confirmed deficiency in 
platelet αIIbβ3 expression and normal blood cell counts
50; a patient with severe immunodeficiency 
syndrome (SCID), ORAI1 mutation and abolished store-regulated influx in platelets51; a patient 
with May-Hegglin anomaly (MYH9 gene mutation) displaying macrothrombocytopenia (9 × 109 
platelets/L) and a relatively high hematocrit level (46%); a patient with confirmed Hermansky-Pud-
lak syndrome (HPS3 gene mutation), characteristically lacking platelet dense granules, as con-
firmed by flow cytometry (280 × 109 platelets/L , hematocrit 31%); a patient with suspected gray 
platelet syndrome with major deficiency in platelet α-granules and reduced P-selectin expression, 
which was accompanied by macrothrombocytopenia (37 × 109 platelets/L, hematocrit 33%). Blood 
samples from every patient were run in parallel to blood samples from healthy travel controls.
Blood collection 
Blood collection was into 0.1 volume of saline containing PPACK (40 µM) and fragmin (40 U/mL, 
final concentrations); alternatively, where indicated, collection was into 0.1 volume of sterile 129 
mM trisodium citrate. Citrated blood samples were recalcified with 3.75 mM MgCl2 and 7.5 mM 
CaCl2 (final concentrations) in the presence of PPACK (40 µM) and fragmin (40 U/mL) prior to the 
flow experiment. Prior to perfusion, blood samples were checked for platelet counts and the ab-
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sence of visible clots.
 
Flow chamber device and flow perfusion protocol
Microspot-coated coverslips were mounted onto a transparent parallel-plate flow chamber (50 µm 
depth, 3 mm width and 20 mm length), and pre-rinsed with HEPES buffer pH 7.45 containing 0.1% 
BSA. Anticoagulated whole blood samples (400-500 µL) were perfused through the flow chamber 
for a time period sufficient for full thrombus formation on collagen I spots, i.e., 6 min at 150 s-1, 
4 min at 1000 s-1, and 3.5 min at 1600 s-1. Where indicated, blood samples were pre-incubated 
for 5 min with DiOC6 (0.5 µg/mL), and fluorescence images were recorded from the microspots 
during blood perfusion. In other cases, thrombi formed after blood flow were poststained by 2-min 
perfusion (1000 s-1) with color-selected combinations of the following platelet activation markers: 
FITC-labelled anti-fibrinogen mAb (1:100), FITC-labelled anti-P-selectin mAb (1.25 µg/mL) and/or 
AF647-annexin A5 (0.25 µg/mL), all in HEPES buffer pH 7.45 supplemented with 0.1% BSA. After 
2 min of staining (stasis), unbound label was removed by a short perfusion with the same HEPES 
buffer. No fixative was used.
 To assess the role of thrombin on thrombus formation under high shear flow conditions, 
tissue factor (500 pM) was immobilized together with a dual coating of VWF with fibronectin or 
collagen I. Corn trypsin inhibitor (CTI, 5 µg/mL) was present in the blood collecting tube to in-
hibit the contact activation pathway of coagulation. Blood was drawn on 0.32% trisodium citrate 
and Gly-Pro-Arg-Pro (5 mg/mL) was added to block fibrin polymerization and thus clot formation. 
During the flow perfusion the blood was recalcified with 6.3 mM CaCl2 and 3.2 mM MgCl2 to allow 
thrombin to be formed via co-coated tissue factor. Platelet activation markers were determined as 
described for the noncoagulating conditions.
Standardized recording of microscopic images 
Phase-contrast bright-field images were recorded from all three microspots during buffer perfu-
sion immediately after outflow of the red blood cells, using an inverted Nikon Diaphot microscope, 
equipped with a 40× oil-immersion objective (N.A. 1.3), a 1.8× relay lens, and a CCD camera (640 
× 480 pixels)38. For measuring platelet activation markers, the flow chamber was placed on the 
stage of a confocal BioRad/Zeiss MRC-600 microscope, equipped with a 60× oil immersion objec-
tive (N.A. 1.4). Dual-color confocal fluorescence 8-bit images (512 × 512 pixels) were recorded at 
488 and 633 nm excitation and settings, as described previously52. Thrombus volume was deter-
mined using a fast line-scanning Zeiss LSM7 microscope system, equipped with a 63× oil objective. 
Confocal z-stacks were recorded of DiOC6-labelled platelets in thrombi (8-bit images of 512 × 512 
pixels; 106 × 106 μm, stack distance 0.5 μm). The same label and system was used to measure 
stable platelet adhesion during blood flow (8-bit images, taken at 2-s intervals). For each flow run, 
5 representative microscopic images were taken from each of the microspots. Flow assays per 
blood sample were performed in duplicate or in triplicate, if duplicates showed marked variation.
Quantitative analysis of recorded images 
Phase-contrast and fluorescence images were analysed by standardized journals, using Metamorph 
software (Molecular Devices), or in the case of LSM7 images with Axiovision Rel.4.8 software (Carl 
Zeiss). End-stage phase-contrast images of adhered platelets were judged as follows. The mor-
phological score was obtained by visual inspection of the platelet features per microspot: 0, no or 
hardly any adhered platelets; 1, multiple single adhered platelets; 2, extensive coverage of single 
adhered platelets; 3, small platelet aggregates; 4, intermediate platelet aggregates; 5, full thrombi 
with large-size platelet aggregates. Platelet deposition was determined as surface area coverage 
by using supervised image analysis journals. In brief, auto-enhanced images were filtered vertically 
and horizontally and thresholds were set. The resulting binary images were subjected to a close 
and open filter, which resulted in identified regions of single or clustered adhered platelets. The 
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integrated feature size was determined as a parameter, taking into account a proportional contri-
bution of large and small thrombi on microspots. It was defined as the cumulative contribution of 
squared feature areas (f2), ranked from small to large (1-N), to the total feature size (Sf) (Equation 
1): 
 (1)
In cumulative plots, where larger size features appear at the right, the area above the curve rep-
resents a value of the integrated feature size.
 Time series of images of DiOC6 fluorescence (1 min, 2-s intervals) were converted into sub-
tracted, differential images using Metamorph software, and analyzed for changes in pixel intensity 
above background53, thus producing a value for stable platelet adhesion. Confocal fluorescence 
images were thresholded with predefined journals using Metamorph software, to obtain percent-
age values of SAC for each platelet activation label: FITC-anti-fibrinogen mAb (αIIbβ3 activation), 
FITC-anti-P-selectin mAb (α-granule secretion; correction for non-specific labeling), AF647-annexin 
A5 (phosphatidylserine exposure)38. Z-stacks of confocal images of DiOC6 fluorescence were ana-
lyzed with Axiovision software to obtain a summed thrombus volume per surface area37. Protocols 
were checked by three different observers, who were blinded to the experimental variables.
Bioinformatics and statistics 
For comparative analysis, mean values of all thrombus parameters from 52 surfaces were linearly 
normalized to a range from 0-10 (values of all parameters were normally distributed). Two-way 
unsupervised hierarchical clustering was performed using the R package version 2.3 (www.r-pro- 
ject.org). Euclidean distances were calculated, and clustering was by complete linkages. Robust-
ness of the clusters was checked using the R program, Pvclust. The clusters were rebuilt based 
on 10,000 randomizations, and their significance was assessed using an approximately unbiased 
P>90. Pvclust was also used to evaluate the robustness of the clusters by leaving out particular 
surfaces or parameters, with the aim to select those surfaces and parameters giving non-redun-
dant information. Partial least squares regression models with β-matrices were built in Matlab, and 
were employed to make 2-3 component prediction models for thrombus type and platelet receptor 
contribution. All models were checked by cross-validation predictions.
 Parameters were correlated or compared by multiple regression analysis using the statistical 
package for social sciences (SPSS 19.0). Patient data were compared to normal ranges established 
for healthy control subjects, and statistically analyzed by probability analysis. Effects of antibodies 
and heatmap subtractions were compared using a two-tailed Student’s t-test.
Results
Arrays of adhesive surfaces to assess thrombus formation
To compare the roles of established platelet-adhesive receptors in thrombus formation, we se-
lected ligands of these receptors that are present in either the vessel wall or platelet aggregates. 
In addition, we used a number of chemically synthesized peptides binding to the same receptors 
(Suppl. Table 1). In preliminary experiments, we used different coating concentrations to assure 
that the selected proteins and peptides: (i) remained bound to degreased glass coverslips after 
repeated rinsing (Coomassie staining), and (ii) showed optimal platelet adhesion under static con-
ditions (S.M.d.W., personal communication). Optimized surfaces for platelet adhesion consisted of 
the following proteins: collagens I and III, decorin, fibrinogen, fibronectin, laminin 511/521, oste-
opontin, thrombospondin-1, vitronectin and/or VWF (Figure 1). Also included were the snake ven-
om rhodocytin, four collagen-mimetic triple-helical peptides, i.e. GFOGER-(GPP)n, GFOGER-(GPO)
n, (GPO)n, and a VWF-binding peptide (VWF-BP). Immobilized bovine serum albumin (BSA) served 
C
h
ap
te
r
 4
49
Figure 1. Protein surfaces used for flow studies and assignment map of platelet receptors interacting with 
indicated proteins. Assignment of interactions of platelet receptors to immobilized protein or peptide ligands was as 
represented in Suppl. Table 1. Surfaces were numbered 1-52, based on unsupervised hierarchical cluster analysis of 
thrombus parameters (see Figure 4). Color code: white, not involved; black, involved at low/high wall shear rate.
as negative control surface. Optimally effective coating concentrations of the collagen-mimetic 
peptides were established before24,37.
 By coating these proteins/peptides alone or in combinations as a row of three microspots 
(diameter 1000 μm, separation 2000 μm), and mounting the coated coverslips in a standard 
parallel-plate perfusion chamber38, it was possible to determine the thrombus-forming activity of 
multiple surfaces at the same time (Figure 2A). Tile scans performed after perfusion of DiOC6-la-
belled whole blood indicated homogeneous adhesion of platelets to the microspots, either as single 
cells or in aggregates depending on the surface coating (Figure 2B). Control experiments further 
established that the order of coated proteins in microspots did not affect platelet deposition. For 
instance, microspotting of fibrinogen, fibronectin or collagen I, at upstream or downstream posi-
tions, resulted in the same amount of platelet adhesion and aggregation (Suppl. Figure 1). This 
pointed to the absence of significant paracrine cross-talk from activated platelets on adjacent mi-
crospots.
 For a comparative analysis, whole blood from healthy subjects was perfused over microspots 
(three per run) containing the 52 combinations of substrate proteins and peptides at a high (ar-
terial) wall shear rate of 1600 s-1. Thrombus formation on all surfaces was measured using stan-
dardized microscopic procedures (see Methods). Stable platelet adhesion of DiOC6-labelled plate-
lets was evaluated from sequential fluorescence images captured in real time during blood flow. 
Thrombus volume was assessed from z-stacks of confocal images of DiOC6 fluorescence at end 
stage. End stage, phase-contrast images were captured to determine overall platelet deposition 
(surface area coverage) and platelet aggregate size. Activation of the platelets per surface was re-
solved from confocal fluorescence images after labeling with fluorescein isothiocyanate (FITC)-la-
belled anti-fibrinogen monoclonal antibody (mAb) (fibrinogen binding, integrin αIIbβ3 activation), 
FITC-anti-CD62P mAb (P-selectin expression), or AF647-annexin A5 (procoagulant activity). As 
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illustrated in Figure 3, platelet adhesion, aggregation and activation markedly differed between the 
various microspots. No platelets adhered to spots coated with BSA (negative control), while single 
platelets with low activation state adhered to coated fibrinogen. Small aggregates of platelets with 
activated integrin αIIbβ3 and surface expressed P-selectin formed on coated VWF or collagen III. 
Large platelet aggregates staining for all three activation markers formed on collagen I microspots, 
as expected39.
 Control experiments were performed with blocking antibodies (all at 20 µg/mL) to verify the 
involvement of specific receptors (Suppl. Table 1) to the flow-dependent deposition of platelets 
on microspots with single or double coatings (S.M.d.W., personal communication). These antibody 
experiments affirmed the previously established roles of: GPVI and α2β1 in thrombus formation on 
collagen I or III (10B12 Ab against GPVI22,24 and mAb 15D7 against integrin α2β1 (ref. 24)); and 
GPIb-V-IX for surfaces with VWF or VWF-BP (Fab 6B4 against GPIbα24). The blocking mAb 15D7 
had a moderate reducing effect on platelet deposition on surfaces with expected contribution 
of α2β1 [VWF/GFOGER-(GPP)n, VWF/GFOGER-(GPO)n], i.e., -42% and -28%, respectively (n = 
3, P<0.05). Blocking experiments with the anti-CD36 antibody Fab-152 gave a reduced platelet 
response to thrombospondin-1 (n=3, P<0.05), but unchanged platelet deposition to VWF/throm-
bospondin-1. Other blocking experiments were performed using mAb1976 against integrin αvβ3 
and mAb1969 against integrin α5β1 (20 µg/mL). Single αvβ3-binding (vitronectin, osteopontin) and 
α5β1-binding (fibronectin) surfaces did not show platelet adhesion at high shear rate, either in the 
presence or the absence of the corresponding blocking antibody. In the presence of VWF, the an-
tibodies caused a small but insignificant inhibition of platelet adhesion (n = 3, P>0.06). Based on 
published analyses22,24,37, an assignment matrix was constructed of the contribution of individual 
adhesive receptors to platelet interaction with the different surfaces (Figure 1). Herein, the well-
known VWF-capturing ability of collagens I and III was taken into account.
Identification of thrombus type by multi-parameter analysis 
Replicate measurements of blood perfusion experiments over all 52 coated microspots and using 
different fluorescent labels (n ≥ 4 donors per condition and label) resulted in detailed insight into 
the contribution of each surface to thrombus formation (see wall chart in Suppl. Figure 2). Stan-
dardized analysis of microscopic (fluorescence) images provided the following parameters of 
Figure 2. Measurement of thrombus for-
mation on microspot arrays of platelet-ad-
hesive surfaces. (A) Schematic drawing of the 
used parallel-plate flow chamber (3 mm width, 50 
μm depth) and microspot-coated coverslip. Note 
the small-angular (11°) chamber inlet and outlet, 
preventing flow perturbations. (B) Distribution of 
DiOC6-labelled platelets adhered to consecutive 
microspots of collagen type I, collagen type III and 
vWF, after 3.5 min flow of blood at wall shear rate 
of 1600 s-1. Given are tile scans of fluorescence im-
ages of the full microspots (bar = 100 μm). Black 
rims are image artifacts due to the tile scanning. 
Lower panels are enlarged images.
C
h
ap
te
r
 4
51
Figure 3. Different types of thrombi formed on various microspots. Blood from control subjects was perfused 
over microspots with indicated coating for 3.5 min at 1600 s-1. Shown are representative microscopic images (>5 do-
nors), from left to right: phase-contrast images of adhered platelets (i); fluorescence images of platelets binding FITC-la-
belled anti-fibrinogen mAb (ii), FITC-labelled anti-CD62P mAb (iii), or AF647-annexin A5 (iv); further, z-stacks from 
aggregates of DiOC6-labelled platelets (v). Bars = 10 μm. Images from typical surfaces are given (for all 52 surfaces, 
see Suppl. Figure 1).
thrombus formation: morphological score, integrated feature size, stable platelet adhesion, fibri- 
nogen binding, P-selectin expression, overall platelet deposition, thrombus volume and procoag-
ulant activity. Unsupervised hierarchical cluster analysis of all data (52 microspots, 8 parameters) 
revealed separation into three patterns of thrombus formation, indicated as types I-III (Figure 4A). 
Surfaces producing type I thrombi consisted of single-protein coatings causing limited adhesion of 
few platelets. Type II thrombi mostly formed on surfaces co-coated with VWF or VWF-BP causing 
deposition of multiple platelets, single or in small aggregates, and showing limited activation (fi-
brinogen binding, P-selectin expression). Type III thrombi formed on several combined surfaces, 
giving rise to large aggregates of platelets, high in activation markers. With the exception of col-
lagen I (which binds VWF from plasma), type III thrombi only appeared at double or triple coated 
surfaces containing VWF, VWF-BP and/or laminin combined with rhodocytin or (GPO)n peptides. 
Robustness of the unsupervised cluster analysis was checked by data re-sampling and rebuilding 
the tree by 10,000 randomizations with an approximately unbiased P value of 90, indicative of a 
strong fit (Figure 4B).
 The eight output measurements clustered into adhesion-related parameters (morphological 
score, integrated feature size, stable platelet adhesion) on the one hand, and activation-related 
parameters on the other hand. Cohesion of the parameters was confirmed by multiple regression 
analysis (Table 1), indicating that all eight parameters contributed significantly to the clustering 
into type I-III thrombi (P<0.001). The strongest coefficients of determination for thrombus type 
were the linked parameters, morphological score and integrated feature size; the linked parame-
ters, fibrinogen binding, P-selectin expression and platelet deposition; and procoagulant activity. 
Individually, two parameters, stable platelet adhesion and thrombus volume, were still significantly 
but less strongly determinative (R2 = 0.71-0.68). Complete linkage analysis after removal of the 
latter two parameters resulted in a cluster plot showing the same division into type I-III thrombi 
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Figure 4. Clustering of thrombus formation at 52 microspots using 8 outcome parameters. Whole blood 
from control subjects was perfused over arrays of microspots in a parallel-plate flow chamber for 3.5 min at 1600 s-1. 
Numbering of coatings with different adhesive proteins or peptides as in Figure 1. Recorded phase-contrast images were 
analyzed for morphological score, integrated feature size and platelet deposition (surface area coverage). Following in 
situ DiOC6 labeling, fluorescence images were recorded to assess stable platelet adhesion (during blood flow) and throm-
bus volume (after blood flow). Thrombi were post-stained to determine fibrinogen binding (FITC-labelled anti-fibrinogen 
mAb), P-selectin expression (FITC-anti-CD62P mAb), and procoagulant activity (AF647-annexin A5). Mean values of the 
parameters (n = 5-7, thrombus size: n = 4-6) were normalized from 0-10, and arranged by unsupervised hierarchical 
cluster analysis. (A) Clustered heatmap for 52 different surfaces (columns) and 8 measurement parameters (rows). 
Clustering of surfaces revealed three different types of thrombus formation, (B) Robustness of data set, assessed by 
bootstrapping randomizations of all data with Pvclust. Shown are the pro forma clusters obtained, using Approximately 
Unbiased (AU) P values of 90 and 95, indicative for a strong fit. 
(Suppl. Figure 3A-B). Overall, this analysis indicates that the distinction into three types of thrombi 
is not dependent on the specific measurement parameters. However, a further division into sub-
types would be parameter-dependent.
Contributions of VWF and shear rate to thrombus type
Given the established role of VWF/GPIb in platelet adhesion at high-shear blood flow2,21, we 
performed a sub-analysis of thrombi formed on microspots co-coated with indirectly or directly 
GPIb-binding substances, that is, VWF-BP or VWF, respectively. The resulting heatmaps of Figure 
5A show that, for the majority of microspots, the presence of VWF-BP or VWF increased thrombus 
formation, as assessed from the morphological score, integrated feature size, stable platelet adhe-
sion, platelet deposition and thrombus volume. Values of these parameters significantly increased 
(P<0.05, Student’s t-test) compared to the surfaces without VWF (-BP), with the exception of mi-
crospots containing α6β1 ligand, laminin (Figure 5B). Other parameters, such as fibrinogen binding 
and P-selectin expression, increased to a lesser extent, still significant with co-coated VWF but not 
VWF-BP. Procoagulant activity was not increased. Overall, the analysis identified most prominent 
roles of VWF (-BP) on thrombus formation co-coated with, in decreasing order, (assigned receptors
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Table 1. Multiple regression analysis of measurement parameters for the assessment of type I-III throm-
bi. Given are R2 values (Pearson correlation coefficient) with statistical significance for the contribution of each measure-
ment parameter to the type of thrombus formation at shear rate of 1600 s-1 for 52 surfaces (150 s-1 for 36 surfaces).
Parameter R2 P R2 P
Morphological score 0.92 (0.68) <0.001
Integrated feature size 0.91 (0.73) <0.001 0.94 <0.001
Stable platelet adhesion 0.71 <0.001
Fibrinogen binding 0.73 (0.67) <0.001
P-selectin expression 0.95 (0.68) <0.001 0.72 <0.001
Platelet deposition 0.85 (0.75) <0.001
Thrombus volume 0.68 <0.001
Procoagulant activity 0.79 (0.42) <0.001 0.69 <0.001
in brackets): rhodocytin (CLEC-2) > (GPO)n (GPVI), GFOGER-(GPP)n (α2β1) > decorin, osteopontin, 
fibrinogen, fibronectin, vitronectin (integrins α2β1, α5β1, αIIbβ3, αvβ3) > laminin, thrombospondin-1 
(α6β1, CD36).
 To substantiate this further, we also investigated the role of VWF by comparing thrombus for-
mation at high (1600 s-1) and low (150 s-1) wall shear rates, using 36 surfaces. At low shear rate, all 
six parameters analyzed contributed to formation of type I-III thrombi with high coefficients of de-
termination (Table 1). Heatmaps indicated that, in general, many surfaces that actively supported 
thrombus formation at wall high shear rate performed less well at low wall shear rate (Figure 6A, 
B). On the other hand, several of the surfaces less active at high shear rate, particularly those not 
containing VWF, became more active at lower shear rate. These effects were even more apparent 
after subtraction analysis (Figure 6C), pointing to improved thrombus formation at high shear rate 
for all VWF-containing surfaces (P<0.05) on the one hand. Interestingly on the other hand, com-
binations of laminin (α6β1), rhodocytin (CLEC-2) and GFOGER-(GPO)n (GPVI, α2β1) provoked high 
and often increased thrombus formation in the absence of VWF at lower shear rate. Confirmation 
of these shear-dependent effects was obtained by perfusion studies with 19 surfaces at three wall 
shear rates of 150, 1000 and 1600 s-1. In general, platelet deposition at 1000 s-1 was somewhat 
lower than at 1600 s-1, the exception being laminin-containing surfaces where highest values were 
obtained at 1000 s-1 (Suppl. Figure 4).
Receptor combinations in type of thrombus formation 
A partial least-squares regression model was built in Matlab using all output parameters to verify 
the division of thrombi into three types, determined by unsupervised cluster analysis (Figure 4). 
In the first model obtained, it was found that two components determined most of the variation 
(82.9% and 7.9%) in the data set assessing type I, II and III thrombi; furthermore, the six key 
parameters contributed similarly to this division. This allowed us to calculate mean values of these 
parameters as a proxy for the type of thrombi formed per surface and wall shear rate (Suppl. Table 
2).
 A second model was then built, again using partial least-squares regression data analysis, by 
fitting in the data obtained at low shear rate (which were not used in the first model). This model 
made it also possible to predict the thrombus type under low shear conditions (Suppl. Table 2). 
From this analysis it appeared that 6 out of 11 surfaces, which each produced type I thrombi at 
high shear, formed type II thrombi at low shear. Furthermore, 2 out of eight VWF-containing sur-
faces producing type III thrombi at high shear formed type II thrombi under low-shear conditions. 
This class analysis thus confirmed the heatmap subtraction analysis of Figure 6C.
}
}
}
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Figure 5. Stimulating effect of co-coating of microspots with VWF-BP or VWF. Whole blood from control sub-
jects was perfused over arrays of microspots for 3.5 min at 1600 s-1, and analyzed for thrombus formation as in Figure 1. 
(A) Sub-heat maps of thrombus formation parameters of single coatings (left panel), co-coatings with VWF-BP (middle 
panel), or co-coatings with VWF (right panel). Formation of type I, II and III thrombi is represented by color bars from 
gray to black. (B) Subtraction heat maps, indicating the effects of co-coating with VWF-BP (middle) or with VWF (right). 
Color code is from -1 to 10. *P<0.05 (2-tailed Student’s t-test) compared to single coating, per row or column.
 By combining the analysis of thrombus types and the receptor assignment matrix per surface 
(Figure 1), we then evaluated the combinations of receptors contributing to formation of type III 
thrombi. First, computational analysis was performed for the high-shear condition of the surfaces 
binding GPIb (VWF, VWF-BP) in combination with the key integrins α2β1/α6β1 and the signaling 
receptors GPVI/CLEC-2. In combination these three receptor/ligand classes consistently produced 
type III thrombi (Figure 7). Integrins seemed to play a stimulatory but not essential role, with α6β1 
being more active than α2β1. This was also clear from the mean scores of laminin-containing sur-
faces (α6β1 binding), which performed better than GFOGER- or decorin-containing surfaces (α2β1 
binding) (Suppl. Table 2).
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Figure 6. Effect of wall shear rate on thrombus formation on microspot surfaces. Whole blood was perfused 
over surfaces with or without VWF at indicated wall shear rates. (A) Measured parameters of thrombus formation at 1600 
s-1 (2 × 18 surfaces, clustering order as in Figure 4). (B) Measurement parameters of thrombus formation at 150 s-1. 
(C) Linear subtraction heatmapof outcome parameters at low shear rate compared to high shear rate. *P<0.01 (2-tailed 
Student’s t-test).
Figure 7. Contribution of platelet-adhesive receptors to formation of type I-III thrombi. Schematic repre-
sentation of thrombus type formed at high shear rate on surfaces capturing platelets via adhesive receptors (GPIb, and 
integrins α2β1, α6β1) as well as signaling-linked receptors (GPVI, CLEC-2).
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Receptor
1600 s-1 150 s-1
β constant 0.947
GPIb-V-IX 0.687 0.049
GPVI 0.858 0.903
CLEC-2 0.763 0.964
α6β1 0.653 0.879
αIIbβ3 0.527 0.877
α2β1 0.193 0.165
CD36 -0.262 0.898
α5β1 -0.102 -0.834
αvβ3 -0.159 -0.746
              
 
 A similar analysis was performed by partial least-squares regression analysis linking the 
various receptors to thrombus type (high shear rate). For the 52 surfaces of the main heatmap, 
a new model was built with 3 components (together 72% of the variance), which after rounding 
gave three predicted thrombus types. A confusion matrix indicated that only 10 of the 52 sam-
ples appeared in the wrong class, with miss-assignment predominantly (8 out of 10) in the lower 
classes of thrombi (type I-II), where severity was overestimated. This model was confirmed by 
cross validation. Using the receptor assignments per surface, a β-weight matrix was constructed to 
calculate the contribution of each receptor to the type of thrombus formation (Table 2). The matrix 
confirmed prominent differences in contribution of the various receptors, pointing to major roles 
for GPIb, the signaling receptors GPVI and CLEC-2, as well as for the integrins α6β1 and αIIbβ3. While 
contribution of α2β1 is less pronounced, the other integrins α5β1 and αvβ3 along with CD36 score 
lowest. Note that negative values in the matrix only indicate relative inability of the receptor to 
contribute to type III thrombus formation. Overall, these findings identify highly stimulatory roles 
of CLEC-2 and α6β1 in type III thrombus formation at high shear rate, in addition to the established 
roles of GPIb, GPVI and α2β1.
 Using the same receptor assignments and partial least-squares regression analysis, a new 
β- matrix was built to predict the contributions of individual receptors at low shear rate, that is, 
by clustering the low-shear data into the matrix of high-shear data. Cross-validation predictions 
showed that only 7 of the 36 surfaces were wrongly predicted for thrombus type. The resulting 
β-weight factors (2 components, 58% of the variance) pointed to a minimized contribution of GPIb 
to thrombus type at low shear rate (Table 2). Further, this analysis indicated similarly high contri-
butions of GPVI, CLEC-2, α6β1 and αIIbβ3. At low shear rate, CD36 had a positive role, while αvβ3 
and α5β1 again did not contribute to formation of type III thrombi. Finally, the model was rebuilt 
by exclusion of a contribution of GPIb at low shear rate, giving essentially the same results (only 4 
out of 36 surfaces wrongly predicted). This calculated absence of the GPIb-V-IX at low-shear flow 
conditions is in good agreement with the literature2.
Platelet function disorders leading to impaired thrombus formation 
A panel of nine microspot surfaces (all major receptors and VWF co-coated) was selected to de-
termine reference values of all parameters for n≥6 healthy subjects (Suppl. Table 3). To assess 
intra-individual variability, blood samples were analyzed from six healthy volunteers, taken each at 
four different days. For all surfaces together: intra-individual coefficient of variations (CVs) 
Table 2. Predicted contribution of platelet re-
ceptors in formation of type III thrombi at high 
shear rate. Beta matrix values after principal com-
ponent analysis of weight factors, predicting the con-
tribution of individual adhesive receptors to formation 
of type III thrombi. The model built for shear rate of 
1600 s-1 was based on 52 surfaces and 6 parameters 
(71% of variance). A separate scaled model was built 
for shear rate of 150 s-1, based on 36 surfaces and 
6 parameters (58% of variance). Both models used 
the assignment matrix of Figure 1. Note that negative 
values designate relative inactivity of the receptors to 
participate in type III thrombus formation.
Weight factor
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Figure 8. Abnormal thrombus formation in blood from patients with rare platelet function defects. Whole 
blood from controls subjects or indicated patients was perfused over microspots of nine different surfaces (three mi-
crospots per run, 2–3 runs per surface). Surface numbering as in Figure 1. (A) Heatmap of average parameters of throm-
bus formation for blood samples from control subjects (left), and blood samples from day control subjects (right). (B) 
Heatmaps and (C) subtraction heatmaps of parameters of thrombus formation for patients with indicated syndromes: 
SCID, May–Hegglin anomaly, grey platelet syndrome, Glanzmann’s thrombasthenia or Hermansky–Pudlak syndrome. 
*P<0.05 compared with control subjects (two-tailed Student’s t-test). (D) Significance map of parameters from a rep-
resentative control subject and a day control subject, as well as from all patients. Colour key: red=deviating <mean−2 
SD; green=deviating >mean+2 SD, relative to normal values. Thrombus formation was also assessed in blood from rare 
patients with established platelet function disorders. Heatmap mean data were generated for the control subjects and 
the individual patients under investigation (Figure 8A, B). These data were further evaluated in subtraction heat maps 
and significance maps (Figure 8C, D).
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for the morphological score (5.7%) were 2.0 times lower than inter-individual CVs (11.2%); for 
platelet deposition, intra-individual CVs (10.8%) were 3.1 times lower than inter-individual CVs 
(33.7%). Similarly, for the platelet activation markers, that is, fibrinogen binding, P-selectin expres-
sion and phosphatidylserine (PS) exposure, intra-individual CVs were 3.4 times, 2.6 times and 3.5 
times lower, respectively, than the corresponding inter-individual CVs.
 Thrombus formation was also assessed in blood from rare patients with established platelet 
function disorders. Heatmap mean data were generated for the control subjects and the individual 
patients under investigation (Figure 8A, B). These data were further evaluated in subtraction heat 
maps and significance maps (Figure 8C, D).
 Thrombus formation was assessed in blood from a patient with severe immune deficiency 
syndrome (SCID)40, associated with near-complete deficiency in store-induced calcium entry in 
hematopoietic cells including platelets. In spite of a reduced morphological score of thrombus 
formation, platelet activation parameters on surfaces producing type III thrombi, that is, VWF/
rhodocytin and collagen I, were increased in comparison to control subjects (Figure 8D, E). This 
may point to increased CLEC-2- and GPVI-dependent platelet activation under high shear flow, for 
example compensating for absence of one of the calcium entry pathways. Blood samples were 
also examined from a patient with May-Hegglin anomaly41, characterized by a myosin cytoskeletal 
defect and macrothrombocytopenia, in which disease the consequences for platelet function are 
not well understood. Thrombus formation parameters were mostly within the normal range, with 
the exception of reduced platelet aggregate formation (morphological score, integrated feature 
size, platelet deposition) on GPVI-binding surfaces (VWF, VWF/GFOGER-(GPO)n, collagen I). Most 
values for non-GPVI-binding surfaces were in the normal range. However, platelet procoagulant 
activity tended to be higher on two-component surfaces.
 Also investigated was blood from a patient with gray platelet syndrome41, phenotyped with 
a partial deficiency in platelet a-granules. The thrombi formed were reduced in most parameters, 
with the exception of procoagulant activity, typically on type III-inducing surfaces, that is, VWF/
rhodocytin, VWF/GFOGER-(GPO)n and collagen I (Figure 8D). P-selectin expression was markedly 
reduced on all surfaces, as expected. Overall, these results may point to impaired thrombus for-
mation due to reduced ɑ-granule release, in particular on surfaces activating via CLEC-2 or GPVI. 
Furthermore, testing the blood from a patient with Glanzmann’s thrombasthenia (deficiency in 
αIIbβ3) resulted in a significant reduction in platelet aggregation tendency (morphological score, 
integrated feature size and/or fibrinogen binding) on most surfaces, thus substantiating αIIbβ3 as 
being invariably implicated in platelet-platelet interactions. Platelet activation parameters (P-selec-
tin expression, platelet deposition) were most prominently reduced on VWF/fibrinogen surface. A 
final blood sample was used from a patient with Hermansky-Pudlak syndrome41, characterized by 
absence of dense granules. In this case, parameters of thrombus formation decreased with VWF/
vitronectin, VWF/rhodocytin, VWF/GFOGER-(GPO)n and collagen I. Thrombus formation hence di-
minished on surfaces binding GPIb plus αvβ3, CLEC-2 or GPVI. For all patients together, thrombus 
formation was mostly altered on VWF-containing surfaces with rhodocytin, GFOGER-(GPO)n or 
collagen I; the most affected parameters were morphological score, integrated feature size and 
fibrinogen binding.
Additional role of thrombin 
To determine the role of thrombin, as a potent platelet agonist in thrombus formation, recalcified 
blood samples were flowed over microspots containing surfaces co-coated with tissue factor. Corn 
trypsin inhibitor and GPRP were added to prevent contact activation and fibrin polymerization, 
respectively. Representative results are given in Suppl. Table 4. On a VWF/fibronectin surface, all 
parameters of thrombus formation increased in the presence of thrombin generation. However, on 
coated collagen I, platelet deposition and fluorescence markers of platelet activation parameters 
appeared to decrease in the presence of thrombin. This paradoxical effect was due to contraction 
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of the thrombi on collagen, resulting in lower surface area coverage of the (labelled) platelets 
in the presence of thrombin. Incidental presence of fibrin clots on the surfaces made this assay 
variant less suitable for standardization. Overall, these data pointed to a more complex way of 
thrombus phenotyping in the presence of thrombin, which requires further evaluation in the future.
Discussion
The present results aim to contribute to the recognized high need for full standardization and 
exploitation of flow assays for integrative whole blood platelet function testing9. By systematic 
assessment of thrombus formation under high shear flow on 52 microspot surfaces using eight 
outcome parameters, we have identified the most determinative parameters of this process. These 
reflect overall platelet adhesion and aggregation (morphological score, integrated feature size, 
platelet deposition), and determinants of platelet activation (fibrinogen binding, P-selectin expres-
sion, procoagulant activity). Leaving out two parameters – stable platelet adhesion and thrombus 
volume – did not change the initial clustering of surfaces with different types of thrombi. The 
remaining six parameters contributed equally to the thrombus-forming process, and were hence 
combined in least-squares regression analyses to build a model for the formation of thrombi with 
different phenotypes. The division into three thrombus types was almost identical to that achieved 
by unsupervised cluster analysis of all data (52 surfaces, 8 parameters).
 The cluster analysis indicated a robust distinction of surfaces into three classes, supporting: 
adhesion of few single platelets (type I); extensive adhesion with small aggregates and minimal 
platelet activation (type II); or large aggregates with fully activated platelets (type III). Thrombi 
of type III were only present on combined microspots containing VWF or VWF-BP, an exception 
being collagen I which binds VWF from plasma; other necessary components were laminin (bin-
ding α6β1), peptides containing (GPO)n (binding GPVI) or rhodocytin (binding CLEC-2). Other ad-
hesive proteins tested appeared to be less active in combined surfaces (fibrinogen > osteopontin, 
collagen III > fibronectin, vitronectin, thrombospondin-1, decorin). Note that the CLEC-2 ligand 
podoplanin is not present in the arterial wall or in plasma35.
 A particular role in high-shear thrombus formation is played by VWF, because it binds to two 
abundant platelet receptors, GPIb and αIIbβ3 and to several matrix proteins
2, that is, fibrillar colla-
gens (via its A3 domain)19 and, as recently demonstrated, to laminins42. The latter finding explains 
why we could not identify cooperative roles of VWF and laminin on microspots and high activity of 
laminin/rhodocytin co-coatings. For the majority of other surfaces, co-coating of VWF (or VWF-BP) 
increased the parameters of thrombus formation at high shear rate, but not at low shear rate. The 
platelet-activating effect of surface-immobilized laminin has been observed before under stasis, 
and was attributed to α6β1 and GPVI
32,43. However, using GPVI inhibitors we did not find a role of 
GPVI in flow-dependent platelet adhesion and activation on laminin. Our data with microspotted 
peptides agree with the earlier conclusion that synthetic peptides designed to mimic platelet-col-
lagen interactions via GPVI, VWF/GPIb and α2β1, namely (GPO)n, VWF-BP and GFOGER peptides, 
can completely replace native collagen fibers in supporting thrombus formation24,37,44.
 Regression models built to predict the involvement of different platelet receptors to full 
thrombus formation yielded interesting results. In addition to the established contribution of GPIb 
and GPVI, we find major roles for CLEC-2 and the integrins α6β1 and αIIbβ3. At high shear rate, 
platelet adhesion via integrin α2β1 contributed less to type III thrombus formation, while other 
receptors αvβ3, α5β1 or CD36 were even less effective. This conclusion is in full accordance with 
the major and additive roles of GPVI, CLEC-2 and integrin α6β1 in arterial thrombus formation in 
established mouse models of arterial thrombus formation in vivo35,42. Importantly, fitting the low 
shear data into these regression models pointed to an almost annulled contribution of GPIb, which 
is in accordance with the current concept of the GPIb-V-IX complex as key receptor for platelet 
adhesion at high-shear conditions 2. Although these results indicate a strong role of this complex in 
the formation of type III thrombi at high shear, they do not prove that GPIb itself triggers signal-
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ing events in platelets. According to the built model, the other most remarkable change in weight 
factors at low shear rate is a positive contribution of CD36.
 Normal values were determined for nine surfaces and six outcome parameters. In particular, 
the parameters fibrinogen binding, P-selectin expression, platelet deposition and platelet procoag-
ulant activity showed high inter-sample variation. High inter-individual variability in platelet depo-
sition on collagen surfaces has also been reported by others, and could be correlated to plasma 
levels of VWF, platelet count, hematocrit, sex and platelet receptor genotype14. Using different 
types of microfluidic devices, it was also possible to correlate outcome parameters of thrombus 
formation to platelet calcium responses (under stasis)15, and to aspirin and/or clopidogrel intake 
in patients with heart disease16. Taken together, the inter-individual variability in this kind of whole 
blood measurements seems to be linked, at least in part, to clinically relevant determinants of 
platelet function in cardiovascular disease.
 Consistent results were obtained upon application of the multi-parameter microspot assay 
to blood from patients with established platelet deficiencies in platelet functions. With the excep-
tion of blood from the SCID patient, the overall effect of disease on all parameters was reduced 
thrombus formation (9-18 out of 54 parameters reduced) (Figure 8D). Spots of collagen I, VWF/
GFOGER-(GPO)n and VWF/rhodocytin were most discriminative, all normally resulting in type III 
thrombi. Of the type II thrombus-inducing surfaces, only VWF/vitronectin showed two reduced 
parameters for the majority of patients. Together, the patient data indicate that this multi-para- 
meter, multi-surface test detects the consequences of actin cytoskeleton alterations (May-Hegglin), 
deficient alpha or dense granule secretion (gray platelet, Hermansky-Pudlak), and impaired αIIbβ3 
activity (Glanzmann). However, in the case of impaired store-operated calcium entry (SCID pa-
tient), we find a similar number of parameters decreased and increased.
 In conclusion, we developed a standardized procedure to systematically test thrombus for-
mation upon whole blood perfusion over arrays of microspotted adhesive surface. Using systems 
biology approaches, we built a model predicting the roles of platelet receptors in shear-dependent 
thrombus formation, and generated templates to determine aberrations in this process in patients 
with platelet dysfunctions. This knowledge of surfaces and output parameters is pivotal in the 
planned design of microscope-independent flow devices. Applications of this advanced technique 
are numerous, not only in the profiling of patients with a (suspected) bleeding disorder or a 
pro-thrombotic tendency, but also in the monitoring of functional aberrations in platelet count and 
of antiplatelet therapy. Furthermore, in a modified way, it can be used to assess the platelet-ad-
hesive properties under flow of blood-derived leukocytes, natural stem cells and malignant cells in 
cancer.
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Abstract
Multimeric glycoprotein von Willebrand factor (VWF) exhibits a unique triplet structure of individual 
oligomers, resulting from ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin 
type 1 motifs-13) cleavage. The faster and slower migrating triplet bands of a given VWF multi-
mer respectively have one shorter or longer N-terminal peptide sequence. Within this peptide se-
quence, the A1 domain regulates interaction of VWF with platelet glycoprotein (GP)Ib. Therefore, 
platelet-adhesive properties of two VWF preparations with similar multimeric distribution but dif-
ferent triplet composition were investigated for differential functional activities. Preparation A was 
enriched in intermediate triplet bands, while preparation B predominantly contained larger triplet 
bands. Binding studies revealed that preparation A displayed a reduced affinity for recombinant 
GPIb, but an unchanged affinity for collagen type III, when compared to preparation B. Under 
high-shear flow conditions, preparation A was less active in recruiting platelets to collagen type III. 
Furthermore, when added to blood from patients with von Willebrand disease (VWD), defective 
thrombus formation was less restored. Thus, VWF forms lacking larger size triplet bands appear 
to have a decreased potential to recruit platelets to collagen-bound VWF under arterial flow condi-
tions. By implication, changes in triplet band distribution observed in patients with VWD may result 
in altered platelet adhesion at high-shear flow.
Introduction
Hemostasis requires the combined action of blood platelets and vascular and plasmatic factors, 
with von Willebrand factor (VWF) having a key role. In blood, VWF circulates as a large glycopro-
tein consisting of multimers of heterogeneous sizes. At high-shear flow conditions, VWF mediates 
platelet adhesion via the glycoprotein (GP)Ib-V-IX complex, in particular by depositing to collagen 
fibres, at which it avidly binds. Collagen-bound VWF thus plays a critical role in platelet tethe- 
ring, translocation, and stable adhesion at arterial flow conditions above a critical shear rate of 
500-1000 s-1 1,2. VWF binds to collagen types I and III via its A3 domain, whereas binding to type 
VI collagen has been attributed to VWF A1 domain 3-5. In addition, VWF is implicated in platelet 
GPIb-dependent pro-coagulant activity and fibrin formation 6, and it protects factor VIII from rapid 
proteolytic inactivation 7. 
 It is well established that large VWF multimers, which are secreted from endothelial cells, 
are cleaved into smaller forms by the metalloproteinase ADAMTS-13 (a disintegrin and metallo-
proteinase with thrombospondin type 1 motifs 13). This protease cleaves the Y1605-M1606 peptidyl 
bond within the A2 domains of VWF multimers, thus generating smaller size multimers of VWF 
8. Because of asymmetric cleavage in the VWF A2 domain, ADAMTS-13 degradation results in 
larger and smaller size monomeric forms of 176 kDa (C-terminal peptide sequence) and 140 kDa 
(N-terminal peptide sequence), respectively (Figure 1A). On agarose gels these represent the two 
satellite bands, flanking the major band of all VWF multimers 9,10 forming a so-called VWF triplet. 
The slower and faster migrating triplet bands thus either contain or lack one 140 kDa N-terminal 
peptide sequence compared to the intermediate VWF triplet band, respectively 11. The variable part 
of individual VWF triplets resides in the N-terminal protein part comprising the A1 domain, which 
contains binding sites for heparin, coagulation factor VIII and GPIb and, hence, is highly relevant 
to VWF function.
 Because the properties of individual VWF triplet bands have not been investigated so far, 
we aimed to separate normal plasma-derived VWF into sub-fractions with a similar multimeric 
composition, but different triplet band patterns. Therefore, we made use of the property that the 
longer-chain, slower migrating triplet bands of VWF multimers containing one additional N-ter-
minal 140 kDa peptide sequence more avidly bind to heparin 12. We used heparin affinity column 
separation, followed by size exclusion chromatography to obtain VWF preparations with a similar 
multimer profile, but distinct pattern of triplet bands, resulting in different affinities to GPIb and dif-
ferent capabilities to promote GPIb-dependent platelet adhesion under high-shear flow conditions.
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Figure 1. Domain structure of VWF and flow-chart to obtain preparations with different VWF triplet distri-
bution. (A) VWF domains indicating binding sites for heparin and GPIb in the A1 domain. The pro-peptide of AA 23-763 
after cleavage of the pre-pro-peptide is depicted below the domain structure as well as the mature VWF protein starting 
with AA 764-2813 (numbering according to the pre-pro-protein). Glycosylation is indicated as squares (N-linked glycans) 
and circles (O-linked glycans). ADAMTS-13 cleavage site in the A2 domain is indicated as well. This cleavage results in a 
140 kDa N-terminal fragment comprising the D3-A1 domains and part of the A2 domain with binding sites for e.g. GPIb 
and heparin. Cleavage also results in a larger 176 kDa C-terminal fragment, comprising part of the A2 domain as well as 
VWF domains A3D4C1C2C3CK. Information source: P04275, UniProtKB/Swiss-Prot database. (B) Flow-chart to separate 
plasma-derived VWF into preparations with different triplet composition, but similar multimeric composition. Application 
of desalted VWF concentrate (Wilate) on heparin affinity chromatography column results in three fractions, fraction F1 
(discarded) and fractions F2 and F3 with distinct triplet composition. By using size exclusion chromatography, F2 and 
F3 are resolved in sub-fractions of similar molecular weight ranges and, hence, similar multimeric composition, giving 
preparations A and B, respectively. Desalted whole VWF concentrate is also subjected to size exclusion chromatography 
to obtain a control preparation with similar molecular weight ranges to preparations A and B.
Distinct role of von Willebrand factor triplet bands in glycoprotein lb-dependent platelet adhesion 
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Figure 2: Obtaining VWF preparations with different triplet forms by heparin affinity and size exclusion 
chromatography. (A) Plasma-derived VWF concentrate was applied to a heparin affinity column, and eluted step-wise 
with 190, 230 and 500 mM NaCl (gray line of eluent conductivity). Protein peaks were collected as fractions 1-3 (F1-3), 
and subjected to Western blotting (1.6% agarose gels). Note differences in multimeric and triplet band composition of 
the fractions. F1 containing mostly small VWF multimers with little biological activity was discarded. F2 predominantly 
contained the medium to large VWF multimers with only intermediate triplet bands, while F3 consisted of more of the 
larger VWF multimers enriched in slower migrating triplet bands. (B) Size exclusion chromatography of unseparated 
VWF concentrate, resulting in initial elution of larger VWF multimers. Western blots of 1.2% agarose gels illustrate the 
multimeric sizes of individual fractions, and pooling of fractions to obtain the control VWF preparation. Note that prepa-
rations A and B were obtained using the same size exclusion chromatography as shown for the control in Figure 2B, but 
starting from fractions F2 and F3, respectively (not shown in this figure)
Materials and methods
Materials 
Plasma-derived VWF/factor VIII concentrate Wilate (lot no. A925A189) used for fractionation was 
from Octapharma (Vienna, Austria). First international standard VWF concentrate 00/514 (NIBSC, 
Hertfordshire, UK) was used as reference for quantification. VWF levels are given as antigen con-
centrations, unless indicated otherwise. Standard normal human plasma (SHP) was from Haemo-
chrom Diagnostica (Essen, Germany). Collagen type III from human placental villi was obtained 
from Biozol Diagnostica (Eching, Germany). F(ab)2 fragments of monoclonal antibody (Ab) 6B4 
against the VWF-binding epitope on GPIbα was a kind gift of Dr. H. Deckmyn 13. H-Phe-Pro-Arg 
chloromethyl ketone (PPACK) came from Calbiochem (La Jolla, CA, USA).
Isolation of VWF preparations with different triplet composition 
Plasma-derived VWF concentrate (Wilate) was desalted using a PD-10 column and eluted with 20 
mM Tris, pH 7.4 (GE Healthcare, Uppsala, Sweden). The VWF concentrate was then fractionated 
according to triplet structure by fast protein liquid chromatography (FPLC), employing a 5 mL 
HiTrap heparin HP affinity column (GE Healthcare) and stepwise gradient elution with 190, 230 
and 500 mM NaCl in 20 mM Tris, pH 7.4 (Figure 1B). Of the three fractions (F1-3), only F2 and 
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F3, obtained at 230 and 500 mM NaCl elution, respectively, were used for further purification. The 
other fraction F1 was enriched in the faster migrating triplet band, but contained only small VWF 
multimers with low biologic activity (Figure 2A), and was hence discarded.
 Each of the fractions F2 and F3 (Figure 2A), as well as the unfractionated Wilate (original 
sample = control preparation) were differentially separated into sub-fractions by FPLC using a 
Sepharose CL2B size exclusion column. Elution was performed with Tris-buffer, pH 7.4 (20 mM Tris, 
0.02% v/v Tween 20). Sub-fractions from this column for each starting sample (i.e., fractions F2 
and F3, and control preparation) were then separately pooled to yield different VWF preparations 
with a similar multimeric distribution. This was done for the control preparation (exemplary shown 
in Figure 2B), as well as for fractions F2 and F3 (not shown but similar process to that shown for 
control preparation in Fig 2B) to give preparations A and B, respectively (see Fig 1B). Each sepa-
rate column fraction pool was then concentrated using an Amicon Ultra-4 centrifugal filter device 
(100K; Millipore, Billarica, MA, USA) at 2000 g to a VWF:Ag level of about 30 IU/mL. Fraction 
analysis for VWF multimer distribution was by 1.2% agarose gel electrophoresis; and analysis for 
VWF triplet composition was by 1.6% agarose gel electrophoresis, followed by Western blotting 15. 
Densitometric analysis of blots was performed with Multi Gauge V3.2 software (Fujifilm, Düssel-
dorf, Germany).
 VWF preparations were assessed for collagen binding using a VWF:CB ELISA (TECHNOZYM® 
VWF: CBA ELISA Kit, Technoclone, Vienna, Austria). VWF ristocetin cofactor activity (VWF:RCo) 
was determined using a BCS XP system (Siemens Healthcare, Eschborn, Germany); all values were 
calibrated against standard human plasma.
ELISA assays 
Antigen concentrations of VWF were determined with a sandwich ELISA with polyclonal anti-human 
VWF antibody (Ab) (A0082, Dako, Hamburg, Germany) for capturing, followed by staining with 
horseradish peroxidase (HRP)-conjugated anti-human VWF Ab (P0226, Dako). Sigma Fast OPD 
tablets were used as chromogenic substrate (order no. P9187; Sigma-Aldrich, Schwerte, Germa-
ny), colour development was terminated with 1 M HCl, and absorbance was measured at 492 nm.
 Binding of VWF fractions to platelet-derived GPIb was determined with an immuno-assay 
employing recombinant, FLAG-tagged GPIbα fragment with two gain-of-function mutations (G233V 
and M239V), enabling VWF binding in the absence of ristocetin 16-18. The rGPIbα fragment was im-
mobilized via its FLAG tag in 96-well plates pre-coated with anti-FLAG Ab (F3165, Sigma-Aldrich). 
Bound VWF was measured using a polyclonal anti-human VWF Ab and a HRP-conjugated secon- 
dary Ab (P0226 and A0082, Dako) in combination with TMB substrate solution (T0565, Sigma-
Aldrich). The colouring reaction was terminated with 0.5 M H2SO4, and absorbance was read at 
450 nm.
 
Surface plasmon resonance 
Binding of VWF preparations to collagen type III was determined by surface plasmon resonance 
(SPR) using a Biacore 2000 (GE Healthcare), CM5 chips and amine coupling chemistry, basically 
as described 19. In brief, collagen type III was immobilized on the chip surface at an amount of 
800-1000 response units (RU). VWF samples were injected at increasing concentrations (0.2, 0.4, 
1.3 and 4 IU/mL) in HBS-EP running buffer (3.4 mM EDTA, 10 mM HEPES, 150 mM NaCl, 0.005% 
Tween 20; pH 7.4) at a flow rate of 20 µL/min. A chip with immobilized polyclonal rabbit anti-hu-
man collagen I-V Ab (Kamiya Biomedical, Seattle, USA) served as reference for unspecific binding. 
Chips were regenerated after each run 20. 
 For determination of rGPIb binding kinetics by SPR, purified gain-of-function rGPIbα frag-
ment carrying a His-tag was immobilized onto NTA-chips (GE Healthcare) at 1000 RU. Samples of 
VWF were injected at increasing concentrations of 0.3, 0.9, 2.8 and 8.4 IU/mL. Analysis of all SPR 
binding curves was done with BiaEvaluation software (GE Healthcare), assuming Langmuir 1:1 
Distinct role of von Willebrand factor triplet bands in glycoprotein lb-dependent platelet adhesion 
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binding kinetics and a molecular weight of the VWF monomer of 270 kDa.
Platelet adhesion and thrombus formation under flow 
Leukocyte-depleted platelet concentrates collected by aphaeresis and red cell concentrates were 
obtained from Haema (Berlin, Germany). These concentrates were used to prepare washed plate-
lets and red cells, respectively. Shear- and VWF-dependent platelet adhesion to collagen type III 
using reconstituted blood was performed, as described elsewhere 21. Briefly, 2.5 x 108 platelets/mL 
were labelled with 5-chloromethylfluorescein diacetate (CMFDA, Invitrogen, Karlsruhe, Germany), 
and reconstituted with washed red cells (hematocrit of 40%) and VWF preparations (1 IU/mL). 
Viscosity of the reconstituted blood samples was measured with an AMVn falling sphere viscometer 
(Anton Paar, Ostfildern, Germany) to ensure a dynamic viscosity of ~3 mPa∙s. Samples were per-
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Figure 3. Triplet and multimer 
composition of fractionated VWF 
preparations. Comparison of control 
preparation with normal triplet structure 
(VWF concentrate subjected to size ex-
clusion chromatography), and prepa-
rations A and B (separated by heparin 
affinity chromatography and then size 
exclusion chromatography) analysed by 
agarose gel electrophoresis and West-
ern blotting. (A) Representative Western 
blots. Left: low-resolution 1.2% agarose 
gels, showing multimer sizes from 1mer 
to 13mer (*1mer band plus dye front). 
Right: high-resolution 1.6% agarose 
gels, showing triplet composition of mul-
timers with faster, intermediate and slow-
er migrating triplet bands (arrowheads). 
Note that preparations A and B, and the 
control preparation were similar in multi-
mer composition (2-13mer). (B) Relative 
distribution of VWF 1-13mer multimers 
of control preparation and preparations A 
and B. (C) Proportions of each of three 
triplet bands in control preparation and 
preparations A and B. Means ± SEM 
(n=4). Note here the difference in trip-
let bands: Preparation A was enriched in 
intermediate triplet bands, while prepa-
ration B predominantly contained larger 
triplet bands.
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fused at a shear rate of 1700 s-1 through a flow chamber coated with collagen type III (µ-slide VI, 
Ibidi, Munich, Germany). Platelet adhesion was monitored in real time for up to 8 min. After per-
fusion and fixation, 24 randomly chosen images in the centre of the flow channel were recorded, 
and analysed using AxioVision 4.6 software (Carl Zeiss, Göttingen, Germany).
 The VWF preparations were also tested in whole-blood perfusion assays, using a miniatur-
ized parallel-plate flow chamber and equipment as described before 22,23. Chamber surfaces were 
coated with collagen type III (0.1 mg/mL), and blocked with HEPES buffer, pH 7.45 plus 1% BSA. 
Experiments were carried out with blood from healthy controls and from two patients with VWD. A 
patient with type 1 VWD had a VWF:RCo activity of 29%. A patient with type 2A VWD had a VWF: 
RCo activity of <10 %, a VWF antigen level of 25-35%, and a factor VIII level of 30%; multimer 
analysis revealed that the highest multimers were lacking, which is compatible with type 2A.
 Blood was drawn into PPACK anticoagulant, as described previously 24. This direct thrombin 
active-site inhibitor achieves complete anticoagulation, while maintaining physiological concentra-
tions of free Mg2+ and Ca2+ ions. Blood samples were spiked with vehicle or VWF preparations at 
final concentrations of 2 IU/mL. The blood was then perfused through the flow chamber at a shear 
rate of 1700 s-1 for 4 min. Four to five randomly chosen phase-contrast images were captured with 
a digital CCD camera at the end of perfusion. Images were analysed as described above. Blood 
donors had given full informed consent, and not taken medication interfering with platelet function 
for at least two weeks.
Statistical analyses 
Significance of data was analysed with GraphPad Prism version 5.01 (GraphPad Software, San 
Diego, CA, USA). Normal distribution was confirmed using the Kolmogorov-Smirnov normality test. 
Differences between grouped data were compared with an unpaired Student’s t-test. Data from 
gels with VWF multimers and SPR analyses were compared by 2way ANOVA, using Bonferroni 
post-testing to compare replicates.
Results
Separation of plasma-derived VWF by heparin affinity chromatography (Figure 1) resulted in two 
fractions (F2 and F3) with markedly differences in triplet structure, but also to some extent in 
multimeric composition (Figure 2A). Each of the fractions, as well as the original VWF preparation 
(used as a control) was further separated by size exclusion chromatography, and sub-fractions 
were pooled to obtain preparations with equal multimeric distribution (process shown in Figure 2B 
exemplary for the control).
 The resulting fractionated VWF pools, preparation A and B, as well as the (unfractionated) 
control preparation, were characterized by electrophoresis on low- and high-resolution agarose 
gels and Western blotting (Figure 3A). Densitometric analysis of blots showed that, as aimed for, 
preparations A and B were similar in multimer composition (2-13mer), as was the control prepa-
ration (Figure 3B, p>0.05). A significant difference in the preparations was only seen in the 1-mer 
composition, but this was not expected to influence subsequent findings. Importantly, the various 
preparations displayed marked and significant differences with regard to triplet band composition 
(Figure 3C). Preparation B was greatly enriched in the slower migrating triplet bands of essentially 
all multimers at the expense of intermediate triplet bands; in comparison, preparation A was great-
ly reduced in the slower migrating triplet bands and contained larger proportions of intermediate 
triplet bands (p<0.001). Accordingly, the two-column separation had resulted in two VWF fractions 
with prominent differences in presence of larger size triplet bands, but with similar multimeric 
composition.
 The original VWF concentrate as well as the various preparations were concentrated to obtain 
solutions with the same VWF antigen concentrations, and further characterized using conventional 
VWF assays, namely VWF:CB and VWF:RCo. VWF:CB to VWF:Ag ratios were: 1.21±0.10 (original 
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Figure 4. Binding of VWF preparations to collagen. Binding kinetics of VWF preparations to collagen type III were 
established by surface plasmon resonance measurements. (A) Representative binding curves with increasing concentra-
tions of 0.2, 0.4, 1.3 and 4 IU/mL for control preparation and for preparations A and B, as indicated. Binding is expressed 
as response units (RU). (B) Calculated affinity constant values (KD) of various VWF preparations. Means ± SEM (n=6).
sample), 0.91±0.02, (control), 0.81±0.02 (Prep. A) and 0.78±0.01 (Prep. B); VWF:RCo to 
VWF: Ag ratios were 0.41±0.04 (original sample), 0.37±0.01 (control), 0.37±0.01 (Prep. 
A), 0.42 ±0.01 (Prep. B). Hence, in comparison to the original VWD concentrate, the column-
separated preparations were slightly reduced in collagen binding and ristocetin cofactor activity, 
most likely due to partial retaining of the highest multimers on the heparin column (see be-
low). Notably, preparation B had higher VWF:RCo but similar VWF:CB compared to preparation A.
 Using SPR, we analysed binding properties of the three preparations to surface-immobilized 
collagen type III. Preparations A and B gave similar binding curves, when applied at increasing 
concentrations of 0.2 to 4 IU/mL (Figure 4A). Determination of the affinity constants, assuming 
conventional Langmuir kinetics, resulted in similar dissociation equilibrium constant (KD) values of 
15-25 nM (Figure 4B), indicating no significant difference in binding affinity of the two preparations 
to collagen type III (p=0.95). Both preparations displayed a tendency to diminished collagen bin-
ding in comparison to the unseparated control preparation.
 Using a newly established method, a gain-of-function rGPIb fragment was immobilized to 
Biacore chips for investigating binding of the preparations to the platelet GPIb receptor. Binding 
curves were generated after injection of increasing concentrations of the VWF preparations (Fi-
gure 5A). Strikingly, the binding affinity of preparation A in this case was significantly lower than 
of preparation B (Figure 5B, p=0.0014). This lower affinity was due to a slower association rate 
in combination with a faster dissociation rate. Furthermore, at equal antigen concentrations, the 
maximal binding was on average 30% lower for preparation A than for preparation B, likely as a 
consequence of the lower affinity.
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Figure 5. Binding of VWF preparations to recombinant GPIb. Surface plasmon resonance measurements to as-
sess binding of VWF preparations to a gain-of-function rGPIb fragment. (A) Representative binding curves, expressed 
as response units (RU) at increasing concentrations of 0.3, 0.9, 2.8 and 8.4 IU/mL for control and preparations A and 
B. (B) Corresponding KD values. (C) Binding of VWF preparations to rGPIb obtained with ELISA. Data are expressed as 
percentage of binding seen in standard human plasma (SHP). Means ± SEM (n=5).
 To confirm these differences in binding to GPIb, we also used an ELISA setup, where the 
same gain-of-function rGPIb fragment was immobilized on well plates. In this immuno-based assay, 
preparation A again showed a lower binding to GPIb than preparation B (Figure 5C, p<0.0001), 
such in agreement with the results obtained by SPR.
 For functional analyses, we then investigated the ability of the VWF preparations to support 
GPIb-dependent platelet adhesion to type III collagen at high shear flow conditions. In the first 
set of experiments, reconstituted blood samples containing platelets (CMFDA-labelled) and red 
blood cells were supplemented with the control VWF preparation or with preparation A or B at 1 
IU VWF/mL. After perfusion over collagen, the coverage of adhered platelets was determined by 
fluorescence microscopy. In this flow assay, preparation A was significantly less active in suppor- 
ting platelet adhesion than preparation B (Figure 6, p<0.0001). To demonstrate the importance 
of VWF-GPIb interaction, similar flow experiments were performed in the presence of 6B4 mAb, 
directed against the VWF binding site of GPIb 25. As indicated in Figure 6B, this antibody completely 
annulled the platelet-adhesive effect of the most active preparation B (Figure 6B, p<0.0001).
 In a second range of experiments, we compared the effects of addition of a re-combined 
F1-F3 preparation with that of the original VWF concentrate. The combination of F1, F2 and F3 
gave a multimeric distribution pattern similar to that of the VWF preparations A/B (Suppl. Figure 
S1).  Addition of either preparation (2 IU VWF/mL, final) to the reconstituted blood resulted in a 
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similar increase in platelet deposition on collagen as seen with the combination of preparations A 
and B (Suppl. Figure S2). This indicated that most of the biological activity of VWF was retained in 
the preparations A and B.
 In addition, we performed perfusion studies with whole blood from VWD patients containing 
reduced baseline levels of VWF. Blood was thus obtained from a patient with VWD type 1 (29% 
VWF:RCo activity) and a patient with VWD type 2A (<10% VWF:RCo activity). Samples of blood 
were spiked with the control preparation or with preparation A or B. After 4 min perfusion at 1700 
s-1 shear rate, platelet deposition in thrombi was determined by enhanced contrast video micros-
copy. As shown in Figure 7, supplementation of all VWF preparations (control, A or B) at 2 IU/mL 
VWF resulted in a significant increase in platelet deposition with both type 1 and type 2A patient 
blood (p<0.05). For the type 1 VWD patient, no significant difference was seen between prepara-
tions A and B. However, for the type 2A VWD patient, preparation A was significantly less effective 
than preparation B in stimulating thrombus formation (p=0.0133). Further control experiments 
showed that none of the preparations modified platelet deposition, when added to blood from 
subjects with normal VWF levels (data not shown). Together, these findings suggest that VWF 
triplets lacking an additional 140 kDa N-terminal peptide sequence with the VWF A1 domain con-
taining a GPIb binding site, are decreased in binding affinity to platelet GPIb, and are less active 
in supporting platelet thrombus formation on collagen type III under high-shear flow conditions.
Discussion
Distinct cleavage of VWF multimers in the A2 domain by the metalloproteinase ADAMTS-13 results 
in VWF forms of various multimeric sizes, but with flanking satellite bands (so-called triplet bands) 
10-12,26,27. The slower migrating triplet bands of VWF multimers thereby contain an additional 140 
kDa N-terminal peptide fragment, whereas this N-terminal part is missing in the faster migrating 
triplets, when compared to the respective intermediate VWF triplet bands 11. Importantly, the 
N-terminal part of VWF monomers that is cleaved off by ADAMTS-13 proteolysis comprises the 
D1D2D3A1 domains and part of the A2 domain. This part is known to be involved in the binding of 
VWF to coagulation factor VIII, heparin, collagen and platelet GPIb (reviewed by 28).
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Figure 6. Effect of VWF preparations on shear- dependent platelet adhesion in reconstituted blood. Flow 
chamber experiments performed with reconstituted blood containing CMFDA-labelled platelets (2.5×108/mL) and 
washed red blood cells (40% hematocrit), flowed over a type III collagen surface at 1700 s-1 shear rate. Reconstituted 
blood samples were supplemented with control VWF preparation or preparation A or B (1 IU/mL). The 6B4 mAb (20 μg/
mL) against the VWF binding site of GPIb was added, as indicated. Samples without VWF (baseline) served as negative 
control. (A) Representative fluorescence images (bars, 50 μm) after 8 min perfusion. (B) Analyzed surface area cove-
rage of fluorescence after 8 min perfusion. Means ± SEM (n=6; 3 different platelet preparations).
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The literature provides indirect evidence that distinct triplet bands of the VWF multimers may differ 
in functional properties, but so far this has not directly been shown. For instance, an altered VWF 
triplet composition is detected in type 2A or 2B VWD, i.e. in forms of VWD that are characterized 
by altered VWF binding to platelets, likely as a consequence of changes in VWF proteolysis 29,30. In 
other disease forms, like type 2M VWD, satellite bands can even be absent, despite the presence of 
normal or even supra-normal multimers, which associates with defects in platelet-VWF interaction 
31. 
 For this paper, we have functionally characterized two VWF preparations separated by hepa-
rin affinity and size-exclusion chromatography, which are equal in VWF multimeric distribution pat-
terns, but markedly differ in triplet band composition. Binding studies using SPR- and ELISA-based 
approaches indicate that preparation A, lacking an extra N-terminal peptide sequence compared to 
preparation B, shows a significantly lower affinity for GPIb. In contrast, both preparations display 
an equal binding affinity for type III collagen. The relatively decreased function of preparation A 
is confirmed by two sets of flow studies, investigating platelet adhesion and thrombus formation 
due to interaction of the GPIb-V-IX complex with VWF. High-shear flow experiments over type III 
collagen, using either reconstituted blood21 or whole blood from VWD patients 22, thus show signifi-
cantly lower platelet deposition and thrombus formation in the presence of preparation A than of 
preparation B. Together, these finding suggest that the larger size VWF triplet bands, containing an 
additional N-terminal peptide sequence, are more potent in recruiting platelets under arterial flow 
conditions. However, a limitation of our work is that the heparin fractionation had resulted in the 
partial loss of very high VWF multimers.
 The presence or absence of the N-terminal fragment with GPIb binding site in the A1 domain 
may be considered theoretically negligible for platelet recruitment, taking into account the overall 
sum of other GPIb binding sites present in VWF multimers. However, given the present results, it 
is well feasible that this one additional GPIb binding site, located at the outer surface of globular 
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Figure 7. Effect of VWF preparations on platelet adhesion added to blood from VWD patients. Whole blood 
from two VWD patients (type 1 VWD and 2A VWD with 29% and <10% VWF:RCo activity, respectively) was spiked with 
control VWF preparation or preparation A or B (2 IU/mL), and then perfused over collagen type III at a shear a rate of 
1700 s-1. (A) Representative brightfield images after 4 min perfusion of spiked blood from type 2A patient (150×150 
µm). (B) Analyzed surface area coverage of platelets after perfusion of spiked blood from type 2A VWD patient (left side) 
and type 1 VWD patient (right side). Means ± SEM (n=3 independent experiments).
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multimers, has a considerable impact on protein function, with regard to its sensitivity to confor-
mational transition in response to fluid dynamic conditions and mechanical forces. Others have also 
reported on functional consequences due to the absence of the heparin-binding site within the 
A1 domain of VWF, following ADAMTS-13 cleavage 32,33. The present results suggest that different 
functional properties of individual triplet bands are not only relevant for heparin affinity, but also 
for GPIb binding affinity.
 Overall, the present results point to a distinct role of the VWF triplet band composition re-
garding GPIb-dependent platelet adhesion to VWF. The larger size, slower migrating VWF triplet 
bands appear to be functionally more active in supporting thrombus formation in collagen type III 
surfaces. The implication of these findings is that the altered triplet band composition, regularly 
observed in type 2 VWD patients, may contribute to an altered VWF-dependent platelet adhesion 
at high-shear flow.
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Abstract
Platelets abundantly express the membrane receptor CD36 and store its ligand thrombospondin-1 
(TSP1) in the ɑ-granules. We investigated whether released TSP1 can support platelet adhesion 
and thrombus formation via interaction with CD36. Mouse platelets deficient in CD36 showed 
reduced adhesion to TSP1 and subsequent phosphatidylserine expression. Deficiency in either 
CD36 or TSP1 resulted in markedly increased dissolution of thrombi formed on collagen, although 
thrombus build-up was unchanged. In mesenteric vessels in vivo, deficiency in CD36 prolonged the 
time to occlusion and enhanced embolization, which was in agreement with earlier observations 
in TSP1-deficient mice. Thrombi formed using wildtype blood stained positively for secreted TSP1. 
Releasate from wildtype but not from TSP1-deficient platelets enhanced platelet activation, phos-
phatidylserine expression and thrombus formation on collagen. The enhancement was dependent 
on CD36, since it was without effect on thrombus formation by CD36-deficient platelets. These 
results demonstrate an anchoring role of platelet-released TSP1 via CD36 in platelet adhesion 
and collagen-dependent thrombus stabilization. Thus, the TSP1-CD36 tandem is another platelet 
ligand-receptor axis contributing to the maintenance of a stable thrombus.
Introduction
Glycoprotein IV or CD36 forms one of the most abundant glycoproteins on the surface of mouse 
and human platelets, expressed at up to 25,000 copies per cell1, 2. CD36 consists of a double 
membrane-spanning protein with one large extracellular domain and two short N- and C-terminal 
cytoplasmic domains3, 4, 5. Its function has remained unclear for long. Earlier, CD36 was believed to 
be a platelet collagen receptor6, 7, but it was shown that platelets from CD36-deficient patients have 
an unchanged response to collagen8, 9. Subsequent studies suggested a role for CD36 as receptor 
for thrombospondin-1 (TSP1)10, 11. It was also found that CD36 can bind oxidized lipids, including 
oxidized low density lipoproteins (oxLDL), particularly at conditions promoting atherogenesis12, 13. 
Earlier, we and other have demonstrated that interaction of CD36 with surface-immobilized TSP1 
or oxLDL leads to outside-in signaling events in platelets via the protein kinases JNK and Syk, and 
enforced via autocrine loops of secreted ADP and P2Y12 receptors
14, 15. Interestingly, this signalling 
promotes Ca2+-dependent exposure of procoagulant phosphatidylserine at the platelet surface.
 The multi-domain matrix glycoprotein TSP1 is one of the most highly expressed proteins in 
platelet ɑ-granules (~101,000 copies per cell)2. TSP1 is also found in the blood vessel, likely after 
deposition secreted by platelets and vascular cells16, 17, 18. In addition to CD36, several other platelet 
receptors for TSP1 have been proposed. These include the glycoprotein Ib-V-IX complex19, 20, 21. 
and glycoprotein CD4722. TSP1 can also indirectly influence platelet activity via binding to collagen, 
fibrinogen and von Willebrand factor (VWF), and protect the latter from cleavage by matrix pro-
teinases23. 
 Lack of platelet α-granules is associated with a mild to moderate bleeding tendency in pa-
tients with the congenital gray platelet syndrome24. The genetic defect has recently been attributed 
to mutations in the neurobeaching-like 2 (NBEAL2) gene25, 26. In mice deficiency in Nbeal2 similarly 
results in defective α-granule biogenesis, accompanied by diminished platelet adhesion, phosphati-
dylserine exposure and thrombus formation27. So far, it has remained unclear which of the proteins 
stored in platelet α-granules contribute to these responses.
 In the present paper, we hypothesized that the abundantly expressed TSP1, secreted from 
the α-granules and interacting with its counter-receptor CD36, starts an additional autocrine 
feed-forward loop and supports the interactions of platelets in a thrombus. This hypothesis was 
tested using mice deficient in either CD36 or TSP1 by assessment of platelet adhesion, activation 
and thrombus formation.
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Materials and Methods
Materials
H-Phe-Pro-Arg chloromethyl ketone (PPACK) and TSP1 from human platelets were obtained from 
Calbiochem (La Jolla CA, USA). Bovine serum albumin (BSA), ADP and thrombin and FeCl3 were from 
Sigma-Aldrich (St. Luis MO, USA). Low molecular weight heparin (fragmin) was from Pfızer (Ca-
pelle a/d IJssel, The Netherlands). Glycoprotein VI agonist, convulxin, was purified to homogeneity 
from the crude venom of Crotalus durissus terrificus (Latoxan, Valence, France)28. Fibrillar Horm 
type I collagen was from Nycomed Pharma (Munich, Germany). Annexin A5 (detecting surface-ex-
posed phosphatidylserine) labeled with fluorescein isothiocyanate (FITC) was from PharmaTarget 
(Maastricht, the Netherlands). FITC-labeled anti-mouse CD62P mAb (detecting surface exposure 
of granular P-selectin) and PE-labeled JON/A mAb (detecting the activated conformation of mouse 
integrin αIIbβ3) were from Emfret Analytics (Würzburg, Germany); biotin-conjugated anti-mouse 
TSP1 mAb from Abcam (Cambridge, UK); blocking anti-mouse CD36 mAb (MAB1258, clone 63) 
from Millipore (Temecula, CA, USA); blocking antibody against mouse CD47 (clone miap301) from 
eBiosciences (San Diego, CA, USA). Annexin A5 labeled with Alexa fluor (AF)647 and streptavidin 
labeled with AF532 were from Molecular Probes (Eugene OR, USA). Rhodamine 6G was from Invi-
trogen (Grand Island, NY, USA). Other materials were from sources described before29. 
Animals 
Experiments were approved by the local Animal Experimental Committees. Mice homozygous in 
CD36 deficiency (Cd36-/-) were generated as described, and crossed back >6 times to a C57Bl/6 
genetic background30. Mice deficient in TSP1 (Tsp1-/-) also of C57Bl/6 background were kindly pro-
vided by dr. J. Lawler (Harvard Medical School, Boston MA, USA)31. Wild type mice (C57Bl/6) were 
used from the same sources. Blood counts of platelets and erythrocytes of knockout and wild type 
mice were in the normal ranges.
Blood collection and platelet preparation
Mice were anesthetized by subcutaneous injection of ketamine and xylazine (0.1 mg/g and 0.02 
mg/g body weight), after which blood was obtained by retro-orbital puncture. For flow studies, 
blood was collected into 40 µmol/L PPACK, 5 U/mL heparin and 40 U/mL fragmin. For platelet 
preparation, blood was collected into acid citrate dextrose (ACD). Isolated platelets were washed 
and resuspended in modified Tyrode’s Hepes  buffer (5 mmol/L Hepes, 136 mmol/L NaCl, 2.7 
mmol/L KCl, 0.42 mmol/L NaH2PO4, 2 mmol/L MgCl2, 0.1% glucose and 0.1% BSA, pH 7.45)
29. 
Platelet count was determined with a Coulter counter. 
 To prepare platelet releasates, aliquots of suspended Tsp1+/+ or Tsp1-/- platelets (1 × 109/
mL) were activated with thrombin (20 nmol/L) for 10 minutes, after which PPACK (200 nmol/L) 
was added to inactivate residual thrombin. Releasates were isolated by centrifuging for 1 minute 
at 2650 g, and were stored at -80 °C until use.
Flow cytometry 
Washed platelets (1 × 108/mL) in modified Tyrode’s buffer with 2 mmol/L CaCl2 were activated 
with ADP (0.5-5 μmol/L) or convulxin (20-50 ng/mL) without stirring. After 10 minutes, activation 
of integrin αIIbβ3, α-granule secretion, and phosphatidylserine exposure were detected with PE-la-
beled JON/A mAb (150 µg/mL), FITC-labeled anti-CD62P mAb (1:40) and AF647-labeled annexin 
A5 (1 µg/mL), respectively32. Fluorescence was measured with a BD Accuri C6 flow cytometer (San 
Jose, CA, USA).
Static platelet adhesion and activation 
Round glass coverslips were coated with purified TSP1 (3 µL, 100 μg/mL) or releasate from acti-
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vated platelets (3 µL, ~3 × 106 platelets), and blocked with 1% BSA in modified Tyrode’s buffer. 
Coverslips were mounted in an open chamber and incubated with platelets in buffer containing 2 
mM CaCl2 (1.5 × 10
8/mL). Platelet adhesion was determined by phase-contrast microscopy, and 
exposure of phosphatidylserine by labeling with FITC-annexin A5 and fluorescence microscopy33. 
Thrombus formation under flow 
Rectangular coverslips were coated with fibrillar type I collagen (3 µL, 50 µg/mL), and blocked with 
1% BSA in modified Tyrode’s buffer. Where indicated, coated coverslips were post-incubated with 
releasate from activated platelets (3 µL, ~3 × 106 platelets). After mounting into a transparent 
parallel-plate flow chamber (depth 50 µm, width 3 mm), coverslips were perfused with PPACK/
heparin-anticoagulated mouse blood for 4 minutes at a wall shear rate of 1000 s-1 (Ref. 29) Using 
confocal microscopy, surface expression of activation markers on adhered platelets was measured 
by staining with PE-labeled JON/A mAb (probing activated integrin αIIbβ3) and AF647-annexin A5 
(probing phosphatidylserine exposure)32. Using Metamorph software (Molecular Devices, Sunny-
vale CA, USA), brightfield and fluorescence images were analyzed for surface area coverage, mean 
thrombus size, or fluorescence intensity34. Where indicated, images were recorded with an EVOS 
inverted digital fluorescence microscope (AMG, Bothell WA, USA).
 Thrombus stability was assessed by post-perfusion of thrombi with modified Tyrode’s buffer 
containing 1 U/mL heparin for 6 minutes, during which period images were taken every 30 se-
conds38. Differential images were obtained with Metamorph software, and analyzed for changes in 
pixel intensity above background.
Figure 1. TSP1 released from platelets during thrombus formation supports phosphatidylserine exposure. 
(A-B) Blood from Tsp1+/+ or Tsp1-/- mice was perfused during 4 minutes over collagen at a wall shear rate of 1000 s-1. 
(A) Representative brightfield and fluorescence images recorded after post-staining (bars, 25 µm). (B) Quantification 
of covered area of all platelets (platelet deposition); labelling with PE-JON/A mAb (αIIbβ3 activation); labelling with 
AF647-annexin A5 (PS exposure); and staining with biotin anti-TSP1 mAb followed by AF532-streptavidin (TSP1 stain). 
(C-D) Tsp1+/+ or Tsp1-/- thrombi formed on collagen in the presence of ADP (10 µmol/L), staining with biotin anti-TSP1 
mAb and AF532-streptavidin. (C) Representative images (bars, 25 µm). (D) Quantification of covered area of TSP1-
stain. Means ± SEM (n = 3-4). *P <0.05 vs. Tsp1+/+; n.s., not significant.
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Figure 2. Platelet-derived TSP1 supports thrombus formation on collagen in a CD36-dependent way. Co- 
verslips were coated with releasate (RL) from thrombin-stimulated Tsp1+/+ or Tsp1-/- platelets, collagen alone (coll), or 
collagen post-incubated with RL, as indicated. Blood from Cd36+/+ or Cd36-/- mice was perfused during 4 minutes at 1000 
s-1. (A) Representative brightfield images of thrombi formed after flow (bars, 25 µm). (B) Quantification of platelet sur-
face area coverage. (C) Morphometric analysis of images for mean thrombus size. Means ± SEM (n = 4-6). *P <0.05, 
#P <0.1 vs. Cd36+/+ control.
Immunostaining of thrombi 
Coverslips coated with collagen and/or platelet releasates, before or after thrombus formation, 
were stained with biotin-conjugated anti-murine TSP1 mAb (4 µg/mL) for 15 minutes. After rinse 
with modified Tyrode’s buffer, the coverslips were post-stained with AF532-streptavidine (1:200) 
for 15 minutes. Control stainings were without primary mAb. No fixation or permeabilization was 
performed. Fluorescence images were recorded after a second rinse using an LSM7 Live confocal 
microscope (Zeiss, Jena, Germany).
In vivo thrombosis in mesenteric vessels 
Mice were anesthetized by sodium pentobarbital (60 mg/kg, i.p.) and thrombus formation in the 
mesenteric vessels was provoked, as described previously35. Briefly, Rhodamine 6G was injected 
i.v. (3.3 mg/kg) for fluorescent labeling of circulating cells. After opening of the abdomen, mesen-
teric vessels were exposed on the table of an inverted epifluorescent microscope with 20x objective 
(Zeiss Observer, Jena, Germany), coupled to Axiovision software (Zeiss). A standardized vascular 
injury was induced by placement of a filter paper soaked with 5% FeCl3 for 5 minutes. Platelet 
deposition, thrombus formation and embolization in arterioles and venules were monitored by 
microscopic fluorescence imaging in real-time until complete occlusion occurred. Time to occlusion 
was defined as the arrest of blood flow for at least 1 minute. Per animal, 2 measurements were 
performed. When occlusion had not occurred for 60 minutes, the experiment was terminated and 
occlusion time was determined as 60 minutes.
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Figure 3. Platelet-derived TSP1 enhances phosphatidylserine exposure in thrombus formation in the pres-
ence of CD36. Blood from Cd36+/+ or Cd36-/- mice was perfused during 4 minutes at 1000 s-1 over a surface of releasate 
(RL) from Tsp1+/+ platelets, over collagen alone (coll), or collagen post-incubated with RL from Tsp1+/+ or Tsp1-/- plate-
lets, as indicated. (A,C) Representative fluorescence images (bars, 25 µm) of thrombi stained for activated αIIbβ3 (PE-
JON/A mAb) and phosphatidylserine exposure (AF647-annexin A5). (B,D) Quantification of fluorescence area covered 
by thrombi. Means ± SEM (n = 6-7); *P <0.05 vs. Cd36+/+ control. 
Statistical analysis 
Significance of differences was determined with a parametric t-test or a non-parametric Mann-Whit-
ney U test, as appropriate. The statistical package for social sciences was used (SPSS version 17, 
Chicago IL, USA).
Results
In human platelets, CD36 acts as an adhesive receptor for immobilized TSP115. To assess this 
for the mouse system, we measured the adhesion of platelets from Cd36+/+ and Cd36-/- mice to 
surfaces coated with purified human TSP1 or a TSP1-containing releasate from activated mouse 
platelets. With either surface, deficiency in CD36 resulted in a markedly reduced static adhesion 
(Suppl. Figure 1A). Labelling with FITC-annexin A5 indicated that the lower adhesion of Cd36-/- 
platelets was accompanied by a lower phosphatidylserine exposure, suggesting reduced platelet 
activation (Suppl. Figure 1B). Immmunofluorescence experiments indicated that surface-coated 
releasate from wildtype platelets stained positively for TSP1, whereas surface-coated releasate 
from Tsp1-/- platelets failed to stain (Suppl. Figure 2A-B). We determined whether phosphatidylse- 
rine-exposing microparticles as possible CD36 ligands36 may contribute to the adhesion of platelets 
to surface-coated releasates. However, staining of these coatings with FITC-annexin A5 did not 
result in a detectable fluorescence signal, pointing to the absence of microparticles on the coated 
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surface (Suppl. Figure 3). Together, the data indicated that CD36 acts as an adhesive receptor for 
mouse platelets on released and immobilized TSP1.
 To determine the activation tendency of platelets from mice, we measured integrin αIIbβ3 ac-
tivation, α-granule secretion and phosphatidylserine exposure in response to ADP or a glycoprotein 
VI agonist, convulxin. No difference was observed in any of the responses between the knockout 
and wildtype platelets (Suppl. Figure 1C-E). These results are in agreement with our previous data 
that blockage of CD36 does not affect agonist-induced activation of suspended human platelets.15 
Similarly, other authors have described that CD36-deficient mouse platelets in suspension are un-
changed in activation properties12, 37. 
Figure 4. Platelet CD36 and TSP1 support thrombus stabilization on collagen. Thrombi were formed by 4 
minutes perfusion over collagen at 1000 s-1, using blood from Cd36-/-, Tsp1-/- or corresponding wildtype mice. Stability of 
thrombi was evaluated during 6 minutes of post-perfusion with modified Tyrode’s buffer, containing 2 mmol/L CaCl2 and 
1 U/mL heparin. (A) Representative phase-contrast images taken during post-perfusion (bars, 25 µm). (B) Dissolution 
of thrombi during post-perfusion calculated by subtraction analysis. Representative data of at least 4 experiments. See 
also movies in online-only supplement. 
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Figure 5. Platelet CD36 supports formation of stable thrombi in vivo. Thrombus formation was induced in me-
senteric vessels from Cd36+/+ and Cd36-/- mice by FeCl3 injury. Animals were pre-injected with rhodamin 6G to fluores-
cently label circulating cells. (A) Representative images showing thrombus instability and embolization in injured arteri-
oles from Cd36-/- mice. Dotted lines indicate vessel walls; right image is 50s later than left image (bar, 100 µm). See also 
movies in online-only supplement. (B) Distribution plots of occlusion times in arterioles (top panel) and venules (bottom 
panel) following injury. Horizontal lines represent median values (* P <0.05).
 Considering that CD36 mediates platelet adhesion to immobilized TSP1, we investigated 
whether platelet-released TSP1 contributes to thrombus formation under flow conditions. Whole 
blood from Tsp1-/- or corresponding wildtype mice was perfused over collagen at high wall shear 
rate. Thrombi formed with Tsp1-/- and Tsp1+/+ blood differed neither in deposition of platelets (sur-
face area coverage) nor in integrin ɑIIbβ3 activation (staining with PE-JON/A mAb) (Figure 1A, B). 
However, thrombi formed with Tsp1-/- blood were significantly reduced in platelet phosphatidylser-
ine exposure. Immunostaining indicated the presence of released TSP1 in wildtype thrombi, but 
not in Tsp1-/- thrombi. To stimulate activation and secretion, thrombi on collagen were treated with 
ADP, and then immunostained for TSP1 (Figure 1C, D). Strong staining of the Tsp1+/+ thrombi was 
observed, but not of the Tsp1-/- thrombi.
 The roles of CD36 and TSP1 in thrombus formation were studied using Cd36-/- blood, which 
was perfused over collagen surfaces containing releasate from Tsp1-/- or Tsp1+/+ platelets. Control 
experiments indicated that surfaces with only releasates did not result in adhesion of Cd36+/+ or 
Cd36-/- platelets (Figure 2A, B). However, in combination with collagen, releasate from Tsp1+/+ 
platelets but not from Tsp1-/- platelets enhanced the process of thrombus formation in perfusions 
with Cd36+/+ blood only (P = 0.035). Image analysis indicated that mean thrombus size was largest 
for the combination of Tsp1+/+ releasate and Cd36+/+ blood (P = 0.001, Figure 2C). When using 
Cd36-/- blood, no increase in thrombus size was observed in the presence of releasate from Tsp1+/+ 
or Tsp1-/- platelets.
  Staining for integrin ɑIIbβ3 activation did not show marked differences between Cd36
-/- and 
Cd36+/+ thrombi formed on collagen alone (Figure 3A, B). However, ɑIIbβ3 activation and phospha-
tidylserine exposure were significantly increased in Cd36+/+ thrombi (P = 0.005 and 0.027, respec-
tively), when these were formed on a surface with collagen plus releasate from Tsp1+/+ (but not 
Tsp1-/-) platelets (Figure 3A-D). Notably, the stimulating effect of Tsp1+/+ releasate was absent in 
Cd36-/- thrombi. Together, this pointed to a platelet-activating effect of immobilized TSP1 via CD36, 
thus supporting collagen-dependent thrombus formation and procoagulant activity.
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 Considering that paracrine platelet agents like ADP, thromboxane, and Gas6 contribute to 
thrombus stabilization38,39, we investigated the stability of thrombi formed with Cd36-/-, Tsp1-/- or 
wildtype blood. This was done by measuring the rate of dissolution of preformed thrombi during 
a high shear post-perfusion protocol38. Strikingly, whereas the wildtype thrombi remained stable 
for a longer period, the thrombi of platelets deficient in either CD36 or TSP1 disintegrated within 
several minutes (Figure 4A; see movies in the supplemental material). Quantification of thrombus 
dissolution during a 6 minutes period indicated a significant increase in this parameter for Cd36-/- 
and Tsp1-/- platelets in comparison to wildtype (Figure 4B).
 Control experiments pointed out that in Tsp1-/- blood the blocking anti-mouse CD36 antibody 
MAB1258 did not have an additional effect (data not shown), suggesting that no other CD36 ligand 
was involved in thrombus stabilization. Furthermore, pretreatment of Cd36+/+ or Cd36-/- blood with 
a blocking antibody against CD47 did not change platelet deposition or thrombus stability (data not 
shown). Together, these findings pointed to a role of TSP1-CD36 interaction in the stabilization of 
thrombi at high shear flow.
 To investigate this under in vivo conditions, we measured the thrombotic process in mes-
enteric arterioles and venules from Cd36+/+ and Cd36-/- mice, injured with FeCl3. In the vessels 
from Cd36-/- mice, thrombus formation was delayed and more unstable, i.e. more embolization, in 
comparison to wildtype mice (Figure 5A, and movies in the online-only Supplement). This resulted 
in prolonged occlusion times in both the arterioles and venules of Cd36-/- mice (Figure 5B). These 
results are compatible with our earlier finding that also in mesenteric vessels of Tsp1-/- mice throm-
bus formation is delayed and accompanied by embolization 23.Together, these data indicate that 
both CD36 and TSP1 play a role in thrombus stabilization in vivo.
Discussion
In this study we hypothesized that platelet-secreted TSP1 by interacting with CD36 provides an ad-
ditional autocrine feed-forward loop that enforces the interactions of platelets in a growing throm-
bus. The results of this paper agree with a stimulatory effect of the TSP1-CD36 axis in thrombus 
formation and stabilization. Our data indicate that, similarly to purified human TSP1, the releasate 
from wildtype but not from Tsp1-/- platelets augments platelet adhesion and phosphatidylserine 
exposure in a CD36-dependent way, i.e. detectable with wildtype but not Cd36-/- platelets. In addi-
tion, we find that only the releasate from wildtype platelets enhances collagen-induced thrombus 
formation, integrinactivation and phosphatidylserine exposure at high shear flow conditions. Fur-
thermore, we find that stable thrombus formation is impaired in mice deficient in TSP1 or CD36 
both in in vitro and in vivo experiments. In vitro, we could establish that the impairment was not 
further increased by blockage of CD36. 
 Jointly, these results indicate that platelet-derived TSP1 and CD36 support adhesion and acti-
vation of platelets to PS exposure and thrombus stabilization. These are considered to be relevant 
findings since TSP1, although also present in the vessel wall, is accumulated within the blood in 
platelet α-granules2, 16, 17. The TSP1 that is secreted from activated platelets thus may deposit on 
collagen or a growing thrombus, and then act in an autocrine way to enforce the thrombus-forming 
process. Interestingly, the present findings with Cd36-/- and Tsp1-/- platelets are reminiscent - al-
though with a less strong phenotype - to those published for Nbeal2-/- platelets. These platelets 
(lacking α-granules) show impaired adhesion, reduced phosphatidylserine exposure, and dimin-
ished thrombus formation accompanied by increased thrombus instability27. Hence, TSP1 may be 
one of the α-granular proteins contributing to full and stable thrombus formation. This idea is sup-
ported by the fact that both TSP1 and CD36 are highly expressed in (mouse and human) platelets, 
thus allowing multiple possible interaction sites. Likely, also other α-granule-derived proteins than 
TSP1 will play a role in thrombus formation, but we like to note that TSP1 - differently from VWF, 
fibrinogen and Gas6 - is mostly stored in the blood in platelets, and is present in plasma at only 
low concentrations.
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 The present results are in agreement with earlier data, showing that immobilized TSP1 acti-
vates human platelets via CD36 through a Syk kinase-dependent mechanism, resulting in increased 
Ca2+ signaling, activation of αIIbβ3, and exposure of phosphatidylserine
15. Also in endothelial cells, a 
role for TSP1 in signaling via CD36 has been proposed40. Others have provided evidence that TSP1 
can promote platelet activation via the glycoprotein CD4722. However, in our experiments, blocking 
CD47 did not influence the process of thrombus formation in the presence or absence of CD36. 
These experiments, however, do not rule out that TSP1 can act by binding to other platelet ligands 
in the extracellular space, e.g. VWF and fibrinogen. In the absence of TSP1 also other effects may 
occur, given the previously identified role of TSP1 in protecting VWF from ADAMTS-13 degrada-
tion23. Similarly, in the absence of CD36, also the interaction with other ligands like oxLDL will be 
prevented. In other words, although the present results clearly point to an overlap of the functions 
of CD36 and TSP1 in thrombus formation, they do not impose that these functions are identical.
 Various authors have pointed to a role of either CD36 or TSP1, although in a different con-
text and not focusing on the TSP1-CD36 axis. Platelet CD36, by acting as a scavenging receptor 
of oxLDL, was found to contribute to atherosclerotic lesion development41, and hyperlipidemia-as-
sociated enhanced platelet reactivity12. The oxLDL-CD36 pathway is supposed to signal via the 
mitogen-activated protein kinases JNK14, and p38MAPK13, and the tyrosine kinase Syk15. 
 In earlier work, we demonstrated that continued inside-out signaling via ADP/ADP receptors 
and Gas6/Gas6 receptors, as well as PEAR1, contributes to perpetuated αIIbβ3 activation and main-
tenance of platelet-platelet interactions, and thereby to stabilization of a formed thrombus30, 31, 42. 
The present findings extend this concept by revealing the involvement of another autocrine axis in 
thrombus stabilization, namely the interaction of CD36 with platelet-derived TSP1.
 Taken together, our results point to defined roles of murine CD36 and platelet-derived TSP1 
in collagen-dependent thrombus formation under high shear flow conditions. Thus, TSP1 binding 
to platelet CD36 can be considered as another of the multiple receptor-ligand interactions required 
for the buildup of a stable thrombus.
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Abstract
The coagulation process is activated by tight control mechanisms, in which platelets play promi-
nent and unique roles. In thrombosis and hemostasis, activated platelets control the coagulation 
system in various ways: by exposing a phosphatidylserine surface for thrombin formation, by 
supporting fibrin formation, and by regulating the retraction of a fibrin clot. In this review we dis-
cuss the involvement of platelet receptors, other membrane proteins, downstream signaling pro-
teins, cytoskeleton-linked proteins and plasma proteins in these coagulant functions. Studies with 
both genetically modified mice and pharmacological inhibitors indicate that, in collagen-adhered 
platelets, in part common signaling pathways lead to phosphatidylserine exposure, generation of 
thrombin and fibrin, and retraction of the fibrin clot. However, prolonged Ca2+ elevation leads to 
thrombin generation, whereas integrin-dependent signaling stimulates fibrin clot retraction. Con-
tact-dependent signaling pathways, triggered by homotypic platelet-platelet interactions, seem to 
act in particular via the integrin route.
Introduction
The coagulation process is regulated by tight control mechanisms. During thrombosis and hemo-
stasis, platelets provide prominent and unique roles in supporting and confining the coagulant 
activity1, 2. Particularly studies with genetically modified mice and with inhibitors using human 
platelets have provided detailed insights into the molecular determinants of platelet-based coa- 
gulation. In this review, we discuss these findings regarding three mechanisms, how platelets: (i) 
form a procoagulant surface with exposed phosphatidylserine; (ii) provide sites for thrombin and 
fibrin formation; and (iii) steer fibrin clot retraction (Figure 1).
Regulation of platelet phosphatidylserine exposure
Flow chamber devices have extensively been used to study the process of thrombus formation at 
arterial shear conditions in order to evaluate not only platelet aggregation, but also platelet proco-
agulant activity (PS exposure) and fibrin formation within the same experiment. The current 
Figure 1. Platelet-based coagulation processes in a thrombus. The extrinsic and intrinsic coagulation systems 
are initiated after vascular disruption via tissue factor (TF) and collagen, respectively. Collagen-adhered platelets and 
patches of platelets in a thrombus expose PS, which serves as an efficient surface for assembly of the tenase (factors 
IXa/VIIIa) and prothrombinase (factors Xa/Va) complexes, resulting in thrombin generation and fibrin formation. At 
low shear rates, GPIb interaction with VWF mediates focal fibrin formation at the platelet surface via PS exposure. The 
aggregated platelets in a thrombus display activated αIIbβ3 and accomplish clot retraction by contracting fibrin fibers in 
the presence of thrombin.
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methodology, using small-size chambers in combination with fluorescence microscopy, has re-
vealed key roles of many platelet receptors and signaling proteins in the buildup of a thrombus 
and the formation of procoagulant platelets3. Table 1 provides an overview of published studies, 
where thrombus formation together with PS exposure is assessed under arterial shear conditions 
using blood from genetically modified mice. Table 2 shows corresponding data with human blood 
containing specific pharmacological inhibitors. Whereas the earlier literature concentrated on un-
derstanding the role of collagen receptor-induced Ca2+ fluxes in PS exposure, recent papers re-
vealed the contribution of various downstream signaling events and of autocrine products secreted 
from platelet granules. In addition, adhesive receptors other than collagen receptors have been 
examined for a role in procoagulant activity.
Collagen-induced Ca2+ signaling as the classical route
At high, arterial wall-shear rate, platelet adhesion to von Willebrand factor (VWF) via glycoprotein 
Ib-V-IX (GPIb), and to collagen via the receptors glycoprotein VI (GPVI) and integrin α2β1 leads to 
strong activation and to the formation of a stable thrombus 1, 4. A subpopulation of the platelets in 
the thrombus, particularly those platelets in direct contact with the collagen and the platelets that 
are co-activated by thrombin assume a round morphology, which is accompanied by PS exposure 
and microparticle shedding 5, 6. In contrast to the aggregated platelets in the thrombus core, the 
PS-exposing cells lack activation of the fibrinogen receptor, integrin αIIbβ3 
7. The main mechanism 
underlying PS exposure is a prolonged elevation in cytosolic Ca2+ level 8, 9. Hence, signaling mo- 
lecules downstream of the GPVI-Fc receptor γ chain (FcRγ) complex and involved in Ca2+ mobi-
lization via phospholipase Cγ (PLCγ) and phosphatidylinositol 3-kinase (PI3K) will contribute to 
PS exposure 1. As indicated in Table 1, platelets from knockout mice deficient in several signaling 
molecules show a decreased ability to thrombus formation as well as PS exposure. These signaling 
proteins include the receptors GPIb (via VWF), GPVI, FcRγ, α2β1 and αIIbβ3; various adapter and 
scaffold proteins, e.g. linker for activated T-cells (LAT); effector proteins such as the PI3K iso-
forms a/b , Src family kinases, and PLCγ2. Inhibitory studies with human blood indicate a similar 
involvement of receptors (GPIb, GPVI, α2β1, αIIbβ3) and signaling molecules (PI3K isoforms α and β 
and Src family kinases) in thrombus formation and PS exposure (Table 2). These findings support 
the concept that the reduced PS exposure is a direct consequence of diminished GPVI signaling to 
elevated Ca2+, rather than to a reduced platelet deposition per se 9.
 Collagen- and GPVI-dependent PS exposure is greatly enhanced by co-stimulation of plate-
lets with thrombin (acting via the Gqɑ protein), at both static and flow conditions, an effect that 
is explained by the more prolonged Ca2+ mobilization in response to two agonists 10. Other soluble 
agonists, in particular ADP, have been shown to enforce GPVI-induced Ca2+ signaling, PS exposure 
and thrombin generation, particularly via the P2Y12 receptors, and hence contribute to platelet 
procoagulant activity. Consequently, knock-out (mouse) or inhibition (human) of P2Y12 resulted in a 
smaller thrombus size and decreased PS exposure 11, 12, 13. However, thrombus formation not always
coincides with PS exposure. For instance, the interaction of plasma-derived Gas6 with the platelet
Gas6 receptors (TAM receptors), while enforcing integrin activation and contributing to thrombus 
stability, did not contribute to platelet PS exposure5, 14.
Insights into the role of elevated Ca2+
Platelets contain well-developed Ca2+ entry mechanisms for inducing and maintaining high cyto-
solic Ca2+ levels 15. Recent work has pointed to a role of the so-called store-operated and recep-
tor-operated Ca2+ entry pathways in PS exposure. The integral membrane protein, stromal inter-
action molecule (STIM)1, has been identified as the central Ca2+ sensor in the platelet reticular 
membrane that regulates store-operated Ca2+ entry 16. Via a direct coupling mechanism, STIM1 
activates the Ca2+ entry channel Orai1. Deficiency in either STIM1 or Orai1 resulted in decreased 
thrombus formation and PS exposure on collagen (Figure 2A) 17, 18. Interestingly, in the presence of 
Insights into platelet-based control of coagulation
C
h
ap
te
r
 7
94
Table 1. Mouse proteins and genes involved in platelet procoagulant activity and fibrin formation under 
high-shear flow conditions. Abbreviations: Ab, antibody; GOF, gain-of-function; LOF, loss-of-function; PS, phosphati-
dylserine, TS, thrombus size; = unchanged; ↑ increased; ↓ decreased.
Target protein Perturbation Effect on thrombus formation
Effect on 
coagulation Reference
Platelet receptors and membrane proteins
Axl Axl -/- TS ↓ (instability) PS = 14
Cyclophilin D Ppid -/- TS ↑ PS ↓ 7
Glycoprotein Ib p0p/B Ab TS ↓ PS ↓ 82
Glycoprotein VI Fcer1g -/-, JAQ1 Ab TS ↓ (no thrombi) PS ↓ 34,83,84
Gqα Gnaq -/- TS ↓ PS ↓ 83
Integrin α2β1 α2-null, β1-null TS ↓ PS ↓
83-85
Integrin αIIbβ3 JON/A mAb TS ↓ PS ↓
82
LAT Lat null, Lat +/-,Lat -/- TS ↓ PS ↓ 33,34
Mer Mer -/- TS ↓ (instability) PS = 14
Orai1 Orai1 -/-, 2-APB TS ↓ PS ↓, fibrin ↓ 17,18
P2Y1 MRS-2179 TS ↓ PS ↓
83
P2Y12 P2yr12 
-/-, cangrelor TS ↓ PS ↓ 12
STIM1 Stim1 -/- 
Stim1 (LOF)
TS ↓
TS =
PS ↓, fibrin ↓
PS =
17
23
Tyro3 Tyro3 -/- TS ↓ (instability) PS = 14
Platelet signaling proteins (kinases)
PI3 kinases Pik3r1 -/-, wortmannin TS ↓ PS ↓ 27
PI3 kinase α/β PIK-75, TGX-221, Pik3r2 (LOF) TS ↓ PS ↓ 27,48,86
Protein kinase Cα Prkca-/- TS ↓ PS ↓ 87,88
Protein kinase Cβ Prkcb-/- TS ↓ (no thrombi) PS ↓ 87
Protein kinase Cδ Prkcd-/- TS ↑ PS = 87
Protein kinase Cθ Prkcq-/- TS ↑/↓ PS ↑ 26,87
Protein kinase D2 Pkd2-/- TS ↓ PS = 89
Src family kinases PD0173952 TS ↓ (no thrombi) PS ↓ 33,85
Platelet signaling proteins (non-kinases)
α-Granules Nbeal2 -/- TS ↓ PS ↓ 30
CalDAG-GEF1 Rasgrp -/- TS ↓ PS ↓ 23
Calpain-1 Capn1 -/- TS = PS ↓ 7
CLP36 Clp36 (LOF) TS ↑ PS ↑ 31
Gas6 Gas6 -/- TS ↓ (instability) PS = 14
Phospholipase Cγ2 Plcg2 (GOF),
Plcg2 +/-, Plcg2 -/-
TS ↑
TS ↓
PS ↑
PS ↓
90
34
Phospholipase D1 Pld-/- TS ↓ PS ↓ 54
Plasma proteins
Factor XI F11 -/- TS ↓ PS ↓, fibrin ↓ 34
Factor XII F12 -/-, CTI TS ↓ PS ↓, fibrin ↓ 34
Factor VII FVIIai TS ↓ PS ↓, fibrin ↓ 34
(Pro)thrombin melagatran TS ↓ PS ↓, fibrin ↓ 35
VWF saratin TS ↓ PS ↓ 33,82
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Table 2. Human proteins involved in platelet procoagulant activity and fibrin formation under high-shear 
flow conditions. Abbreviations as for Table 1
Target protein Intervention Effect on thrombus Effect on coagu-lation Reference
Platelet receptors and membrane proteins
Glycoprotein Ib 6B4, 12G1 Abs TS ↓ PS ↓ 91
Glycoprotein VI 9O12, 10B12 Abs TS ↓ (no throm-
bi) 
PS ↓ 11,92,93 
Integrin α2β1 6F1, 15D7 Abs TS ↓ PS ↓ 
85,92-94
Integrin αIIbβ3 agrastat, latrofiban TS ↓ (no thrombi) PS ↓
85,94
Orai1 2-APB TS ↓ PS ↓ 18
P2Y12 ticagrelor, cangrelor TS ↓ (instability) PS ↓, fibrin ↓ 11,12,48
Platelet signaling proteins (kinases)
PI3 kinases wortmannin TS ↓ (instability) PS ↓ 27,48
PI3 kinase α/δ PIK-75, YM-024 TS ↓ PS ↓ 27
PI3 kinase β TGX-221 TS ↓ PS ↓ 27
PI3 kinase g AS-252424 TS = PS = 27
PI3 kinase d IC-87144 TS = PS = 27
Protein kinase C GF-109203X, 
RO-318425
TS ↓ (no thrombi) PS ↑ 25
Src family kinases PD-0173952 TS ↓ (no thrombi) PS ↓ 85
high thrombin concentrations, STIM and Orai1 appeared to be less important for PS exposure 17. 
This was recently explained by the finding that thrombin-dependent Ca2+ signaling in part relies on 
receptor-operated Ca2+ entry via TRPC channels 19.
 The Ca2+ signal in procoagulant platelets is enhanced by the release of mitochondrial Ca2+ 
via mitochondrial permeability transition pore formation (Figure 2A) 20. A key regulator in this 
pore formation is the mitochondrial localized peptidylprolylisomerase, cyclophilin D 21. Accordingly, 
GPVI-induced PS exposure is reduced in platelets from mice lacking cyclophilin D 7. However, in 
these platelets ionomycin-induced PS exposure is unchanged 22, designating that mitochondrial 
collapse as such is not a strict requirement for PS exposure.
Redundancies downstream of diacylglycerol and Ca2+
Isoforms of PLC produce two second messengers, diacylglycerol (DAG) and inositol-trisphosphate 
serving as an intracellular Ca2+ mobilizer. Recent investigations have examined the roles in platelet 
procoagulant activity of two sets of Ca2+- and DAG-dependent effector proteins, which are activated 
downstream of PLCγ2, namely CalDAG-GEF1 and isoforms of protein kinase C (PKC). Interestingly, 
these effector proteins can also modulate the Ca2+ signal itself, in a not yet completely understood 
way (Figure 2A). Platelets from mice lacking CalDAG-GEF1 are greatly impaired in thrombus forma-
tion as well as PS exposure 23. However, the situation for PKC is more complex as described next.
 Human and mice platelets express both the conventional PKC isoforms α and β and the 
novel PKC isoforms δ and θ 24. In human blood, addition of a general inhibitor for all PKC isoforms 
resulted in greatly abolished thrombus formation, but in increased PS exposure of the remaining 
adhered platelets 25. Studies with knockout mice indicated a positive role in both thrombus for-
mation and PS exposure of the two conventional PKC isoforms α/β, whereas the two novel PKC 
isoforms δ/θ were inhibitory 26, 27. The precise phosphorylation events through which these PKC 
isoforms operate are still unclear 24. Jointly, these data point to non-redundant and positive roles 
of CalDAG-GEF1 and PKCα/β, and to antagonistic and negative roles of PKCδ/θ in the regulation of 
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thrombus buildup and PS exposure.
 Calpain is another Ca2+-dependent effector protein controlling platelet activation. While de-
ficiency in mouse calpain-1 had no effect on thrombus size, this resulted in a markedly lower PS 
exposure 7, 22.
Additive roles of dense- and alpha-granule secretion
Platelet dense (δ) and alpha (α) granule constituents are known to amplify platelet responses, such 
in agreement with the bleeding phenotype seen in patients lacking these granules 28. Novel data in-
dicate that granule secretion supports not only platelet aggregation, but also platelet procoagulant 
activity. The δ-granules contain calcium, serotonin, ADP, ATP and polyphosphates. The observed 
impairment of collagen/thrombin-induced PS exposure of platelets deficient in P2Y12 or in the pre- 
sence of P2Y12 inhibitors 
12, 13, is explained by inability of secreted ADP to interact with this receptor 
on neighboring platelets and thereby diminished signaling to platelet procoagulant activity. Lack of 
δ-granules is the underlying cause of the Hermansky-Pudlak bleeding disorder 28. Mice deficient in 
one of the Hermansky-Pudlak genes (Hsp3) show an impaired thrombosis tendency in vivo, but PS 
exposure has not yet been assessed.
 The α-granules store multiple proteins, several of which can support thrombus formation, 
e.g. VWF, fibrinogen, factor V and thrombospondin 29. Mutations in the Nbeal2 gene associate with 
gray platelet syndrome, a rare bleeding disorder characterized by macrothrombocytopenia and the 
absence of platelet α-granules. Mice lacking expression of the Nbeal2 gene have been reported to 
be decreased in both thrombus formation and PS exposure 30. These mice provide an excellent tool 
for further determination of the roles of α-granule proteins in hemostasis, thrombosis and inflam-
mation. 
 Secretion of both α- and δ-granules is increased in CLP36-deficient mice, thus explaining a 
larger thrombus size and higher PS exposure under flow 31. CLP36 is an adaptor protein that binds 
to α-actinin-1 and associates with actin filaments and stress fibers 32. Jointly, these findings seem 
to indicate that both types of secretion granules have additive roles to PS exposure along with 
thrombus formation (Figure 2A).
Regulation of platelet-dependent thrombin generation and fibrin formation
Platelet membranes with exposed PS provide an efficient surface for assembly of the tenase (fac-
tors IXa, VIIIa) and prothrombinase (factors Xa, Va) complexes, accomplishing high thrombin ge-
neration and subsequent fibrin formation 1. Interestingly, genetic ablation or pharmacological inhi-
bition of factors of either the extrinsic (VII) or the intrinsic (XII, XI) coagulation pathways dimin-
ished thrombin generation under stasis (Tables 3-4). Several of the signaling proteins that con-
tribute to GPVI-induced PS exposure under flow have also been shown to control GPVI-mediated 
thrombin generation under stasis, as depicted for GVPI, PI3Kb, Syk, Orai1, STIM1 and P2Y12.
 Platelets bind almost all coagulation factors, including thrombin and fibrin 8. At high shear 
rate in the presence of tissue factor, fibrin is predominantly confined to the core of platelet thrombi, 
which implies platelet support of the extrinsic coagulation system, triggered by the tissue factor/
factor VIIa complex 33. Studies carried out in the absence of tissue factor also point to a role of 
the intrinsic coagulation system via factors XI and XII. In flow studies on collagen with recalcified 
blood, collagen fibers were found to play a dual role, i.e. as a ligand for GPVI resulting in platelet 
activation, and as a substrate for the binding and activation of factor XII 34. Consequently, defi-
ciency in factor XII or XI resulted in a decreased thrombus size, reduced PS exposure, and delayed 
fibrin formation (Table 1). Inhibition of thrombin was even more suppressive 35. On the other hand, 
signaling downstream of P2Y12 amplified these processes 
12, 13. Factor XIIa may also play another 
role, i.e. by directly binding to fibrin and regulating clot structure 36. Jointly, these findings point 
to involvement of both the intrinsic and extrinsic coagulation systems in thrombin generation and 
ensuing fibrin formation at high-shear flow conditions. Furthermore, formed thrombin generates a 
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Figure 2. Signaling pathways implicated in platelet-dependent procoagulant activity, thrombin genera-
tion and clot retraction. (A) Platelets on collagen signal to second messenger generation (PLCg2, CalDAG-GEF1, PKC 
isoforms) and Ca2+ mobilization combined with store-operated Ca2+ entry (STIM1, Orai1) and release of mitochondrial 
Ca2+ via mPTP formation, resulting in sustained high cytosolic Ca2+ levels, secretion and PS exposure. These processes 
are supported by a- and d-granule constituents. The PS-exposing platelets show procoagulant activity by catalyzing te-
nase and prothrombinase activities (see also Figure 1). (B) Continuous inside-out signaling via PI3K, Rap1b and calpain 
leads to sustained αIIbβ3 activation, enabling integrin outside-in mediated actin cytoskeleton reorganization via Rac1, 
RhoA, WASP and talin resulting in clot retraction. Homotypic interactions via connexins, ESAM and JAM-A differentially 
regulate clot retraction, while tetraspanins may directly interact with αIIbβ3. 
positive feed-forward loop to enhanced PS exposure via activation of the PAR receptors on plate-
lets8.
 Classically, insufficiently controlled coagulation is regarded as key mediator of thrombosis un-
der venous shear conditions. Recently, several insights also point to a role of platelets, in interplay 
with VWF and coagulation factors, in the thrombotic process under flow at low, venous wall-shear 
rates. Under coagulant conditions and low shear rate (implying accumulation of thrombin), a fibrin 
network is formed on the platelet surface with an outward-directed star-like appearance 37. This 
focal fibrin formation relies on the VWF-GPIb axis, causing rises in cytosolic Ca2+ and PS exposure 
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37. The signaling mechanism may involve GPIb-dependent changes of the actin cytoskeleton 38, 39. 
Interestingly, the fibrin fibers incorporate thrombin that is relocating from PS-exposing and factor 
Xa-binding platelets 40.
 The role of neutrophils in murine venous thrombosis models is a research topic that recent-
ly received much attention. It was reported that neutrophils, which are trapped in murine veins 
subjected to partial stasis, produce neutrophil extracellular traps (NETs), i.e. large extracellular 
DNA strands fibers surrounded by histones and neutrophil antimicrobial proteins 41. In venous and 
microvascular thrombosis models, NETs formation can be a stimulus and scaffold for the forma-
tion of large thrombi of platelets, fibrin and erythrocytes 41, 42. Furthermore, NETs appeared to be 
formed in the vasculature during sepsis, where they may help to reduce microbial infections 43, 44. 
The underlying mechanisms of platelet responses to neutrophils and NETs have to be elucidated.
Towards understanding platelet-dependent fibrin clot retraction
In hemostasis, the process of platelet-dependent clot retraction provides a means to tighten wound 
edges after clotting 45. Especially under conditions of coagulation and fibrin formation, thrombi that 
are formed under flow can undergo a mechanism of retraction, which can be considered as equi- 
valent to clot retraction 8. However, clot retraction as such has mostly been examined under static 
conditions, e.g. by determining the condensation of a platelet/fibrin clot in thrombin-stimulated 
platelet-rich-plasma. In general, clot retraction is regarded as a platelet response evoked by αIIbβ3 
inside-out signaling, thus implying dependency of (thrombin-induced) αIIbβ3 activation and binding 
of fibrinogen to platelets 46. Table 3 provides an overview of published effects of genetic knockout 
in mouse on clot retraction, while Table 4 gives corresponding data for human blood. Below we 
describe new insights into the molecular mechanisms with emphasis on integrin inside-out and 
outside-in signaling, homotypic platelet-platelet interactions, and the role of the actin cytoskeleton.
Enforcement of αIIbβ3 inside-out signaling
While clot retraction for long has been recognized as a process that reflects integrin outside-in 
signaling, new data provide insight into the underlying signaling events in platelets via activated in-
tegrins. The ADP receptor P2Y12 prolongs integrin activation and platelet aggregation 
47. Continued 
signaling via this receptor (via Gi and PI3Kβ) maintains αIIbβ3 in the active conformation and thus 
prevents platelet disaggregation 48, 49. Likely, similar signaling mechanisms are implicated in clot 
retraction, since mouse platelets lacking integrin β3 or PI3Kβ are impaired in this process (Table 3, 
Figure 2B).
 An enforcement loop that acts in a similar, though weaker way is that of (plasma-derived) 
Gas6 interacting with the platelet Gas6 receptors, also called TAM receptors (Tyro3, Axl and Mer). 
Activation of these receptors by Gas6 supports platelet aggregation and tyrosine phosphorylation 
of the β3 integrin chain, again in a PI3K-dependent way 
47, 50. Overall, TAM receptor signaling can 
enforce the activation of αIIbβ3, and thus help to prevent platelet disaggregation. Platelets from 
mice deficient in one of the TAM receptors have a decreased ability to clot retraction, which sup-
ports a role for Gas6 and its receptors in integrin outside-in signaling (Figure 2B) 50.
 Calcium also play a central role in integrin activation via the Ca2+- and DAG-dependent effec-
tor proteins CalDAG-GEF1 and isoforms of protein kinase C (PKC), which are activated downstream 
of PLCγ2. Activation of Rap1b – via CALDAG-GEF or PKC – promotes the assembly of an activation 
complex with RIAM (Rap1 interacting adaptor molecule) and talin. Cleavage of talin mediated by 
RIAM, calpain and phosphatidylinositol 4,5-biphosphate (PIP2) enables talin binding to the integrin 
β3 chain, thereby activating the integrin and enabling ligand binding 
51. An additional level of regu- 
lation is provided by phospholipase D (PLD) 1 and 2. Both isoforms are present in platelets and 
translocate to the plasma membrane during platelet activation and produce phosphatidic acid to 
stimulate the production of PIP2 
52, 53. Mice deficient in PLD1 display impaired thrombus formation 
and PS exposure due to impaired integrin αIIbβ3 inside-out signaling 
54. 
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Table 3. Mouse proteins and genes involved in platelet-dependent thrombin generation and clot retrac-
tion under stasis. Abbreviations: see Table 1. In addition: CR clot retraction; TG thrombin generation; * also involved 
in PS exposure, see Table 1.
Target protein Perturbation Effect on coagulation Reference
Platelet receptors and membrane proteins
Axl Axl-/- CR ↓ 50
Connexin 37 Gja4-/- CR ↓ 59
Connexin 40 Gja5-/-, 40Gap27 CR ↓ 60
* Cyclophilin D Ppid-/- CR ↓ 22
ESAM ESAM-/- CR ↓ 67
Galectin-1 Lgals1-/- CR ↓ 55
* Integrin αIIbβ3 β3-null CR ↓
95
JAM-A F11r-/- CR ↑ 61
Mer Mer-/- CR ↓ 50
* Orai1 Orai1-/- TG ↓ 17
* P2Y12 cangrelor, ticagrelor TG ↓
11-13
PECAM-1 Pecam1-/- CR = 72
* STIM1 Stim1-/- TG ↓ 17
Tetraspanin 32 (TSSC6) Tspan32-/- CR ↓ 70 
Tetraspanin CD151 Cd151-/- CR ↓ 71
TMEM16F (anoctamin 6) Ano6-/- TG ↓ 96
Tyro3 Tyro3-/- CR ↓ 50
Platelet signaling proteins (kinases/phosphatases)
AMPKα2 Prkaa2-/- CR ↓ 97
PDK1 Pdpk1-/-, Pdpk1 (LOF) CR ↓ 98
* PI3 kinase LY-294002 CR ↓ 76
* PI3 kinase β Pik3cb-null, TGX-221 CR ↓ 75
Protein phosphatase 1 Pp1cg-/- CR ↓ 99
PTP1B Ptp1b-/- CR = / ↓ 100,101
Cytoskeleton linked proteins
Rac1 EHT-1864 CR ↓ 102
Rap1b Rap1b-/- CR ↓ 103
RhoA Rhoa-/- CR ↓ 79
Talin-1 Tln1-null CR ↓ 104
WASP Wasp-/- CR ↓ 81
Platelet signaling proteins (other)
* Calpain Capn1-/- CR ↓ 100
Cbl Cbl-/-, Cbl (LOF) CR ↓ 105
Gas6 Gas6-/- TG = 14
Lnk Sh2b3-/- CR ↓ 106
mTOR rapamycin CR ↓ 107
NF-κB BAY-117082 CR ↓ 108
PER2 Per2-null CR ↓ 109
Phosphodiesterase 3 milrinone TG ↓ 110
* Phospholipase Cγ2 Plcg-/- CR ↓ 111
SHIP1 (PIP3 phosphatase) Inpp55-null CR ↓ 
112
Plasma proteins
* Factor XII F12-/-, CTI TG ↓ 34
* Factor XI F11-/- TG ↓ 34
* Factor VII FVIIai TG ↓ 34
* (Pro)thrombin melagatran TG ↓ 35
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Table 4. Human proteins involved in platelet-dependent thrombin generation and clot retraction coagula-
tion under stasis For abbreviations, see Table 3.
Target protein Intervention Effect on coagulation Reference
Platelet receptors and membrane proteins
IP receptor prostaglandin E1 TG ↓
113,114
G13 protein mSRI peptide CR ↓ 115
Gap junctions carbenoxolone, Gap27, 18β-GA CR ↓ 59
* Glycoprotein VI 9O12 Ab TG ↓ 113,114
* Integrin α2β1 6F1 Ab TG ↓ 
113
* Integrin αIIbβ3 Glanzmann patients, abciximab CR ↓, TG ↓ 
113,114,116
* Orai1 2-APB TG ↓ 18 
* P2Y12 cangrelor, ticagrelor TG ↓ 
12,113,114,117
Platelet signaling proteins (kinases)
* PI3 kinase β TGX-221 TG ↓ 117
SFK PD0173952 CR ↓ 78
Syk Syk inhibitor II TG ↓ 118
Platelet signaling proteins (non-kinases)
Cbl OXSI-2, PP2 CR ↓ 105
Cyclooxygenase aspirin TG ↓ 113
WASP WAS patients CR ↓ 81
Plasma proteins
Factor XII Corn trypsin inhibitor TG ↓ 34
Factor VII FVIIai TG ↓ 34
Fibrin clot retraction is also reduced in these mice, similarly as in mice lacking Rap1b or talin [54, 
103, 104].
 Recently, galectin-1 has been recognized as a new platelet agonist perhaps acting by direct 
activation of αIIbβ3. Galactin-1 binding to platelets evokes common activation signals, such as Ca
2+ 
mobilization, phosphorylation of PLCγ2, Syk of and mitogen-activated protein kinases 55. Mice la-
cking galectin-1 were found to be impaired in clot retraction, likely because of diminished out-
side-in signaling.
Homotypic interactions regulating αIIbβ3 activity
Platelets contain a whole repertoire of receptors and signaling molecules that regulate the for-
mation of tight platelet-platelet contacts and can trigger contact-dependent signaling events via 
homotypic interactions 56. Among these are proteins forming gap junctions via the inter-cellular 
coupling of two hemichannels between adjacent cells 57, 58. Two members of the family of connexins 
– implicated in hemichannel formation – i.e. connexins 37 and 40, are highly expressed in plate-
lets. Knockout (mouse) and inhibitor (human) studies indicated that both connexins participate in 
platelet-dependent clot retraction 59, 60. Surprisingly, however, these connexins also appeared to 
contribute to other activation processes, such as platelet aggregation, integrin activation, Ca2+ sig-
naling and α-granule secretion 59. Hence, it seems that connexins have an overall role in the plate-
let activation process, rather than a specific role in tight junction formation during clot retraction. 
Clearly, more research is needed to elucidate the precise action mechanisms of platelet connexins.
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 Junctional adhesion molecule (JAM)-A is another established molecule exhibiting homotypic 
interactions in platelets 61, 62. Recently, JAM-A was identified as a negative regulator of platelet acti-
vation and, hence, of thrombus formation 61. Along the same line, integrin outside-in signaling and 
clot retraction were increased in mouse platelets lacking JAM-A. Earlier data suggested that JAM-A 
acts as a co-receptor for stimulatory antibodies via interaction with the FcγRIIA receptor on human 
platelets 63, 64. The mechanism proposed is suppression by JAM-A of integrin outside-in signaling 
through downstream protein kinases, such as Src, Syk and focal adhesion kinase 65, 66. An earlier 
suggestion, that JAM-A interferes with fibrinogen binding to the activated integrin, could not be 
confirmed in recent work 61.
 In spite of the examples above, integrin outside-in signaling and clot retraction are not always 
affected in the same ways. In platelets lacking endothelial cell specific adhesion molecule (ESAM), 
spreading on immobilized fibrinogen (reflecting outside-in signaling) was unaffected, while fibrin 
clot retraction was delayed 67. Similarly to connexins and JAM-A, also ESAM is considered to cluster 
platelets via homotypic interactions.
 Platelet integrins form multi-molecular complexes with other membrane proteins such tetra-
spanins. Reported are high expressions of tetraspanin-32, CD151, CD9 and CD63 68. It has been 
suggested that tetraspanins support integrins in the regulation of contact-dependent signaling 69. 
Although the precise molecular mechanism is still unclear, tetraspanin interaction with integrins is 
likely, since deficiency in tetraspanin-32 or CD151 was found to lead to impaired clot retraction 70, 
71.
 Another ‘difficult’ membrane protein in terms of platelet function is PECAM-1. Platelets from 
mice lacking PECAM-1 have been reported as no more than slightly impaired in agonist-induced 
responses, with unchanged clot retraction 72. This is in contrast to an earlier detected inhibitory 
role of PECAM-1 in human platelet function 73, 74. The reason for this discrepancy is unclear. Taken 
together, the various platelet proteins implicated in homotypic interactions seem to contribute in a 
balanced way (positive and negative) to platelet clot retraction, often in a similar way as to integrin 
activation (Figure 2B).
Actin cytoskeleton rearrangement
Traditionally, clot retraction is thought to be a thrombin- and fibrin-dependent process initiated by 
fibrin binding to αIIbβ3. Subsequent actin and myosin cytoskeleton rearrangements generate con-
tracting forces that are transmitted to the fibrin clot (Figure 2B) 75, 76. More recent findings point to 
the existence of a clot retraction mechanism involving Rho kinase and Src family kinases, which 
precedes the actin-dependent process 77, 78. In agreement with this, genetic ablation of RhoA was 
found to diminished clot retraction 79. Furthermore, integrin-dependent phosphorylation by Src and 
Syk kinases of the ubiquitin ligase Cbl leads to the recruitment of  SH2 domain containing proteins 
that mediate platelet spreading and clot retraction 80.
 The Wiskott-Aldrich syndrome, caused by a deficiency in the Wiskott-Aldrich syndrome pro-
tein (WASP), is accompanied with thrombocytopenia and a small platelet size 28. Platelets from 
mice deficient in WASP are decreased in ability to clot retraction, likely because of abnormal actin 
filament formation 81. A similar phenotype is observed in platelets from Wiskott-Aldrich syndrome 
patients.
 In human (thrombin-stimulated) platelet-rich plasma, weakened clot retraction is measured 
upon pharmacological inhibition of αIIbβ3, G13 protein, Cbl or gap junction proteins (Table 4). Taken 
together, the findings with mouse and human platelets may indicate that especially impairments 
in sustained integrin activation, in platelet-platelet contacts or in actin filament formation lead to 
diminished clot retraction. Whether deficient clot retraction is a marker for impaired hemostasis 
(bleeding), is an attractive hypothesis. However, this has not systematically been studied.
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Conclusion
Studies with both genetically modified mice and pharmacological inhibitors indicate that, in col-
lagen-adhered platelets, in part common signaling pathways lead to PS exposure (procoagulant 
activity), generation of thrombin and fibrin, and retraction of the fibrin clot. However, signaling 
events causing prolonged Ca2+ elevation particularly stimulate PS exposure and thrombin genera-
tion, whereas integrin-dependent signaling events rather enforce fibrin clot retraction. Contact-de-
pendent signaling pathways, triggered by homotypic platelet-platelet interactions, seem to act via 
the integrin route.
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Summary
Current antiplatelet and anticoagulant therapies effectively, albeit partly, reduce cardiovascular di-
sease by preventing arterial thrombosis and thromboembolism. However, this ameliorating effect is 
at the expense of increased risk of bleeding. Hence, continued search is needed to find new targets 
for antithrombotics without side effects. Studies in which mice with genetic modification or mice 
treated pharmacology are subjected to experimental in vivo arterial thrombosis, thromboembolism 
and/or in vitro thrombus formation provide unique insight into the roles of hundreds of proteins 
in the thrombotic process. We performed an extensive PubMed search over the years 1980-2013 
to identify such studies. Subsequently, a scoring procedure to quantitatively compare the effect 
of genetic modification or pharmacological inhibition on time-dependent, mass-dependent and 
stability dependent parameters of in vivo arterial thrombosis and in vitro thrombus formation, 
experimental thromboembolism, and tail bleeding time was developed. A meta-analysis of the 
scores for 1080 published mouse studies, representing 315 genes, resulted in 44 genes/proteins 
controlling arterial thrombus formation without affecting hemostasis. Class analysis indicated a 
strong correlation between collagen-dependent in vivo and in vitro models of thrombus forma-
tion. Transfer of the current scores per mouse gene (protein) to human databases indicated that 
a substantial part of the Reactome pathways in the hemostasis field were covered. Analysis using 
human networks further revealed that several of the identified 44 genes were on highly connected 
nodes, suggesting that these may provide effective targets for antithrombotic therapy. In summa-
ry, this work demonstrates that a meta-analysis integrating small size mouse studies: (i) provides 
a contribution to 3R alternative approach for in vivo experimentation, (ii) establishes a high degree 
of homology of murine and human thrombotic processes, and (iii) identifies new molecular targets 
for antithrombotic therapy.
Introduction
Cardiovascular disease, resulting from arterial thrombosis or thromboembolism, is still a leading 
cause of major disability and death worldwide1. Research during the last decades has resulted in 
successful therapeutic means to reduce cardiovascular disease manifestations, e.g. by drugs low-
ering plasma lipids and blood vessel wall tension. In particular, antiplatelet and anticoagulant drugs 
- directed to a dozen of molecular targets - are used for the secondary prevention of thrombotic 
events and infarctions 2, 3. However, while these treatments are effective in thrombosis reduction, 
they have an increased risk of minor or major bleeding as common side effect 4. Hence, there is 
continued interest to search for new targets of drugs that are thromboprotective without causing 
or aggravating hemorrhages. For the identification of such targets, experimental thrombosis mo-
dels using genetically modified mice have appeared to be invaluable 3, 5, 6.
 Up to now, hundreds of mouse studies have been performed to evaluate the molecular 
mechanisms of arterial thrombus formation or thromboembolism in vivo. The majority of this 
work concerns general or tissue-specific genetic modifications or pharmacological interventions, 
resulting in an altered platelet or coagulant function or a modification of endothelial processes. 
Small size reviews, published so far, provide qualitative descriptions of the changes in thrombus 
formation in genetically modified mice 3, 6, 7. This qualitative approach however makes it not easy to 
compare studies using different methodologies. With respect to mouse models of bleeding risk, a 
review of Wei et al. describes the effects of genetic modification on tail bleeding time in relation to 
changed platelet properties 8. Importantly, widely used in vivo mouse models of arterial thrombosis 
and bleeding appear to be sensitive to the majority of antithrombotic drugs with established thera-
peutic efficacy in man. Accordingly, these models may help to identify novel genes that contribute 
to thrombus formation with minimal bleeding risk 9, 10.
 Flow chamber devices operating with isolated blood are increasingly being employed as a 
proxy outcome for in vivo thrombus formation, for instance to assess the effect of gene modifica-
tion on thrombus formation in vitro 11, 12, 13. These in vitro methods not only can serve as alterna-
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tives for in vivo animal experiments (for each of the 3Rs: refinement, reduction and replacement), 
but also are relevant from a translational point of view to investigate effects of new pharmaco-
logical agents. Although there is a need for further standardization for use with human blood 14, 
flow chamber assays have been shown to detect genetic or acquired deficiencies in platelet func-
tion and to sense the efficacy of antithrombotic medication 15, 16, 17, 18. In addition, they provide 
increased knowledge into signaling processes implicated in hemostasis and thrombosis 19, 20.
 In general, published studies on arterial thrombosis or thromboembolism in mice have a com-
mon experimental approach, in that vascular damage is induced by either activation or denudation 
of the endothelium, with in the latter case exposure of the collagen-containing subendothelial ma-
trix. However, experimental procedures of the studies can greatly differ in: the type vascular bed 
used, the type and strength of trigger to disturb the endothelium or provoke thromboembolism, 
the equipment and detection method employed and the parameters used for thrombosis quantifi-
cation. The experimental outcome is furthermore known to be influenced by the high complicity of 
the interventions and the experimental skills of the operating technician 10.
 Considering that repetition of published mouse studies is not desirable for ethical reasons, 
here we hypothesized that analysis of meta-data obtained through systematic quantitative com-
parison of published studies provides additional insight into the cooperation of genes contributing 
to arterial thrombus formation in vivo and in vitro. Furthermore, by comparing the mouse gene 
networks with those recently obtained from human gene sequence variation data, we supposed 
that the murine meta-data provide novel insight into genes regulating human thrombosis and 
bleeding. To this end, we developed and validated a scoring procedure to quantitatively compare 
published studies on murine arterial thrombus formation, thromboembolism and tail bleeding. This 
scoring method provided novel, comparative insight into the roles of 315 mouse genes in exper-
imental thrombosis with or without altered bleeding, and allowed identification of new molecular 
targets for treatment of human cardiovascular disease.
Methods
Selection of papers and definition of studies
A PubMed search over the years 1980-2013 was performed to identify papers on mouse studies 
and arterial thrombus formation. Keywords were mouse & arterial & thrombus, or mouse & throm-
boembolism in different combinations. We searched for primary papers: (i) in English language; 
(ii) describing effects of modification of a specific mouse gene or protein on arterial thrombosis 
formation or thromboembolism; and (iii) providing quantitative data with statistics. Excluded were 
papers not indicating effects of a well-defined genetic or pharmacological perturbation, on venous 
thrombosis models only or containing only qualitative data. A second PubMed search was per-
formed to identify papers describing quantitative effects of genetic modification on tail bleeding 
times (keywords: mouse, tail bleeding, tail clipping, knockout & gene in different combinations). 
Non-tail bleeding times were not included. All papers of the described sets as well as published 
reviews were further screened for additional primary papers.
 Individual studies were identified from the included papers. A study was defined as the quan-
titative measurement of thrombus formation or thromboembolism in vivo or in vitro under a spe-
cific set of conditions (vascular bed, injury trigger, detection method) for a perturbed mouse group 
(genetically modified or pharmacologically inhibited) in comparison to the unperturbed group (cor-
responding wildtype or pharmacological control), such as defined by the authors. Papers describing 
multiple models to measure thrombus formation, e.g. in different vessels or in vivo and in vitro, 
hence, provided more than one study.
Registry of perturbed genes, experimental variables and outcome data per study
An encompassing registry was made of all studies by categorizing these per gene or protein cor-
Genes in arterial thrombus formation and bleeding: translation of meta-data from mouse studies
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responding to that gene. Full data of this registry are given in Suppl. Table 1, also providing all 
primary references (online available only). Basal genetic data were taken from standard databases 
(http://www.informatics.jax.org): gene symbols and names; mouse genome index; chromosome 
location; Uniprot identification number of the corresponding human protein. Listed for each study 
were the: genetic background; type of genetic modification; pharmacological intervention if appli-
cable; mouse phenotype regarding altered activity of platelets, coagulation, fibrinolysis or vessel 
wall.
 Recorded experimental details on the prothrombotic intervention differed per study class 
(Suppl. Table 1). Listed for class I (arterial thrombosis in vivo) were the vessel and type of injury 
and the dosing with the duration of injury. Recorded for class II (systemic thromboembolism in 
vivo) were: type of intervention (unprovoked or provoked by injection of collagen/epinephrine, tis-
sue factor) and the dosing of intervention. Listed for class III (thrombus formation in vitro) were: 
the type of flow device, thrombogenic surface and blood flow conditions (shear rate, presence of 
anticoagulation). With respect to tail bleeding (class IV), only the bleeding time was listed.
 Each study was searched for quantitative information regarding the thrombotic or throm-
boembolic process for the perturbed (genetic modification or pharmacological intervention) and 
unperturbed (wildtype or control) condition. Also recorded were experimental variables (type of 
measurement, fluorescence, Doppler flow, surface-area coverage, etc.). Differences in mean or 
median values between mice with(out) perturbation were listed as statistically significant, if indi-
cated so in the original publication.
Grouping of studies and outcome parameters
Studies were grouped according to major similarities in intervention protocols (Table 1). Groups 1 
to 12 (class I) were defined by the vascular bed and the way of thrombosis induction. The severity 
(dosing or time) of intervention was not used for grouping, as this is often incompletely described 
and is subjected to investigator-dependent operation procedures 10. Groups 20-23 (class II) were 
formed based on the way of (provoked) systemic intervention or the presence of unprovoked 
thromboembolism. Groups 30-34 (class III) were formed, depending on the type of thrombogenic 
surface during in vitro blood flow. Studies of class IV were not sub-clustered.
 The quantitative data were listed per class (Table 1). For in vivo and in vitro thrombus 
formation (classes I and III), measurements were categorized as time-dependent parameters 
(a), mass-dependent parameters (bi: extent of platelet adhesion; bii: extent of occlusion or sur-
face-area-coverage; biii: number, size or volume of thrombi), or stability parameters (c, number 
or frequency of embolic events). For in vivo thromboembolism (class II), data were categorized 
as provoked (d, percentage of survival, time to death, residual platelet count) or unprovoked (e, 
spontaneous thrombosis or bleeding).
Comparing all data by systematic scoring
Per study and parameter, listed quantitative data were scored at a 3-point and 5-point scale (Figure 
1). On the 3-point scale, measurements pointing to a significant reduction or delay in thrombus 
formation (or thromboembolism) after perturbation (genetic modification or pharmacological in-
tervention) were scored as -1; unchanged effects as 0; and measurements indicating a significant 
increase or acceleration of thrombus formation as +1. On the 5-point scale, a further distinction 
was made between data designating a reduced/delayed thrombus formation with <50% (score -2) 
or ≥50% (score -1); and between data indicating an increased/accelerated thrombus formation 
with ≤200% (score +1) or >200% (score +2). Tail bleeding times were scored at 3-point scale 
only: prolonged (-1), unchanged (0), shortened (+1). The original published values and scored 
parameters are given in Suppl. Table 1. Averaged scores per study, gene, group and class were 
rounded off on 3-point or 5-point scale.
C
h
ap
te
r
 8
113
Overrepresentation analysis in Reactome
Overrepresentation analysis of orthologous human proteins, corresponding to the analyzed mouse 
genes, was performed using the Analyze Data tool in the Reactome pathway database 21.
Chromosome mapping and network analysis
Chromosome mapping was done with the Circos program 22. Networks were constructed in Cy-
toscape to explore effects of other human proteins (genes) on arterial thrombus formation and 
bleeding. Networks were constructed using the Reactome pathways as a core set to find potential 
genes that regulate human thrombosis and bleeding; edges were extended by using protein-pro-
tein interactions from the IntAct database to connect all nodes. Pre-established data from human 
GWAS and Thrombogenomics analyses and transcription profiles in human megakaryocytes were 
implemented in the network constructions as well (S. Meacham & W. Ouwehand, unpublished).
Table 1. Cataloging of analyzed mouse studies. Indicated are assignments of studies to classes and groups, as well as 
listed output parameters of thrombus formation, thromboembolism or tail bleeding.
Class I: in vivo arterial thrombosis
Groups compared (1-12)
 Carotid artery injury  FeCl3 (1); photochemical (2); ligation (3); electrolytic (4)
 Aorta injury  compression (5)
 Mesenteric artery injury  FeCl3 (6); photochemical (7); laser (8)
 Cremaster artery injury  FeCl3 (9); photochemical (10); laser (11)
 Other artery/injury  any (12)
Parameters compared (a-c)
 Time-dependent parameters  time to platelet adhesion, time to occlusion or thrombus (a)
Mass-dependent parameters  extent of platelet adhesion (bi); extent of occlusion (bii);
  number, size or volume of thrombi (biii)
Stability parameters  number or frequency of emboli (c)
Class II: in vivo thromboembolism
Groups compared (20-23)
 Provoked (d) injection of collagen/epinephrine (20); tissue factor (21); or other  
  agent (22)
 Unprovoked (e) pre/after birth (23)
Parameters compared
 Thromboembolism parameters percentage death, time to death, residual platelet count (d); 
  unprovoked thrombosis or bleeding (e)
Class III: in vitro thrombus formation
Groups compared (30-34)
 Adhesive surface collagen I (30); collagen III (31); VWF (32), fibrinogen (33); 
   other (34)
Parameters compared (f-h)
 Time-dependent parameters time to platelet adhesion, time to thrombus formation (f)
 Mass-dependent parameters extent of platelet adhesion (gi); surface area coverage (gii); 
   number, size or volume of thrombi (giii)
 Stability parameters number or frequency of emboli (h)
Class IV: bleeding time tail bleeding time
Genes in arterial thrombus formation and bleeding: translation of meta-data from mouse studies
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Statistics and correlation of parameters
Statistics on the effects of gene perturbation on thrombus formation in individual studies were ta-
ken from the original papers. Correlation analysis was performed to compare, per study and class, 
scores of time-dependent, mass-dependent and thrombus stability parameters. The non-parame-
tric Kendall’s Tau-c test was used to determine association or rank correlation. Herein, the Kendall’s 
t value is computed as the excess of tabled concordant over discordant pairs, divided by a term 
representing the geometric mean of untied pairs. It reaches from 0 to 1.0 for tables where all en-
tries are on one diagonal. The statistical package for the social sciences was used for all analyses 
(SPSS version 22, IBM Statistics).
Results and Discussion
Included mouse studies on arterial thrombosis, thromboembolism and tail bleeding
A PubMed search for scientific papers on arterial thrombus formation or thromboembolism in 
mouse over the period 1980-2013 resulted in 1244 publications. Another PubMed search for pa-
pers on mouse tail bleeding resulted in 626 publications. The majority of these papers did not 
describe effects that could be related to a specific molecular target or did not contain quantitative 
information, and hence were not used. In total, 431 papers contained numeral data on effects of 
a that could be linked to a single gene or protein perturbation, and assessed experimental arterial 
thrombosis in vivo (class I), systemic thromboembolism in vivo (class II), thrombus formation at 
arterial shear rate in vitro (class III), or tail bleeding (class IV). These papers as well as published 
reviews were screened for further primary sources, giving another 35 publications. Individual 
studies taken from these papers were defined as interventions using a particular perturbation and 
a particular vascular bed or method. The result was a large database with information on 1080 
different studies, described in 466 publications. For classes I, II, III and IV, this concerned 435, 83, 
182 and 380 studies, respectively (see meta-data in Suppl. Table 1).
Figure 1. Flow scheme used for scoring, calibration and consistency analysis of parameters of in vivo arterial thrombus 
formation (class I), thromboembolism (class II), or in vitro thrombus formation (class III) in mice with genetic modifica-
tion (GM) or treated pharmacologically, in comparison to wildtype (WT) or control condition. Indicated are scoring rules 
of output parameters at 3- and 5-point scales (values for wildtype normalized to 100%). For full description of groups, 
see Table 1.
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In vivo arterial thrombosis (I)
Groups 1-12
Thromboembolism (II)
Groups 20-23
In vitro thrombus formation (III)
Groups 30-34
a. Time-dependent parameters
b. Mass-dependent parameters (i-iii)
c. Stability parameters
f. Time-dependent parameters
g.  Mass-dependent parameters (i-iii)
h. Stability parameters
d-e. Thromboembolism
parameters
Scoring per parameter and study (GM vs. WT, drug vs. control)       
3-point scale 5-point scale
-1 = reduced -2 = reduced  <50%
0 = unchanged (P≥0.05) -1 = reduced   ≥50%
+1 = increased 0 = unchanged (P≥0.05)
+1 = increased  ≤200%
+2 = increased  >200%
Comparison of parameters per study:
- between sub-parameters: b(i-iii), g(i-iii)
- between parameters: a-c, f-h
- in vivo vs. in vitro: mean parameters
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Comparison of mean parameters per gene:
- between groups: 1-12, 20-23, 30-34
- in vivo vs. in vitro: selected groups
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Scoring of parameters of thrombus formation, thromboembolism and tail bleeding per study
Since different methods have been employed in the field to provoke and assess thrombus forma-
tion in mice (Table 1), we developed a procedure allowing quantitative comparison of the out-
come of published studies independently of the method used. Therefore, we scored predefined 
parameters of arterial thrombus formation in vivo (class I) or in vitro (class III) on both a 3-point 
and 5-point scale (Figure 1). The rationale for this is that such scoring indicates a significant de-
crease or increase (3-point); or alternatively, a moderate/strong decrease or moderate/strong 
increase (5-point) of relevant parameters determining the thrombotic process at the perturbed 
condition, i.e. genetic modification or pharmacological intervention. Correlation analysis, applied 
to the database as a whole, indicated significant correlations of three distinguishable mass-depen-
dent sub-parameters within individual studies of class I or class III, both at 3-point and 5-point 
scale, with Kendall’s t ≥ 0.60 (P ≤ 0.029) (Suppl. Table 2A-B). This indicated that subscores can 
be combined into one mass-dependent score per study. Furthermore, correlation analysis pointed 
to an overall high similarity of time-dependent, mass-dependent and stability parameters, again 
within studies (Suppl. Table 2C-D). In class I, these parameters correlated significantly with P < 
0.001, except when comparing the time and stability parameters at 5-point scale (P = 0.063). In 
class III, with lower sample size, the time- and mass-dependent parameters correlated with P = 
0.046 (3-point) or 0.074 (5-point); the stability parameter was hardly in use. Because of this over-
all similarity of intra-study scores, we decided to combine these into one ‘calibrated’ outcome score 
per study (3- or 5-point scale).
 Studies to arterial thromboembolism (class II) were categorized as provoked or unprovoked, 
and scored in a single category (Figure 2). Since tail bleeding times (class IV) were often reported 
to be prolonged for an undefined time, these were scored on a 3-point scale only.
Figure 2. Score distribution of analyzed studies (A, C) and genes (B, D) for classes I-III and IV, as indicated. Scoring 
was at 3-point scale (A, B) or 5-point scale (C, D). Represented are numbers of studies and genes per class for mice 
with a loss-of-gene-function. Note that studies using mice with non-comparable genetics (for example, gain-of-function 
mutations) are not included.
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Consistency of scores per gene within classes and experimental groups
The large database size allowed analysis of the consistency of the combined scores per study. 
Since a large number of papers included class I or II in vivo studies together with class III in vitro 
studies using the same breeding of animals, we compared the scores in these classes per paper. 
This gave for both class I (P < 0.001, n = 87) and class II (P ≤ 0.012, n = 12) significant correla-
tions at 3- and 5-point scales (Suppl. Table 3A). Hence, for the database as a whole and within 
papers, the study scores for in vitro thrombus formation corresponded well to these of in vivo 
arterial thrombosis and thromboembolism.
 To compare the scores for different thrombosis models, studies were grouped according to 
key experimental variables, in particular the type of artery and the method to provoke vascular 
injury (Table 1). In class I, the mostly used vascular beds were carotid artery > mesentery > cre-
master > aorta; while the most popular injury method declined with FeCl3 > laser > photochemical 
reagent > vessel ligation or compression > electrolytic (Suppl. Figure 1A-B). In class II, the majo-
rity of studies used injection of collagen/epinephrine, with fewer studies using tissue factor or 
other injection or reporting unprovoked thrombosis (Suppl. Figure 1C). Concerning class III, the 
majority of studies used collagen-I as thrombogenic surface (Suppl. Figure 1D). Class IV studies 
were not sub-divided.
 Murine thrombosis studies are usually carried out at small sample sizes (n = 6-12). Hence, 
in comparing groups and classes, we averaged the scores from different papers with mice with 
equivalent genetic modifications (or pharmacological interventions) without weighting. The matrix 
of average scores per group indicated that numbers were mostly too low for statistical comparison 
of individual groups (Suppl. Table 4). Therefore, we performed this analysis for combinations of 
groups, clustered per type of vessel or type of injury. Markedly, scores (averaged per gene) of stu-
dies using the carotis, mesentery or cremaster correlated significantly at 3-point and 5-point scales 
(Table 2). With respect to injury type, scores for FeCl3 injury correlated significantly with those 
for laser or photochemical injury only at 3-point scale. This significance was lost at 5-point scale, 
which is compatible with the evidence that the determinants of collagen-dependent (i.e. FeCl3 or 
ligation/compression) and collagen-independent (i.e. laser or photochemical) thrombosis models 
are partly different22, 23.
 To take this further, we compared the scores (averaged per gene) of collagen-(in)dependent 
in vivo studies of classes I-II with those of class III studies, i.e. thrombus formation on collagen 
in vitro. As indicated in Table 3, this resulted in highly significant correlations for studies using the 
carotis or mesentery, and in less significant correlations for cremaster studies (with frequent laser 
injury, Suppl. Figure 2). Per injury type, correlations were again stronger for studies using FeCl3 
or ligation/compression injury (collagen-dependent) than for studies with laser or photochemical 
injury. For thromboembolism (class II), scores for studies using collagen/epinephrine injection 
correlated well with those of collagen-dependent thrombus formation in vitro (P ≤ 0.032).
Comparing roles of genes in arterial thrombus formation, thromboembolism and tail bleeding
Given the overall agreement of scores per gene, when comparing groups and classes, we conclu- 
ded that, for the database as a whole, the effect of gene modification is larger than the variation 
caused by differences in methodology or measurement parameters. This is a marked result, indi-
cating overall consistency between the various in vivo and in vitro thrombosis models, regarding 
determination of an antithrombotic or prothrombotic phenotype. The 5-point scores typically dif-
fered from the 3-point scores in that the former were more influenced by the known collagen-de-
pendency of the thrombosis model. Since the 5-point (class) scores are more discriminative in 
comparing the roles of different genes in arterial thrombus formation or thromboembolism, these 
were used for further analyses. 
 By combining scores from studies per gene and class, quantitative information was obtained 
on the process of thrombus formation or thromboembolism for 194, 64 and 97 genes in classes I, 
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Table 2. Correlation of study scores between in vivo thrombus formation (class I) with different vascular beds and dif-
ferent triggers (indicated groups). Kendall’s Tau-test for 3- and 5-point scoring scales. Indicated are groups compared 
and numbers (N) of genes compared. For description of groups, see Table 1.
 Groups N  3-Point scale 5-Point scale
    Kendall’s τ	 		P Kendall’s τ	 		P
Compared to carotis (1-4)
  Mesentery 6-8  39 0.86 <0.001 0.57 <0.001
  Cremaster 9-11  20 0.82   0.019 0.55   0.010
Compared to FeCl3 (1,6,9)  
  Laser 8,11  27 0.75 <0.001 0.17   0.293
  Photochemical 2,7,10  18 0.44 0.048 0.36   0.062
  Ligation & compression 3,5  17 0.38 n.d.* 0.40   0.050
*Not determined (constant variable).
Table 3. Correlation of scores for in vivo thrombus formation (indicated groups) with in vitro thrombus formation on 
collagen (group 30). Kendall’s Tau-test for 3- and 5-point scoring scales. N, number of genes compared. For description 
of groups, see Table 1.
Compared to group 30 Groups N  3-Point scale 5-Point scale
    Kendall’s τ	 		P Kendall’s τ	 		P
Class I all (1-12)  71 0.66 <0.001 0.58 <0.001
  Carotis 1-4  46 0.63 <0.001 0.49 <0.001
  Mesentery 6-8  34 0.80 <0.001 0.63 <0.001
  Cremaster 9-11  22 0.51   0.020 0.34   0.076
  FeCl3 1,6,9  53 0.57 <0.001 0.53 <0.001
  Laser 8,11  23 0.75 <0.001 0.40   0.039
  Photochemical 2,7,10  18 n.d.* n.d. 0.21   0.519
  Ligation & compression 3,5  10 0.68 <0.001 0.56   0.010
Class II all (20-23) 23 0.66 0.001 0.30   0.099
  Collagen/epinephrine 20 10 0.97 <0.001 0.64   0.032
*Not determined (constant variable).
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Figure 3. Forest Plot
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Figure 3. Forest Plot (continuous)
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Figure 3. Forest Plot (continuous)
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Figure 3. Forest plot of scored studies on effects of gene modification or drug intervention on murine arterial thrombo-
sis (classes I-III, 5-point) or tail bleeding (class IV, 3-point). Each bullet refers to a single published study. Mouse genes 
are ordered alphabetically according to current nomenclature. For full names, mean values and relevant phenotypic 
changes, see Suppl. Table 5. Open bullets refer to a gain-of-gene-function study, scored as if it concerned loss-of-func-
tion. Score legend: -2, strongly reduced thrombosis; -1, reduced thrombosis or prolonged bleeding time; 0, unchanged 
thrombosis or bleeding time; +1, increased thrombosis or shortened bleeding time; +2 strongly increased thrombosis.
II and III, respectively (Figure 2B). Scores for bleeding times (class IV) were listed for 240 genes 
(Figure 2D). For all classes together, information was obtained on 315 genes (Suppl. Table 1). As 
indicated in Figure 3, showing an overview of all study scores for each of the 315 genes, in the 
majority of cases scores clustered towards an antithrombotic (scores -2, -1), unchanged (score 0), 
or prothrombotic (scores +1, +2) phenotype, regardless of the study class. An extensive list with 
overall scores per gene of class I-III and class IV is given in Suppl. Table 5, also providing addition-
al information on the effect of genetic modification on platelet and coagulant functions.
 For 25 of the most investigated genes (n ≥ 6 studies, 86% collagen-dependent models), we 
analyzed the score distributions (Figure 4A). Acknowledging different effect sizes of these genes 
and assuming this independent of class and group, the chance of ‘correct’ final score was calcula- 
ted as a function of the number of most frequently included studies (Figure 4B, C). This prediction 
analysis indicated for one study a median probability to obtain a correct answer of 0.83 (3-point) 
or 0.50 (5-point). For two studies of the same gene, the median probability was 0.98 (3-point) or 
0.85 (5-point). Overall, for obtaining a ~85% chance of correct answer, a single study is sufficient 
when scored at 3-point scale, and two studies appear to be required when scored at 5-point scale. 
Based on this analysis, use of the 5-point scale becomes most useful with data from two studies 
available.
 Particularly interesting for the thrombosis field are those genetic modifications that lead to 
reduced arterial thrombosis (negative scores) without increased bleeding. In the current data-
base, as many as 44 genes contribute to such a phenotype (Figure 5). On the other hand, gene 
modifications resulting in shortened bleeding times were in 11 out of 12 cases accompanied by 
a prothrombotic tendency (positive scores). Further analysis indicated that a -2 score was more 
frequently (79%) accompanied by bleeding prolongation than a -1 score (51%). This underlines 
the hypothesis that a more severe reduction in arterial thrombus formation is more likely to result 
in a bleeding phenotype. 
 Chromosome mapping indicated even distribution of positive and negative scores on all chro-
mosomes with the exception of chromosome 3, 5, 6, 15, 18 and X. Genes located on chromosome 
3, 5, 6, 15 and X were almost all exclusively associated with an antithrombotic tendency and thus 
an increased risk for bleeding, while genes located on chromosome 18 were associated with a 
prothrombotic phenotype. Genes located on chromosome Y are involved in male development and 
are as such not involved in thrombosis and hemostasis. (Suppl. Figure 3).
Translation to human cardiovascular disease and bleeding
For translation of the scored mouse data to the human situation, first an overrepresentation ana- 
lysis was performed using the Reactome database, which is a curated knowledgebase of biological 
pathways, including human megakaryocytes and platelets 24. Comparing all proteins, orthologous 
to the corresponding human genes, this analysis indicated that a substantial and significant part 
of the hemostasis pathway was covered (Figure 6). Well-covered sub-pathways included the gam-
ma-carboxylation of coagulation factors, G-protein coupled receptors and signaling, as well as se-
veral protein tyrosine phosphorylation and phospholipase sub-pathways. Human Reactome analysis 
of proteins corresponding to mouse genes, scored for arterial thrombosis (class I-III) or bleeding
(class IV), indicated that the majority of the above-mentioned pathways are over-represented in 
the thrombosis studies (Suppl. Figure 4). 
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Figure 4. Ranking of 25 most frequently studied mouse genes for effects on arterial thrombosis tendency in vivo or in 
vitro. (A) Summative study scores per gene for classes I-III; also given are the mean bleeding scores (class IV). Data 
come from 216 studies (87% collagen-dependent models; 9% laser models, 3% photochemical injury). (B, C) Prediction 
of correct score, assuming that only one (B) or two (C) studies are known for each of the 25 genes (3-point or 5-point 
scale, as indicated). Given are histograms of probability deciles and median values.
 The Reactome database was also used as core set for construction of a network of ortholo-
gous human genes (Suppl. Figure 5). Searching for nodes connected to at least to nodes with 
negative scores for thrombus formation resulted in 18 genes, of which 11 have been implicated in 
platelet and/or integrin activation or coagulation (BCAR1, CD2AP, CRK, FADK1, FGA, FGFR2, GGCX, 
IRS1, NPHS1, SPAG9, TEK).
 A more extended network analysis, also using datasets from GWAS, Thrombogenomics anal-
yses and transcription profiles in human megakaryocytes, was performed to compare the mouse 
scores for 44 genes (proteins) which contribute to thrombus formation without effect on bleeding 
time (Figure 7). Phenotyping evaluation indicated that the majority of the corresponding proteins 
are involved in platelet activation (receptors, signaling or granule release), while other proteins 
have a role in the coagulation process (Table 4). On the other hand, interestingly, genes that con-
tribute to the halt of bleeding but not to thrombus formation in part have a regulatory role in the 
platelet actin cytoskeleton and the vascular endothelium (Table 4).
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Table 4. Orthologous human genes, translated from scores of mice with reduced arterial thrombosis without bleeding, 
or prolonged bleeding without reduced arterial thrombosis. Genes are classified according to altered processes in the 
genetically modified mice.
Process    Human gene (orthologue)
Antithrombotic, no prolonged bleeding
Coagulation (plasma)   F12, F11, KNG1, LEPR, SERPINE1, SERPINE2
Platelet aggregation (plasma) FN1, GAS6, VTN
Platelet-granule released  PF4
Platelet receptor   CD36, CLEC1B, FCGR2B, GP6, ITGA2, ITGA6, ITGB1, LRP1,  
      P2RX1, SELP
Platelet signaling   AKT2, CAPN1, FYB, GNA12, HCLS1, LIMK1, LYN, MAPK14,   
      PIK3CG, PLD1, PPIA, PRKCA, PPP1CC, PPP1R9B, PRKAA2,   
      PRKD2, PTPN6, RHOG, SGK1, SH2D1A, SLAMF1, SMPD1
Unknown    Hmtb11 (mouse QTL)
Prolonged bleeding, not antithrombotic
Endothelial activation   NOS2, PTGS1, PTGS2
Platelet cytoskeleton   CDC42, VCL
Platelet-granule released  THBS1
Platelet signaling   AKT1
Figure 5. Effects of gene deficiencies on arterial thrombus formation or thromboembolism (5-point scale, classes I-III), 
in combination with a prolonged (-1), unchanged (0) or shortened (+1) tail bleeding time. Shown are numbers (A) and 
proportions (B) of analyzed genes.
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Figure 6. Reactome hierarchical over-representation analysis of orthologous human proteins corresponding to mouse 
genes with scores for arterial thrombus formation and/or bleeding. Numbers per pathway (Reactome event) are given. 
Each event is coloured according to the probability of seeing the given number or more proteins in this pathway by 
chance. The top-level (root) pathways are ordered according to the lowest p-value of their components. Total number 
of events assessed was 5187, number of matching events was 379, number of proteins (genes) matching submitted 
identifiers was 105.
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Figure 7. Visualization of mouse genes implicated in arterial thrombosis (A) or bleeding (B) using extended network 
of orthologous human genes. Human gene network was constructed copy from GWAS and Thrombogenomics analyses 
and transcription profiles in human megakaryocytes. Highlighted are positions of genes mentioned in Table 4. Color key 
of nodes for A is on the 5-point scale, for B on the 3-point scale. Grey lines are the edges coming from IntAct (protein 
interactions). The size of the nodes is based on the amount of mouse studies performed per gene perturbation. High-
lighted genes are 44 genes as indicated in table 4.
Conclusions
Mouse experimental arterial thrombosis studies, performed in a translational research context, 
have in common several characteristic features, such as genetic homogeneity, small sample size, 
controlled experimental conditions, and real-time monitoring of the thrombus or thromboembo-
lism. On the other hand, the mode and target vessel of injury as well as the recording of output 
parameters can differ greatly from laboratory to laboratory 10. In the present paper, we show that 
uniform scoring of the effect of genetic modification on the thrombotic process is feasible and 
provides better insight in the suitability of different experimental models. Given the similarity in 
scorings, between models and classes, the present meta-analysis points to an overall compara-
ble molecular regulation of the thrombus-forming process in different arterial beds, and even for 
systemic (collagen-induced) thromboembolism. On the other hand, the scoring on 5-point scale 
reveals particular differences between known collagen-dependent and -independent thrombosis 
models. The latter models (laser or photochemical injury) are more dependent on tissue factor 
with mild endothelial damage and less on collagen exposure, although this may depend on the 
severity of the trigger 22, 23, 25. In human disease, collagen exposure due to atherosclerotic plaque 
rupture is considered to be an important factor in arterial thrombus formation 26, 27, but which of the 
current mouse models are best predictive for human thrombotic disorders is still unknown.
 Given the currently limited molecular targets for treatment of cardiovascular disease, the 
present meta-analysis points to a wealth of novel candidate target proteins with a role in murine 
arterial thrombosis and/or hemostasis. Mostly, these are genes modulating functions of platelets, 
blood lipids, coagulation or fibrinolysis, but also genes regulating the vessel wall; it is to be ex-
pected that especially the latter list will grow in the near future. Systematic analysis elucidates 44 
genes encoding for such proteins that markedly affect arterial thrombosis and/or thromboembo-
lism in mouse without affecting hemostasis.
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 The present analysis furthermore shows that, at least for collagen-dependent thrombosis 
models, ex vivo measurement of thrombus formation using flow chambers can be used as a proxy 
test for measurements in vivo. This finding may in several ways support 3R animal alternatives 
approaches to limit in vivo cardiovascular research by: (i) providing quantitative information on 
effects of new genetic modification and multiple gene deficiencies, in order to replace in vivo ex-
periments; (ii) defining when small-volume ex vivo flow assays are valid alternatives for in vivo 
thrombosis measurement, thus reducing numbers of tested animals.
 Transfer of the current scores per mouse gene (protein) to human databases indicated that a 
substantial part of the Reactome pathways in the hemostasis field were covered. Network analysis 
further revealed that several ‘hotspots’ where the (mouse) genes appeared on highly connected 
nodes, suggesting that these also play a role in human cardiovascular disease. In summary, this 
work demonstrates that a meta-analysis integrating small size mouse studies: (i) provides a con-
tribution to 3R alternative approach for in vivo experimentation, (ii) establishes a high degree of 
homology of murine and human thrombotic processes, and (iii) identifies new molecular targets for 
antithrombotic therapy.
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Chapter 9
General discussion
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The goal of this thesis was to untangle the process of thrombus formation in a systematic way. By 
using novel tools of systems biology, it has been possible to clarify the roles of multiple platelet 
receptors, interacting with key adhesive substrates of the vessel wall, in thrombus formation under 
flow. Also by developing scoring tools to compare the process of thrombus formation in vivo and 
in vitro from published mouse studies, new insights could be obtained with relevance for human 
cardiovascular disease.
Advances in the measurement of whole blood thrombus formation
An advantage of the use of flow chamber devices is that they give information on platelet and 
coagulant functions of one blood sample under flow conditions. The recent introduction of small-
sized microfluidic flow chambers is a major step forward, as these need only small blood samples 
1-3. As described in chapter 2, the so-called PDMS microfluidic chambers, which are customer made 
and occur in multiple designs, have the potential of generating high-throughput data on throm-
bus formation. However, since these chambers differ from laboratory to laboratory (for instance 
with multi-channels or discontinuous immobilized thrombogenic surfaces), they are only poorly 
standardized. This also holds for the few commercial flow devices, e.g. the Ibidi, Venaflux, Cellix 
or Bioflux systems4. The conventional Maastricht flow chamber is used in our laboratory in many 
studies with human and mouse blood 5-8 and is also employed in other laboratories 9. In the present 
thesis, we choose for this chamber in the development of a high-throughput flow assay. As de-
scribed in chapters 3-4, this resulted in a test in which the activity and thrombus-forming potential 
of platelets from one individual subject can be tested on an array of microspot surfaces. Moreover, 
the testing can be performed at both arterial or venous flow shear rates. As such, this test is fast 
and has a higher throughput than the current golden standard test for platelet function, i.e. light 
transmission aggregometry. The latter only determines light transmission changes due to platelet 
shape change and aggregation and operates in the absence of flow. 
 The developed microspot flow test clearly provides valuable and new information, but it 
also has some disadvantages. First, it requires the presence of a high-resolution microscope and, 
hence, operation by experts. Second, some of the parameters (fluorescence markers) still had a 
relatively high inter-assay variation. Further refinement of the staining protocols will be needed 
to reduce this variability. A third point of concern is the not always optimal quality of the blood 
samples - in spite of all precautions taken -, implicating that more attention will need to be paid to 
preserve platelet functions while drawing the blood.
Thrombus formation unlocked as a multi-receptor and multi-factorial process
Current knowledge is that platelet interaction with multiple receptors is required for stable adhe-
sion under flow conditions 8, 10. Earlier work has mostly concentrated on the synergy of the collagen 
receptors, glycoprotein VI (GPVI) and integrin α2β1, and the von Willebrand factor (VWF) receptors, 
glycoprotein Ib-V-IX (GPIb) and integrin αIIbβ3, in thrombus formation
 6, 9, 11, 12. In chapter 4, we 
applied for the first time systems biology techniques to compare the roles of these receptors with 
other adhesive platelet receptors in thrombus formation.
 Unsupervised hierarchical cluster analysis allowed the systematic comparison of the effects 
of 52 surfaces interacting with combinations of these four and other adhesive receptors (CLEC-2, 
α6β1, CD36, α5β1, αvβ3). The analysis pointed to clustering of the surfaces into three types, i.e. gi-
ving rise to the formation of type I, II or III thrombi at high shear rate. As schematized in Figure 
1, type I thrombi are formed on surfaces at which only few platelets adhere. Surfaces forming type 
II thrombi induce extensive platelet adhesion with intermediate platelet activation and aggregate 
formation, while surfaces forming type III thrombi produce large aggregates of fully activated 
platelets. It could be established that the clustering into these three types of thrombi was robust 
and relatively independent on the selection and composition of the surfaces. This recognition 
made a following step possible, namely to define which combinations of adhesive proteins – and 
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thus which platelet receptors – are required for the formation of full-size, type III thrombi under 
high-shear flow conditions. Overall, to form full thrombi, we found that a synergy is needed of the 
high shear-dependent vWF receptor GPIb, the major integrins α2β1, α6β1 or αIIbβ3 and the signaling- 
linked receptors GPVI or CLEC-2. Herein, the roles of α5β1, αvβ3 and CD36 were relatively minor.
In chapters 4 and 6, we provide several pieces of evidence for a major contribution of platelet 
granule secretion to the process of thrombus formation. Patients with gray platelet syndrome and 
Hermansky-Pudlak syndrome are characterized by a deficiency in the presence of α- and dense 
granules, respectively. In chapter 4, the defect in gray platelet syndrome was confirmed by a re-
duced P-selectin expression after thrombus formation. Also in a patient with Hermansky-Pudlak 
syndrome, thrombus formation was decreased on various surfaces. 
 Interestingly, a patient with severe combined immunodeficiency (SCID)13, associated with an 
almost complete defect in store-induced operated calcium entry in hematopoietic cells including 
platelets, showed an increase in CLEC-2 and GPVI-dependent platelet activation, which suggests 
the presence of a compensatory mechanism for the defective calcium entry. In comparison, in a 
patient with May-Hegglin anomaly (actin-myosin cytoskeletal defect and macrothrombocytopenia), 
we found a decrease in mostly GPVI-dependent thrombus formation.
Another relevant finding was the relatively strong role of integrin α6β1 in thrombus formation. Lami-
nin has shown to be a major extracellular matrix component, supporting the interaction via α6β1 on 
platelets 14. Recent evidence indicates that laminins are also stored in platelets,15 implicating that 
secreted laminin may support the buildup of a thrombus via α6β1 interactions.
 In chapter 6, we describe a role for the thrombospondin-1 - CD36 axis in collagen-dependent 
thrombus stabilization and thrombus formation. Similarly to laminin, thrombospondin-1 is also pre-
sent in the vessel wall and is released from the α-granules in platelets16. Using murine Cd36-/- and Tsp-
/- platelets, we found that especially platelet procoagulant activity and thrombus stabilization were 
decreased in the absence of these proteins. In comparison, in Nbeal2-/- mice, which completely lack 
α-granules, an even stronger effect has been seen, including impaired adhesion, reduced procoagulant 
activity, diminished thrombus formation and increased thrombus stability 17. It should be noted in this 
context that both thrombospondin-1 and CD36 also have other interaction partners than each other.
Platelet activation also depends on the activity of the endothelium. For instance, the resting endo-
thelium produces sufficient amounts of prostacyclin and nitric oxide to keep flowing platelets in an 
inactivated state. The protein vWF plays a more complex role in the interactions of platelets and 
endothelial cells. Although platelets also contain some vWF, the endothelium is the largest source of 
this multimeric glycoprotein 18, 19. VWF is cleaved by the plasma protease ADAMTS-13, while throm-
bospondin-1 can protect vWF from cleavage 20. Especially long vWF multimers appear to be most 
adhesive for platelets, if extended at high shear shear on microvascular cells or exposed collagen21.
 Cleavage of VWF multimers in the A2-domain by the protease ADAMTS-13 takes place in an 
asymmetric way, resulting in multimers with slower, intermediate or faster migrating triplet bands. 
The slower migrating (larger size) triplet bands of VWF multimers contain an additional 140 kDa 
N-terminal peptide fragment, which is missing for the faster migrating triplets18. Our data in chap-
ter 5 indicate that a preparation of VWF with extra N-terminal peptide sequence of the A2 domain 
had a significant higher binding affinity for recombinant glycoprotein Ib. The same fraction was 
also more active in supporting thrombus formation on collagen under a variety of conditions. These 
results thus indicate that the larger size VWF triplet bands, containing an extra N-terminal peptide 
sequence, are most potent in thrombus formation under arterial flow conditions. This is a relevant 
finding, since changes in the extent of VWF cleavage by ADAMTS-13 may result in von Willebrand 
disease 22 or thrombotic thrombocytopenic purpura23.
Identifying platelet function defects
As described in chapter 4, clustering and arranging of the big dataset for 52 thrombogenic sur-
faces and 8 platelet function outcome parameters led to the identification of the most informative 
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Figure 1. Three types of thrombi formed at high shear rate. Different stimuli, i.e. components that are release 
from platelet granules, vascular components or shear, trigger the formation of different types of thrombi. Type I thrombi 
consist of single adhered platelets (gray) with limited activation. Type II and type III thrombi require first interaction of 
platelet GPIb with VWF. Type II thrombi display intermediate platelet adhesion and activation, evoked by GPVI, CD36 
and/or integrins. Type III thrombi show high adhesion and activation via GPVI or CLEC-2 and/or all integrins. Procoagu-
lant platelets (brown) are almost absent in type II thrombi in comparison to type III thrombi. Underneath every throm-
bus type, the corresponding thrombogenic surfaces are indicated. Left arrow indicates direction of flow. Color bars: blue 
= low, green = intermediate, red = high. 
variables of this process. The cluster analysis resulted in a robust selection of nine surfaces and 
six parameters, which can be used to determine the involvement of all key platelet receptors in 
thrombus formation. Establishment of the intra- and inter- individual variation for these 9 x 6 test 
variables pointed out that there was a marked subject-dependent contribution to almost all of 
these variables. This suggested that aberrant platelet activity in patients with bleeding or a pro-
thrombotic propensity may well be detected. Similar observations have been made by others in 
flow studies using microfluidics devices. Herein, whole blood from healthy subjects, who received 
aspirin or ADP inhibitors, was perfused over a collagen surface, and marked inter-individual varia-
tion was observed in the amount of platelet deposition before and after intake 24, 25.
 As described in the previous section, defective thrombus formation could indeed be detected 
in several patients with rare bleeding disorders. The most discriminative surfaces in this respect 
were combinations of vWF with rhodocytin, GFOGER-(GPO)n peptide or collagen I. The recording 
of multiple parameters gave a kind of platelet “phenoprint’’ of general (platelet aggregation) and 
specific (platelet P-selectin and phosphatidylserine exposure) responses per type of surface, and 
hence type of receptors. In chapter 7 we have provided an in-depth overview of the genes that 
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play a role in platelet phoshatidylserine exposure during thrombus formation. 
 The data of chapter 4 accordingly point to a clinical potency of the microspot test. We see 
a wide range of possible applications, including (i) the detection of increased platelet activity in 
patients with acute cardiovascular infarction or otherwise increased risk of arterial thrombosis, 
(ii) the monitoring of the efficacy of antithrombotic treatment of patients, (iii) the identification 
and treatment of platelet dysfunction or thrombocytopenia, and (iv) the determination of the risk 
of bleeding in patients undergoing fluid dilution during or after major invasive surgery. A further 
development of the flow assay would be to make it microscopic-independent. An interesting pos-
sibility is to use the newly developed lens-free computational microscopic systems in combination 
with our microspot flow device 26, 27.
Translational aspects in thrombosis and hemostasis
Chapter 8 describes a meta-analysis to evaluate the outcomes of published in vivo and in vitro 
studies of murine thrombus formation at arterial shear stress with the help of a novel calibration 
method. This provided insight into the roles of 315 mouse genes in arterial thrombosis with or 
without bleeding, and enabled us to compare the various methods and to identify new human 
targets for treatment of cardiovascular disease. For the meta-analysis, we used a three-point and 
five-point scoring scale to compare the effects of genetic modifications in different publications. 
The five-point scale was more discriminative in distinguishing a moderate or strong increase or 
decrease in thrombus formation, and appeared to be most valuable when at least two study scores 
of the same gene were available. Detailed statistical analysis indicated that the type of vascular 
bed did not influence the study score. In contrast, the type of injury appeared to be of influence, 
in that the scores for laser and photochemical injury compared well with those of FeCl3 injury, but 
only at the three-point and not at the five-point scale.
 Another relevant finding was that strong correlations were obtained between the scores per 
gene for studies of in vivo thrombosis (including thromboembolism) and studies of in vitro throm-
bus formation. This is explaining by the fact that for a considerable part both the in vitro and the 
in vivo studies are collagen-dependent. Thus, in either case the thrombosis process is triggered 
by the exposure or presence of collagen fibers. Interestingly, the meta-analysis led to the iden-
tification of 44 genes, which played a role in murine arterial thrombus formation, but were not 
implicated in tail bleeding. Translating these data to a network of human genes, involved in platelet 
function or cardiovascular disease, showed that most of the 44 genes were located on highly con-
nected nodes, thus suggesting that these can be regulating targets for antithrombotic therapy with 
a limited role in hemostasis. Such therapy may lead to a reduced risk of cardiovascular disease, 
without bleeding as unwanted side-effect. Although we must realize that animal models cannot al-
ways predict of what is occurring in man 28, the present meta-analysis clearly indicates that animal 
research is of advantage in the field of thrombosis and hemostasis.
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Platelets play a crucial role in thrombosis and hemostasis. They contribute to the cessation of 
bleeding by rapid adhesion to the arterial vessel wall at sites of endothelial injury. Uncontrolled 
platelet activation after rupture or erosion of an atherosclerotic plaque can lead to vessel occlusion 
and result in a heart attack or stroke. Intravascular thrombus formation is a dynamic process, 
where platelets adhere to collagen, become activated, secrete, aggregate and contract. Other cells 
from the blood and vessel wall as well as plasma components like the coagulation factors and the 
blood flow conditions have a modulating role herein. In this thesis several aspects of the process of 
thrombus formation have been studied in detail, and systems biology approaches have been used 
as a strategy to analyze and compare the involvement of the many-fold sub-processes. 
 Chapter 1 provides relevant background information on platelet activation and thrombus 
formation. It is described that platelet-adhesive components of the vessel wall other than collagen 
can also trigger thrombus formation. Yet, the traditional model of thrombus formation is still based 
on collagen exposure. In addition, a number of adhesive proteins, which are stored in the platelet 
α-granules such as von Willebrand factor (VWF) and thrombospondin-1, may also play a role in 
thrombus formation, but this has not been explored. Also addressed is how flow chamber assays 
can be used to measure thrombus formation, and what the possible clinical relevance is of such as-
says. The chapter ends with introducing some techniques used in systems biology. This approach 
has a great potential in the handling of ‘big data’ in the field of thrombosis and hemostasis.
 Commercial and custom-made parallel-plate flow chambers are more and more used for 
studies of platelet activation and thrombus formation in whole blood at arterial or venous shear 
rates. Chapter 2 highlights the technical progress that has been made by developing microfluidic 
devices composed of polydimethylsiloxane. With the introduction of this material it has become 
possible to downscale the dimensions of the flow channels and, thereby, the blood volume nee-
ded per flow assay. This chapter furthermore describes that both the commercially available flow 
devices and the custom designed specimens lack standardization, which impairs their suitability 
for (pre)clinical testing of thrombus formation. In the following chapters, various directions are 
proposed for extension and standardization of the conventional flow chamber measurements, for 
instance by using a defined array of platelet-adhesive surfaces and by employing high-throughput 
data analysis.
 In chapter 3, standardized protocols are provided for usage of the Maastricht parallel-plate 
flow chamber to assess thrombus formation on different types of platelet-adhesive, thrombogenic 
surfaces. Detailed information is given on the way of application of adhesive proteins as microspots, 
the preferential way of blood drawing, the required flow perfusion protocols, as well as lists for 
trouble shooting. For several (confocal) fluorescence microscopic systems, methods are given for 
the capturing of brightfield and fluorescence images to determine (stable) platelet adhesion in real-
time, and to assess endpoint parameters of thrombus formation, such as the platelet activation 
status (fibrinogen binding, P-selectin expression and procoagulant activity), and the thrombus size 
and morphology (morphological score, integrated feature size, platelet deposition and thrombus 
volume). Relevant details on software packages and macros for image processing and calculations 
are provided as well.
 According to the classical model of collagen-based thrombus formation at high wall-shear 
rate, initial platelet rolling occurs via the interaction of glycoprotein Ib-V-IX (GPIb) with colla-
gen-bound VWF. Activation of the platelets is accomplished by interplay of the collagen receptors, 
glycoprotein VI (GPVI) and integrin α2β1, while platelet-platelet interactions are mediated by inte-
grin αIIbβ3. However, platelets expose many other adhesive receptors that may also play a role in 
thrombus formation. In chapter 4 we describe the development of a multi-surface and multi-pa-
rameter flow chamber assay to characterize the process of thrombus formation by taking into 
account all abundantly expressed platelet-adhesive receptors. For this assay, we used whole blood 
from healthy subjects and several patients with platelet function defects. Altogether, we compared 
52 adhesive surfaces (with known receptor interactions) and eight output parameters, reflecting 
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distinct stages of thrombus formation. Systems biology analytics allowed us to find distinct pat-
terns between these surfaces (i.e., platelet receptors) and output parameters.
 Unsupervised hierarchical cluster analysis revealed three types of thrombus formation: type 
I thrombi formed on surfaces of single-protein coatings, resulting in limited adhesion of few plate-
lets; type II thrombi being formed mostly on surfaces co-coated with VWF, giving deposition of 
multiple single platelets or small aggregates with limited platelet activation; type III thrombi on 
only particular, combined surfaces, which led to the formation of large aggregates with highly 
activated platelets. Principal component analysis indicated a predicted decreasing contribution of 
adhesive receptors to the formation of type III thrombi at high shear rate in the order of GPVI, 
CLEC-2 > GPIb > α6β1, αIIbβ3 > α2β1. Further, the contribution of CD36, αvβ3 and α5β1 to type III 
thrombus formation at high shear rate was only small.
 Multiple regression analysis indicated that, with blood from healthy controls, all eight pa-
rameters contribute significantly to the clustering into type I-III thrombus formation. However, six 
of these parameters appeared to be sufficient for the proper quantification of this process. A set 
of nine surfaces (VWF co-coated) was then selected - involving all major adhesive receptors - to 
determine reference values for the six parameters of thrombus formation. Whole-blood samples 
from a number of patients with rare genetically linked platelet function defects were analyzed 
for thrombus formation and compared with the control data. Presentation as heatmaps revealed 
distinct abnormalities per surface and parameter for each of the patients. With all blood samples, 
altered thrombi were formed on surfaces binding GPIb in combination with CLEC, GPVI and/or 
α2β1. In particular, parameters of platelet secretion on surfaces were reduced with blood from 
patients with a partial lack in α-granules or dense granules. On the other hand, parameters linked 
to platelet aggregation were reduced with blood from a patient with deficiency in integrin αIIbβ3 
and a patient with a myosin cytoskeletal defect. In contrast, the heatmap of a patient with severe 
combined immunodeficiency syndrome showed an increase in parameters of platelet activation, 
suggesting a compensatory mechanism for absence of one of the calcium entry pathways underly-
ing this disease. Taken together, these findings indicate that the ‘fingerprints’, obtained by multipa-
rameter and multispot analysis of thrombus formation, can be valuable to predict a prothrombotic 
or bleeding tendency in clinical settings.
 Chapter 4 also describes that, for blood from healthy controls, co-coating with VWF resulted 
in an increased thrombus-forming potential at high shear rate, but not at low shear rate. This was 
true for the majority of parameters and types of surfaces tested. In line with this, principle compo-
nent analysis indicated that the contribution of GPIb to type III thrombus formation was markedly 
increased at high shear rate versus low shear rate. Interestingly, some surfaces - not containing 
VWF- became more active at low shear rate. Overall, we could conclude that the VWF-GPIb in-
teraction is by far the most potent axis stimulating platelet adhesion and thrombus formation at 
arterial shear conditions.
 In the Weibel-Palade bodies from endothelial cells and in the platelet α-granules, VWF is 
stored as ultralarge multimers. Once released from these cells, it can be cleaved by the protease 
ADAMTS-13 into smaller, less active multimers. This cleavage occurs in an asymmetric way, re-
sul- ting in multimers with slower, intermediate or faster migrating triplet bands that correspond 
to differences in molecular weights. Only the slower migrating triplet bands (larger molecules) 
contain an extra N-terminal peptide chain, which includes a GPIb binding site. In chapter 5, we 
functionally characterized two VWF preparations which were similar in VWF multimeric distribution 
pattern, but markedly differed in triplet band composition. Binding experiments indicated that the 
preparation with additional N-terminal peptide chain had the highest binding affinity for recombi-
nant GPIb in comparison to other preparations. In agreement with this, flow experiments showed 
that this preparation increased thrombus formation on collagen in vitro, using reconstituted blood 
or blood from patients with von Willebrand disease. We concluded that VWF forms lacking larger 
size triplet bands have a decreased potential to recruit platelets under arterial flow conditions.
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 The abundant glycoprotein CD36 is a receptor for one of the most highly expressed proteins 
stored in the platelet α-granules, namely thrombospondin-1 (TSP1). Yet, the precise role of CD36 
in thrombus formation at high or low shear rate is still under debate. Chapter 6 describes experi-
ments to elucidate this, using blood from mice deficient in either CD36 or TSP1. It is shown that the 
releasate from wildtype platelets, but not from TSP1-deficient platelets, augmented the adhesion 
and phosphatidylserine exposure only in (wildtype) platelets expressing CD36. Moreover, the wild-
type releasate enhanced collagen-induced integrin activation and phosphatidylserine exposure, 
and thereby thrombus formation, under flow conditions in vitro. In agreement with this, less stable 
thrombi with increased embolization were observed in vivo in mice lacking CD36. Altogether, these 
results pointed to an anchoring role of platelet-released TSP1 via CD36 in platelet adhesion and 
collagen-dependent thrombus stabilization. Thus, the TSP1-CD36 tandem appears to be another 
platelet ligand-receptor axis contributing to the maintenance of a stable thrombus.
 Chapter 7 provides an overview on the roles of platelets in control of the coagulation pro-
cess. Comparison of studies using knockout mice and studies using pharmacological inhibitors (hu-
man) showed that collagen-induced phosphatidylserine exposure is regulated by a variety of plate-
let signalling proteins and membrane receptors, for the major part directly or indirectly involved in 
Ca2+ signal generation. Furthermore, also several granular proteins or proteins regulating α- and 
dense granule secretion appear to play a role in phosphatidylserine exposure. Membrane expo-
sure of phosphatidylserine generates an efficient surface for thrombin generation and subsequent 
fibrin formation, which enables fibrin clot retraction of a thrombus. The data analysis revealed a 
marked similarity in platelet proteins implicated activation processes seemingly different from clot 
retraction, such as integrin inside-out and outside-in signalling, establishment of homo-typical 
platelet-platelet interactions, and actin cytoskeleton organization. Overall, this review indicated 
that, for collagen-adhered platelets, in part common signalling proteins and pathways contribute 
to the three hallmarks of platelet-based coagulation, i.e. phosphatidylserine exposure, generation 
of thrombin and fibrin, and retraction of the fibrin clot.
 An expanded overview on mouse studies is given in chapter 8, presenting a meta-analysis 
on the published effects of gene modification on murine arterial thrombus formation in vivo and 
in vitro, such in comparison to effects on tail bleeding. We examined a total of 1080 published 
studies, resulting in a database of 315 mouse genes that have been examined for a role in arterial 
thrombosis and/or hemostasis. Using a calibrated three- and five-point scale to score the effects of 
gene modification, we found that, in general, the type of vascular injury but not the vascular bed 
was a variant parameter influencing the outcome of in vivo studies. Furthermore, we established a 
strong correlation between the outcome of collagen-dependent in vivo models of arterial thrombus 
formation and whole-blood in vitro measurements of thrombus formation in flow chambers. The 
scoring system also identified a total of 44 mouse genes, where a positive contribution to throm-
bus formation was not accompanied by altered tail bleeding. Using systems biology tools, we were 
able to construct a network for orthologous human genes which revealed multiple novel targets 
for antithrombotic therapy. This meta-analysis, quantitatively comparing divergent in vivo and in 
vitro mouse studies, underlines the high degree of homology of murine and human processes in 
thrombus formation. It may also provide a contribution to 3R (replacement, reduction, refinement) 
approaches to reduce animal use for in vivo experimentation.
 Chapter 9 discusses the main findings of this thesis as well as the potential clinical relevance 
of these data. It is argued that the mouse studies and the systems biology tools employed have 
led to more insight into the complex mechanisms of the dynamic process of thrombus formation.
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Bloedplaatjes spelen een cruciale rol bij de trombose en hemostase. Als de kleinste cellen in het 
bloed, helpen bloedplaatjes bij de stelping van bloedingen als gevolg van beschadiging van een 
bloedvat. In geval van ziekte zorgen bloedplaatjes voor trombusvorming, bijvoorbeeld door ruptuur 
van een atherosclerotische plaque, met als gevolg afsluiting van het bloedvat en een hartinfarct 
of beroerte. Trombusvorming is een dynamisch proces dat bepaald wordt door adhesie, activatie, 
secretie, aggregatie en contractie van bloedplaatjes. Daarnaast spelen ook componenten van het 
bloedplasma (zoals stollingsfactoren) en componenten van de bloedvatwand een modulerende rol 
bij de vorming van een trombus. In deze thesis is gebruik gemaakt van nieuwe analysetechnie- 
ken, ontwikkeld vanuit de systeembiologie, om het veelzijdige proces van trombusvorming beter te 
kunnen begrijpen. Hoofdstuk 1 geeft relevante achtergrondinformatie over het proces van bloed-
plaatjesactivatie en trombusvorming. Het klassieke model van trombusvorming gaat uit van bloed-
plaatjesinteractie met collageen. Uit de literatuur van de laatste jaren is echter gebleken, dat ook 
andere adhesieve substraten in de vaatwand een rol kunnen spelen in de trombusvorming. Echter, 
hier is nog maar weinig over bekend. Verder is het onduidelijk in hoeverre eiwitten, die vrijgemaakt 
worden uit de opslaggranulae van bloedplaatjes, zoals von Willebrand factor (VWF) en trombos-
pondine-1, kunnen bijdragen aan het proces van trombusvorming. Het eerste hoofdstuk beschrijft 
verder het gebruik van de flowkamer voor het meten van trombusvorming in geïsoleerd bloed. 
Tenslotte worden enige principes van systeembiologische analysetechnieken geïntroduceerd.
 In-huis ontwikkelde en commercieel verkrijgbare parallel-plaat flowkamers worden meer en 
meer gebruikt voor het bestuderen van het proces van trombusvorming en bloedplaatjesactivatie 
in bloed onder gedefinieerde stromingscondities. Hoofdstuk 2 beschrijft de vooruitgang die ge-
maakt is in de ontwikkeling van flowkamers, met name van de zogenaamde microfluidic devices 
gemaakt van polydimethylsiloxaan, waarmee met kleine bloedsamples gewerkt kan worden. Deze 
techniek maakt het mogelijk om sneller en efficiënter te testen. Echter de veelvormigheid van 
microfluidic devices - ongeveer elk laboratorium heeft zijn eigen flowkamer - maakt het lastig om 
de techniek te standaardiseren, waarmee deze volbloedtest nog maar zelden preklinisch ingezet 
wordt. Aspecten waar standaardisatie gewenst is, zijn onder meer de stromingscondities van het 
bloed, het adhesieve oppervlak voor bloedplaatjes en de manier van analyse van de vele testuit-
komsten, waaronder microscopische beeldjes.
 Voor het gebruik van de conventionele Maastricht flowkamer, waarmee het grootste deel 
van het onderzoek beschreven in deze thesis is uitgevoerd, zijn in hoofdstuk 3 een aantal ge-
standaardiseerde protocollen beschreven. Dit betreft de uitvoering van een multiparameter vol- 
bloedtest voor het bepalen van de trombusvorming op verschillende soorten oppervlakken. Protocols 
zijn opgesteld voor het coaten van plaatjesadhesieve oppervlakken, de manier van bloedafname, 
de experimentele opzet, en de wijze van beeldanalyse. Bijgevoegd is ook een actielijst met wat te 
doen bij technische problemen. Verder beschreven zijn het gebruik van verschillende (confocale) 
fluorescentiemicroscopen, evenals methoden voor het opnemen van witlicht- en fluorescentie-
beeldjes. Uitkomstmaten van deze microscopiebeelden zijn de mate van stabiele adhesie van 
bloedplaatjes en eindpuntparameters, zoals de morfologische score, de grootte van een trombus 
en de depositie van bloedplaatjes. Andere uitkomstmaten geven informatie over de mate van 
bloedplaatjesactivatie, te weten granulaire secretie, fibrinogeenbinding en procoagulante activiteit. 
Tenslotte zijn enige details vermeld van software-toepassingen en protocollen voor beeldverwer- 
king.
 In het klassieke model van trombusvorming op collageen zijn slechts een beperkt aantal 
bloedplaatjesreceptoren actief. Bij arteriële stromingscondities (hoge afschuifsnelheden) vindt 
initiële bloedplaatjesadhesie plaats via glycoproteïne Ib-V-IX (GPIb) met VWF, dat gebonden is 
aan collageen. De bloedplaatjes worden vervolgens geactiveerd door samenspel van de twee col-
lageenreceptoren glycoproteïne VI (GPVI) en integrine α2β1. Aggregatie van bloedplaatjes vanuit 
het bloed vindt plaats via de fibrinogeenreceptor integrine αIIbβ3. Bloedplaatjes hebben echter ook 
verschillende andere receptoren die een rol kunnen spelen bij de trombusvorming. Hoofdstuk 
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4 beschrijft de ontwikkeling van een multiparameter volbloedtest, waarbij de trombusvorming 
gemeten wordt op meerdere adhesieve oppervlakken, die tesamen alle belangrijke bloedplaatjes-
receptoren omvatten. Deze test is uitgevoerd met bloedmonsters van gezonde vrijwilligers en van 
een aantal patiënten met een zeldzame bloedingsziekte. In totaal zijn 52 adhesieve oppervlakken 
(met bekende receptorinteracties) met elkaar vergeleken, en daarnaast acht uitkomstparameters, 
representatief voor verschillende fasen van trombusvorming. Vervolgens hebben we bekende sys-
teembiologische technieken gehanteerd om patronen te ontdekken in de trombusvorming voor de 
verschillende uitkomst-parameters en de soorten van oppervlak.
 Clusteranalyse leidde tot een driedeling van de oppervlakken, elk resulterend in een bepaald 
type van trombus. Oppervlakken waarop type I trombi gevormd werden, lieten alleen adhesie zien 
van losse bloedplaatjes. Type II trombi werden gevormd op oppervlakken, die meestal bestonden 
uit VWF in combinatie met een ander eiwit; dit resulteerde in de depositie van vele losse bloed-
plaatjes of van kleine aggregaten met beperkte plaatjesactivatie. Type III trombi werden gevormd 
op oppervlakken met bepaalde combinaties van eiwitten; deze gaven grote aggregaten bestaande 
uit sterk geactiveerde bloedplaatjes. Componentanalyse stelde ons in staat om een schatting te 
maken van de relatieve bijdrage van de afzonderlijke bloedplaatjesreceptoren aan de vorming van 
een type III trombus. In afnemende volgorde was deze: GPVI, CLEC-2 > GPIb > α6β1, αIIbβ3 > α2β1. 
Bij arteriële stromingscondities (hoge afschuifsnelheden) was de bijdrage van de receptoren CD36, 
αvβ3 en α5β1 verwaarloosbaar klein.
 Regressie-analyse leerde dat alle acht parameters bijdroegen aan de groepering in type 
I-III trombi, althans bij gezonde proefpersonen. Zes van deze parameters bleken voldoende voor 
een volledige kwantificering van dit proces. Op basis van deze analyse zijn negen van de meest 
relevante oppervlakken (met gecoat VWF) geselecteerd voor de bepaling van referentiewaarden 
betreffende zes parameters. Bloedsamples van verschillende patiënten met zeldzame plaatjes-
gebonden bloedingsaandoeningen werden geanalyseerd op trombusvorming en vergeleken met 
de controle-data. Zogenoemde heatmaps werden gemaakt voor elk van de patiënten, om inzicht 
te krijgen in het patroon van afwijkingen per oppervlak en parameter. Bij alle patiëntenmonsters 
waren er veranderingen in trombusvorming op oppervlakken voor GPIb-adhesie (VWF) in combi-
natie met CLEC, GPVI en/of α2β1. Met name parameters van secretie waren verlaagd in bloed van 
patiënten met partieel granulaire defecten. Anderszins waren parameters van bloedplaatjesag-
gregatie verlaagd in bloed van een patiënt met integrin αIIbβ3 deficiëntie en een patiënt met een 
myosine-celskelet defect. De heatmap van een patiënt met gecombineerd immuundeficiëntie-syn-
droom toonde daarentegen een toename in sommige activatie-parameters. Samengevat laten deze 
bevindingen zien dat de fingerprints, verkregen door multiparameter en multi-oppervlakmetingen 
van trombusvorming, waardevol kunnen zijn bij het klinisch voorspellen van een trombotische of 
bloedingsneiging.
 In hoofdstuk 4 is tevens beschreven dat combinaties van oppervlakken met daarin VWF 
een sterkere trombusvorming laten zien bij hoge afschuifsnelheden dan bij lage afschuifsnelheden. 
Dit is in overeenstemming met berekeningen dat GPIb een grote bijdrage levert tot de vorming van 
type III trombi, doch alleen bij hoge afschuifsnelheden. Daarmee hebben we kunnen aantonen de 
VWF-GPIb interactie de meest belangrijke is voor bloedplaatjesadhesie en trombusvorming onder 
arteriële stromingscondities.
 Het eiwit VWF komt voor als zeer grote multimeren in de Weibel-Palade lichaampjes van 
endotheelcellen en in de α-granulae van bloedplaatjes. Na vrijzetting in de bloedstroom knipt het 
matrixmetalloprotease ADAMTS-13 deze grote multimeren in kleinere en daarmee minder actieve 
multimeren. Deze proteolyse gebeurt op asymmetrische wijze, wat resulteert in zogenaamde triplet-
vormen van VWF multimeren met kleine verschillen in molecuulgewicht. De grotere tripletvormen 
hebben een langere N-terminale zijde met daarin een extra GPIb-bindingsplaats. In hoofdstuk 
5 zijn twee VWF-preparaten, die verschilden in samenstelling van tripletten, functioneel gekarak-
teriseerd. Uitvoerige analyse toonde aan dat het VWF-preparaat met extra N-terminus een hogere 
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bindingsaffiniteit voor GPIb had dan het andere preparaat. Verhoogde plaatjesadhesieve werking 
van het eerste preparaat werd bevestigd middels flowkamerexperimenten over collageen onder 
arteriële stromingscondities, evenals met bloed van patiënten met de ziekte van von Willebrand. 
Met deze resultaten tonen we aan dat een veranderde tripletsamenstelling, zoals soms aanwezig 
in deze patiënten, kan resulteren in veranderde bloedplaatjesadhesie onder stromingscondities.
 Het glycoproteïne CD36 wordt gezien als dé receptor van een eiwit dat sterk tot expressie 
komt in de α-granulae van bloedplaatjes, namelijk trombospondine-1 (TSP1). De precieze rol van 
CD36 en TSP1 bij de trombusvorming onder stromingscondities is echter onduidelijk. Hoofdstuk 
6 beschrijft experimenten om hierin opheldering te brengen, gebruikmakend van bloed van muizen 
met een deficiëntie in ofwel CD36 ofwel TSP1. Aangetoond is dat het secretieproduct van normale 
bloedplaatjes, maar niet van bloedplaatjes zonder TSP1, de adhesie en fosfatidylserine-expressie 
verhoogt van bloedplaatjes mits deze ook CD36 bevatten. Bovendien verhoogde het secretie-
product van normale bloedplaatjes de collageengestimuleerde integrine-activatie en fosfatidylse- 
rine-expositie tijdens de trombusvorming onder stromingscondities. In overeenstemming hiermee 
bleken er in vivo minder stabiele trombi gevormd te worden met meer embolisatie in muizen met 
een CD36-deficiëntie. Tesamen duiden deze resultaten op een verankerende rol van plaatjes-gese-
creteerd TSP1 via CD36 bij de adhesie van bloedplaatjes en de collageenafhankelijke trombussta-
bilisatie. Daarmee wordt de TSP1-CD36 interactie gezien als een volgende bloedplaatjes ligand-re-
ceptor as, die kan bijdragen tot de stabiliteit van een trombus.
 Hoofdstuk 7 beoogt meer inzicht te geven in de rol van bloedplaatjes bij de bloedstolling. 
Op basis van analyse van gepubliceerde studies, uitgevoerd met genetisch gemodificeerde muizen 
en met farmacologische remmers, laten we zien dat de fosfatidylserine-expositie van bloedplaatjes 
gestimuleerd met collageen gereguleerd wordt door een veelvoud aan signaleringseiwitten en 
membraanreceptoren, merendeels direct of indirect betrokken bij de calciumsignaalgeneratie. Verd-
er blijken ook regulerende eiwitten van de secretie van α- and δ-granulae alsmede diverse granu-
laire eiwitten van belang te zijn voor de fosfatidylserine-expositie. Het fosfatidylserine-exposerend 
membraan biedt een functioneel oppervlak voor trombine- en fibrinevorming, en daarmee voor de 
fibrine-afhankelijke retractie van een trombus. Onze data-analyse toont verder een opmerkelijke 
overeenkomst tussen de plaatjeseiwitten betrokken bij ogenschijnlijk zo uiteenlopende processen 
als stolselretractie, integrine-signalering, vorming van homotypische plaatjes-plaatjes interacties 
en actine-celskelet organisatie. Samengevat laat deze review zien dat, bij de collageen-adhesie van 
bloedplaatjes, ten dele gemeenschappelijke signaleringseiwitten en gezamenlijke activeringpaden 
zorgen voor de drie kenmerken van de bloedplaatjesafhankelijke stolling, te weten fosfatidylse- 
rine-expositie, vorming van trombine en fibrine, en retractie van het stolsel.
 Een uitgebreid overzicht over muizenstudies is opgenomen in hoofdstuk 8. Uitgewerkt 
hierin is een meta-analyse van gepubliceerde effecten van genetische modificatie op arteriële 
trombusvorming in vivo en in vitro, dit in vergelijking met effecten op de staartbloeding. In deze 
meta-analyse zijn 1080 studies opgenomen, resulterend in een database van 315 muizengenen, 
die onderzocht zijn op een rol in arteriële trombose en/of hemostase. Gebruikmakend van een 
gecalibreerde driepunts- en vijfpuntsschaal, hebben wij de effecten van genetische modificatie zo 
goed en volledig mogelijk in kaart gebracht. Daarbij blijkt dat de manier van vasculaire beschadi- 
ging een sterker variante parameter is voor het gen-effect op de trombusvorming dan het vaatbed 
van beschadiging. Verder vinden wij een sterke correlatie tussen de uitkomst van in vivo trom-
bosestudies en die van in vitro studies met flowkamers, met name bij de collageen-afhankelijke 
trombosemodellen. De scores laten verder zien dat er in totaal 44 genen zijn, waarbij een posi- 
tieve bijdrage aan de trombusvorming niet gepaard gaat met een veranderde staartbloeding. Door 
gebruik te maken van systeembiologische technieken konden wij een netwerk construeren van 
overeenkomstige humane genen, met daarin diverse nieuwe genen en eiwitten die een doel kun-
nen zijn voor antitrombotische therapie. Deze meta-analyse bevestigt de hoge mate van homologie 
tussen muis en mens van de processen en eiwitten betrokken bij de trombusvorming. Verder kan 
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deze systematische vergelijking van in vivo en in vitro studies bijdragen tot de 3V alternatieven van 
proefdieronderzoek (vervanging, vermindering, verfijning).
 In het afsluitend hoofdstuk 9 zijn de meest belangrijke bevindingen van dit proefschrift 
bediscussieerd in het licht van de huidige literatuur en de mogelijke klinische relevantie. Toegelicht 
wordt hoe zowel de muizenstudies als de toegepaste systeembiologische analysemethoden meer 
inzicht bieden in de complexiteit van de trombusvorming.
Samenvatting
S
am
e
n
va
tt
in
g

Dankwoord
D
an
kw
o
o
r
d
146
Tot slot mijn dank aan iedereen die mij gesteund heeft de afgelopen jaren. Als promovendus is 
niets fijner dan om terug te mogen vallen op een plaatjesgroep die enorm motiverend werkt. En 
niet alleen zij, maar ook alle andere collega’s hebben gezorgd voor een goede sfeer. 
Allereerst bedankt aan mijn co-promotor en promotor. Beste Judith, bedankt voor alles! Bedankt 
dat de deur altijd openstond, voor de tijd die je altijd voor mij had maar ook voor je positief, kritisch 
opbouwende houding die mij menigmaal verder heeft geholpen. Beste prof. Heemskerk, beste Jo-
han, dank dat ik altijd bij je binnen kon lopen. Die drempel is nooit hoog geweest, wat ik echt als 
heel prettig heb ervaren. Dank voor jullie enorme steun en inzet!
Mijn directe collega’s, een speciaal woord van dank voor alle gezellige momenten samen! Al die 
uitstapjes en etentjes hebben, naast het feit dat ik een aantal kilootjes rijker ben geworden, ook 
een bijdrage geleverd aan onze “wall-of-fame”! Maar bovenal wil ik jullie bedanken voor al jullie 
hulp, steun, inzet en niet te vergeten vrolijk- en gezelligheid! Zonder jullie was dit boekje niet tot 
stand gekomen! 
Nadine, dank je voor alle gezelligheid en vriendschap! We hebben samen heel wat afgelachen 
de afgelopen jaren, zo erg zelfs, dat onze kamer op een gegeven moment de “lachkamer” 
werd genoemd! Maar we hebben ook vaak de mindere en serieuzere dingen in het leven met 
elkaar gedeeld. Time to grow up! Super gaaf dat je mijn paranimf wilt zijn en we gaan op 
naar jouw promotie, klinisch chemicus in spe ! Dan mijn andere (ex)roomies: Constance, Jil-
ke, Erik, Roosje, Karen en Magdi, ik heb het erg leuk gevonden om bij jullie op de kamer te 
hebben gezeten. Even voor de duidelijkheid natuurlijk: jullie zitten voorlopig nog even aan mij 
vast! Bedankt voor alle fijne gesprekken en heel veel succes met alles wat nog op jullie (pro-
mo-)pad komt! Constance, speciaal wil ik jou bedanken voor al je hulp, inzet en gezelligheid! Ik 
heb natuurlijk ook geleerd dat onze snoeppot niet veilig is voor jou! ;) Magdi, you just started 
your PhD.. Sok sikert a promóciós! (Just blaim Google Translate in case I speak abracadabra.) 
 
Frauke en Tom, zonder jullie humor en jullie gedrevenheid op het werk was mijn PhD traject niet zo 
verlopen zoals het nu is gegaan. Bedankt voor jullie tomeloze inzet en jullie positiviteit! Heel veel 
succes met de afronding van jullie PhD! En Frauke, die CD moeten we toch echt gaan opnemen! 
Tom, waarschijnlijk is dit het goede moment om mij uit de aio-app te verwijderen! :D Siamack, je 
bent altijd erg gedreven en er is geen twijfel over mogelijk, maar jij komt er wel! Heel veel succes 
met het afronden met je PhD! Dan Marion en Marijke. Jullie horen gewoon bij het meubilair van de 
plaatjesgroep! Ik kan mij de groep niet zonder jullie voorstellen. Bedankt dat ik met wat dan ook 
altijd op jullie terug kon vallen. Paola, ook bij jou als Johans part-timer, kon ik altijd binnenlopen. 
Bedankt voor alle leuke gesprekken en gezelligheid! Remco en Ankie, jullie zijn twee van de laatste 
aanwinsten van de plaatjes groep. Ik ben blij jullie te kennen! Remco, je bent net vader geworden, 
heel veel geluk samen met je jonge gezinnetje! Ankie, jij nog heel veel succes met je promotie!  
Dan mijn oud-collegaatjes Roger en Moniek. Roger, je bent nu een leven aan het opbouwen met 
je eigen gezin daar ergens hoog in het noorden. Bedankt voor al je hulp en humor toen je nog lid 
was van de plaatjesgroep, maar ook daarna. Heel veel geluk verder! Moniek, ik kan me de dagen 
met jou op het lab nog goed herinneren. Al die dagen met eindeloze flowproeven die we samen 
deden zal ik niet vergeten! En vooral die muzikale begeleiding van jou zal mij daarbij ook altijd 
bijblijven! Heel veel succes met je verdere carrière als wiskunde lerares! Ik ben blij dat je je weg 
gevonden hebt! Simone, als groep kregen we jou cadeau voor de entertainment tijdens de lunch! 
Je kenmerkt jezelf met altijd spannende en humoristische verhalen! Bedankt voor de ontspanning 
die je met je meebracht! 
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Ook wil ik alle medewerkers van de vakgroep Biochemie bedanken voor de fijne sfeer en gezel-
ligheid op de afdeling en daarbuiten. De vele dagjes uit, pizzaparty’s en de opening van het aca-
demisch jaar zullen mij altijd bij blijven (heus niet alleen vanwege het indische eten, hoor)! Fijn en 
bijzonder dat we zo met z’n allen op deze manier collega’s konden zijn! 
I would also like to thank all my collaborators abroad. Dear Prof. Watson, dear Steve, thank you 
that you gave me the opportunity to visit your lab for a couple of weeks! I have met a great group 
of colleagues over there! I say thank you to all of Steve’s labmembers! Birte, also thanks for the 
great cooperation with your group in Berlin! I like the friendship that we have and sure I will come 
to Berlin some day!  Dear prof. Zieger, dear Barbara, thank you for the nice collaboration. Your 
input means a lot for the research that we do to develop the flow chamber technique even further! 
There are also some (PhD) students that visited our lab during the last five years. Dear Lina, dear 
Sam great to have met you! I wish you all the best in the future! Ook wil ik Anna bedanken. Jouw 
stage heeft de hele systems biology in onze onderzoeksgroep zeker een boost gegeven! 
Ook nog een speciaal woord van dank aan alle co-auteurs die ik nog niet eerder in dit dankwoord 
genoemd hebt. Thank you for all your contributions to the different chapters of this thesis. Without 
all your help I wouldn’t have been able to get that far.
Mijn onderzoek was echt nergens geweest zonder al die vrijwilligers die de afgelopen jaren bloed 
hebben gedoneerd voor mijn onderzoek. Hartstikke bedankt aan iedereen! 
Ook wil ik iedereen in mijn vriendenkring bedanken voor alle interesse en bovenal steun op veler-
lei wijzen! Voor alle momenten van ontspanning en ontlading! Ik ga geen namen noemen, want 
ik ben bang dat ik mensen ga vergeten. Daarom zeg ik tegen jullie (je weet dat ik jou bedoel), 
bedankt voor alle sushi, voor al het Griekse eten, voor al die bezoekjes aan de Mac, voor alle wan-
delingen, uitstapjes, voor al die oneindige romantische films en actiefilms die we keken, voor al die 
openhartige en intense gesprekken waar we samen konden lachen en huilen (zelfs aan de telefoon 
;)), voor die gezellige meidenweekenden, voor dat dansje in de gang bij de keuken, voor al die 
vrijdagen friet of die vrijdagen dat we zelf wat in elkaar flansten, voor al dat lekkere Indonesische 
eten en dat ene joekelige ijsje in Epen, voor dat gezellige weekendje in Engeland en al die tijd dat 
je achter je Macbook voor mij zat… Sjonge! Zonder jullie allemaal was het niet zo gelopen als het 
gelopen is!  Dank jullie wel! 
Last but certainly not least. Mijn gekke familie…  Mama, papa, Marloes, Marjolein en Jeroen in 
het kwadraat, Sophietje, Lien en Jortje. Zonder jullie grenzeloze steun en vertrouwen was ik nu 
niet zo ver gekomen! Ik kan nu wel veel en mooie woorden zoeken om jullie proberen te bedanken, 
maar zelfs die zullen tekort aan alles doen, dus laat ik het zo. Hoewel, dat etentje houden jullie 
tegoed hoor! 
Kortom: thanks to you all! 
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en Dr. J.M.E.M. Cosemans plaats gevonden. Tijdens deze ruim vierjarige periode presenteerde 
ze haar onderzoek op internationale congressen in Cardiff, Liverpool, Birmingham (Engeland), 
Utrecht, Amsterdam en Koudekerken (Nederland). In 2012 werd ze hiervoor onderscheiden met 
een Young Investigators Award. Een gedeelte van haar onderzoek verrichtte zij op het laboratori-
um van Prof. Dr. S.P. Watson (Birmingham, Engeland) waarvoor ze tevens een subsidie verkreeg 
van het Coen Hemker Fonds. In augustus 2014 startte ze als postdoctorale onderzoeker met de 
Kootstra Fellowship, dat in het bijzonder bedoeld is voor getalenteerde PhD studenten. 
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Supplemental Figure 1. Similar platelet adhesion to microspots of fibrinogen or fibronectin located up-
stream or downstream of collagen. Whole-blood was perfused for 3.5 min at 1600 s-1 over microspots containing 
fibrinogen, fibronectin or collagen I. Coating of microspots was at upstream or downstream locations, as indicated. 
Platelet deposition was analyzed as surface-area-coverage. Data are mean ±	S.D (n = 8; Mann-Whitney U test).
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Supplemental Figure 2. Wall chart of representative microscopic images of platelet adhesion and throm-
bus formation on 52 microspot surfaces.
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Supplemental Figure 2. Wall chart of representative microscopic images of platelet adhesion and throm-
bus formation on 52 microspot surfaces.
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Supplemental Figure 2. Wall chart of representative microscopic images of platelet adhesion and throm-
bus formation on 52 microspot surfaces. Whole-blood perfusion for 3.5 min at wall shear rate of 1600 s-1. Numbe- 
ring of surfaces is as for Figure 1. First rows: phase-contrast images (115 ×	115 µm) for analysis of morphological score, 
integrated feature size and platelet deposition (surface area coverage). Second and third rows: confocal fluorescence 
images (200 × 200 µm) captured after staining with FITC-labeled anti-fibrinogen mAb (fibrinogen binding) or FITC-la-
beled anti-CD62P mAb (P-selectin expression). Fourth rows: single plane confocal images (106 × 106 µm) of DiOC6-la-
beled platelets, used for determination of thrombus volume. Fifth rows: confocal fluorescence images (200 × 200 µm) 
after staining with AF647-annexin A5 (procoagulant activity). 
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Supplemental Figure 3. Robustness of clustering of surfaces to determine thrombus type. (A) Unsupervised 
hierarchical clustering of data from 52 surfaces and 8 measurement parameters, as for Figure 3. (B) Similar clustering 
pattern after removal of two parameters (stable platelet adhesion and thrombus volume), using complete linkage ana- 
lysis by Pvclust. Note the similar division into type I-III thrombi. Red boxes indicate corresponding grouping of surfaces 
for either cluster analysis.
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Supplemental Figure 4. Effect of increasing wall shear rate on surface area coverage by platelets. Whole 
blood was perfused over 19 microspot surfaces at wall shear rates of 150 s-1, 1000 s-1 or 1600 s-1. Phase-contrast images 
were analyzed for surface area coverage with platelets. Ranking from low to high according to change between 150 s-1 
and 1600 s-1.
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Supplemental Table 1. Eexpression levels of platelet-adhesive receptors and protein/peptide ligands 
binding to these receptors. Only ligands used in this study are indicated. Synthetic peptide ligands are shown in italic.
Receptor Protein/peptide ligand Copies per platelet Ref(s)
αIIbβ3 fibrinogen, fibronectin, vitronectin 80,000-100,000
 1, 2, 3, 4
GPIb-V-IX VWF, VWF-BP* 30,000-40,000  5, 6
CD36 thrombospondin-1 10,000-25,000 7
α2β1 collagen I*, III*, decorin, GFOGER 2,000-4,000
 8, 9, 10, 11, 12
GPVI collagen I, III, (GPO)n 1,000-2,000
 10, 11, 12
CLEC-2 podoplanin, rhodocytin 1,500  13, 14, 15
α5β1 fibronectin 1,000
 3
α6β1 laminin* 1,000
 16, 17
αvβ3 vitronectin, osteopontin 500
 18, 19
*Binds VWF from plasma 5, 20, 21
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Supplementary Table 2. Prediction of type of thrombus formation on microspot surfaces at low shear 
flow conditions. Given are per surface the calculated mean parameter values for high shear rate (1600 s-1) and low 
shear rate (150 s-1). Also shown are the predictive values of mean parameters and thrombus type, obtained through 
model building using partial least-squares regression analysis of the high-shear data, and fitting into the model the 
low-shear data (UV scaled). Calculated and predicted thrombus types I, II and III are indicated in gray. 
No. Surface Mean parameter values (thrombus type)  
  calculated 
1600 s-1 
calculated 
150 s-1 
predicted 
150 s-1 
type difference 
vs. 1600 s-1 
1 (GPO)n 0.46 (I) 0.44 1.09 (I)  
2 GFOGER-(GPP)n + rhodocytin 0.02 (I) 3.29 2.31 (II) +1 
3 BSA 0.10 (I) 0.00 0.84 (I)  
4 Rhodocytin 0.04 (I) 2.40 1.92 (II) +1 
5 Vitronectin 0.10 (I) 1.01 1.41 (I)  
6 Decorin 0.01 (I) 0.00 0.84 (I)  
7 GFOGER-(GPP)n 0.05 (I) 1.78 1.80 (II) +1 
8 Osteopontin 0.57 (I) 0.00 0.84 (I)  
9 Thrombospondin-1 1.50 (I) 1.93 1.97 (II) +1 
12 Fibronectin 1.06 (I) 1.23 1.55 (II) +1 
14 Fibrinogen  1.07 (I) 2.52 2.05 (II) +1 
15 vWF + GFOGER-(GPP)n* 3.53 (II) 1.66 1.62 (II)  
16 vWF + thrombospondin-1 3.33 (II) 2.26 2.05 (II)  
17 vWF + vitronectin* 2.71 (II) 2.08 1.91 (II)  
18 vWF + fibronectin* 3.43 (II) 1.71 1.73 (II)  
20 Laminin 2.21 (II) 2.58 2.31 (II)  
21 vWF + laminin* 2.37 (II) 1.86 1.81 (II)  
24 Collagen III (vWF) 4.96 (II) 2.59 2.13 (II)  
26 GFOGER-(GPO)n 4.04 (II) 4.53 2.92 (III) +1 
27 vWF + decorin 2.85 (II) 2.81 1.20 (I) -1 
28 vWF* 2.22 (II) 1.30 1.56 (II)  
31 (GPO)n + GFOGER-(GPP)n 4.64 (II) 3.69 2.74 (III) +1 
33 vWF + osteopontin 4.13 (II) 0.70 1.17 (I) -1 
34 vWF + fibrinogen*# 6.02 (III) 2.81 2.24 (II) -1 
35 vWF + rhodocytin* 6.77 (III) 3.06 2.31 (II) -1 
37 (GPO)n + laminin 5.53 (III) 3.99 2.94 (III)  
38 vWF + (GPO)n + laminin 6.76 (III) 3.87 2.83 (III)  
39 vWF + (GPO)n 6.56 (III) 4.06 2.95 (III)  
40 vWF-BP + (GPO)n + 
GFOGER(GPP)n 
5.97 (III) 3.98 3.22 (III)  
42 vWF + (GPO)n + GFOGER-
(GPP)n 
6.26 (III) 4.70 3.22 (III)  
43 vWF + GFOGER-(GPO)n* 8.66 (III) 4.60 2.96 (III)  
44 GFOGER-(GPO)n + laminin 8.30 (III) 3.99 2.69 (III)  
45 vWF + GFOGER-(GPP)n + 
rhodocytin 
8.08 (III) 3.95 2.88 (III)  
47 GFOGER-(GPO)n + fibrinogen 7.94 (III) 3.12 2.45 (II) -1 
48 Laminin + rhodocytin 7.19 (III) 4.22 3.00 (III)  
51 Collagen I (vWF)* 7.95 (III) 4.92 3.25 (III)  
52 vWF + laminin + rhodocytin 8.49 (III) 3.68 2.59 (III)  
*Selected for patient blood analysis; #type II thrombus in unsupervised cluster analysis (Fig. 4). 
Supplemental Table 2. Prediction of type of thrombus formation on microspot surfaces at low shear flow 
conditions. Given re per surface the calculated mean parameter values for high shear ra e (1600 s-1) and low shear 
rate (150 s-1). Al o shown are the predictiv v ues of mean parameters and thr mbus type, ob ained through model 
building using partial least-squares regr ssion analysis of the high-shear data, and fitting into the model th  low-shear 
data (UV scaled). Calcul ted and predicted thrombus types I, II and III are indicated in gray.
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Supplementary Table 4. Effect of thrombin generation on parameters of thrombus formation. Thrombus 
formation was assayed by 3.5 minutes flow of blood samples at 1600 s-1 over indicated microspot surfaces also 
containing tissue factor (0.25 fmol). Perfusion was with PPACK/fragmin anticoagulated blood (- thrombin) or with 
recalcified citrate-anticoagulated blood, containing 5 µg ml-1 corn trypsin inhibitor and 5 mg ml-1 GPRP (+ thrombin). 
Data are mean ± S.D (n = 4; Mann-Whitney U test). * contraction and increased fluorescent intensity.  
     
Coated protein Parameter - Thrombin + Thrombin P-value 
vWF/fibronectin morphological score 3.0 ± 0.0 5.0 ± 0.0 0.008 
 integrated feature size 1.9 ± 0.4 4.3 ± 0.3 0.002 
 fibrinogen binding 5.9 ± 2.7 11.7 ± 1.1 0.021 
 P-selectin expression 14.6 ± 9.2 28.6 ± 2.7 0.027 
 platelet deposition 33.9 ± 10.8 64.4 ± 3.5 0.008 
 procoagulant activity 1.0 ± 1.3 4.4 ± 3.0 0.049 
     
Collagen I morphological score 5.0 ± 0.0 5.0 ± 0.0 1.000 
 integrated feature size 3.5 ± 0.3 3.5 ± 0.6 0.519 
 fibrinogen binding 27.1 ± 10.6 7.7 ± 1.4* 0.021 
 P-selectin expression 48.2 ± 7.5 21.4 ± 2.2* 0.008 
 platelet deposition 58.7 ± 10.3 40.8 ± 5.7* 0.042 
 procoagulant activity 4.5 ± 1.7 7.6 ± 3.8 0.705 
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Supplementary Table 5. Origin of proteins and peptides used for coating of microspots. 
Coated protein 
Coating concentration  
(µg/mL) 
Purified from Company (Ref.) 
Collagen I (Horm) 100 equine tendon Nycomed (10345787) 
Collagen III 100 human placenta Sigma Aldrich (C4407) 
Decorin 250 human plasma Sigma Aldrich ( D8428) 
Fibrinogen 250 human plasma Sigma Aldrich (F3879) 
Fibronectin 250 human plasma Sigma Aldrich (F2006) 
GFOGER-(GPO)n 250 chemical synthesis Ref. 12 
GFOGER-(GPP)n 250 chemical synthesis Ref. 12 
(GPO)n (cross-linked) 250 chemical synthesis Ref. 12 
Laminin (511/521) 100 human placenta Sigma Aldrich (L6274) 
Rhodocytin 250 venom Malayan pit viper Ref. 15 
Thrombospondin-1 100 human platelets Calbiochem (605225) 
Osteopontin 50 recombinant (human) R&D Systems (1433-OP-050) 
Vitronectin 50 human plasma Sigma Aldrich (V8379) 
vWF 50 human plasma Ref. 6 
vWF-BP 100 chemical synthesis Ref. 5 
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Supplemental Figure 1. Multimeric pattern and triplet structure analyses of original VWF concentrate 
sample (Wilate) and recombined fractions F1F2F3 after heparin affinity chromatography. (A) Multimeric 
pattern of original sample and recombined fractions F1F2F3, separated on 1.2% agarose gel. (B) Composition of mul-
timers, as obtained by densitometric analysis of Western blots. (C) Proportions of each of the three triplet bands in the 
original sample and F1F2F3. Values of VWF:RCo activity, as fractions of antigen levels, were determined as 0.41±0.04 
(original sample) and 0.35±0.01 (F1F2F3). Means ± SEM (n=3).
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Supplemental Figure 2. Flow chamber experiments performed with reconstituted blood containing CMF-
DA-labelled platelets (2.5×108/mL) and washed red blood cells (40% hematocrit), flowed over a type III collagen sur-
face. The reconstituted blood samples were supplemented with various VWF preparations (2 IU/mL, final), i.e. original 
VWF concentrate sample, the combined fractions F1F2F3, or equal amounts of preparations A plus B. The 6B4 mAb 
(20 µg/mL) against the VWF binding site of GPIb was added, as indicated. Samples without VWF (baseline) served as 
negative control. (A) Analyzed surface area coverage of fluorescence after 8 min perfusion at 1700 s-1 shear rate. (B) 
Representative fluorescence images (scale bars; 50 µm). Means ± SEM (n=2-3).
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Supplemental Figure 1. Roles of murine CD36 in platelet adhesion to TSP1 and in agonist-induced platelet 
activation. (A-B) Adhesion of washed platelets from Cd36+/+ or Cd36-/- mice (1.5×108/mL) to surfaces coated with 
purified TSP1 or with releasate from activated wild type platelets. Platelet adhesion and activation were measured by 
phase-contrast and fluorescence microscopy after 45 minutes. (A) quantification of adhered platelets (platelets/mm2). 
(B) quantification of FITC-annexin A5 positive platelets (% total). (C-E) Washed platelets from Cd36+/+ and Cd36-/- mice 
were stimulated with ADP (0.5-5 µmol/L) or convulxin (20-50 ng/mL) during 10 minutes, and analyzed by flow cytome-
try. (C) Activation of αIIbβ3 detected with PE-labeled JON/A mAb, (D) expression of P-Selectin detected with FITC-anti-
CD62P mAb, and (E) expression of phosphatidylserine detected with FITC-annexin A5. Means ±	SEM (n=4-5). *P<0.05 
vs. Cd36+/+; n.s., not significant.
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Supplemental Figure 2. Detection of immobilized TSP1 in platelet releasate. Collagen-containing coverslips 
were post-incubated with releasate (RL) from thrombin-stimulated Tsp1+/+ or Tsp1-/- platelets, as indicated. Surfaces 
were stained with biotin-conjugated anti-TSP1 antibody and AF532-streptavidin. (A) Representative images of differen-
tial interference contrast(DIC) and confocal AF532-streptavidin fluorescence (AF532); bars, 25 μm. (B) Integrated flu-
orescence intensity from coated surfaces (arbitrary units). Strep indicates control staining with only AF532-streptavidin; 
TSP1 indicates staining with anti-TSP1 antibody and AF532-streptavidin. Means ±	SEM (n=3).
Supplemental Figure 3. Absence of phosphatidylserine-exposing microparticles in coated releasate from 
Tsp1+/+ or Tsp1-/- platelets. Coverslips were coated with 3 μL releasate from Tsp1+/+ or Tsp1-/- platelets, as in Suppl. 
Figure 2. Surfaces then were blocked with 1% BSA, and stained with 0.5 μg/mL FITC-annexin A5 for 5 minutes. After 
rinse with Tyrode’s Hepes buffer, phase contrast and fluorescence images were captured from the coated surface. Image 
size is 107 x 142 μm.
Supplemental movies of in vitro thrombus formation. 
Movies available online : atvb.ahajournals.org/content/34/6/1187/suppl/DC1
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Supplemental Table 1. Spreadsheet of all tabled meta-data from published mouse studies. 
See mouse_genes_thrombosis.xls (online only).
Supplemental Table 2. Correlation analysis of intra-study parameters scored on 3-point or 5-point scale. 
Panels represent numbers of studies, Kendall’s Tau correlation coefficients, and P values. (A) Comparison of mass-de-
pendent sub-parameters in class I studies (bi, platelet adhesion; bii, extent of occlusion; biii, thrombus size, volume or 
number). (B) Comparison of mass-dependent sub-parameters in class III studies (gi, platelet adhesion; gii, surface-ar-
ea-coverage; giii, thrombus size, volume or number). (C) Comparison of time-dependent (a), mass-dependent (b), and 
stability (c) parameters in class I studies. Time-dependent parameters (a/f) indicated time to occlusion or thrombus 
formation; stability parameters (c/h) referred to number of emboli. (D) Comparison of time-dependent (e), mass-depen-
dent (f), and stability (g) parameters for class III studies.
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Supplemental Table 3. Correlation analysis of comparative studies per class scored on 3-point or 5-point 
scale. (A) Comparison of studies in same papers (same mouse strain). (B) Comparison of studies with loss-of-function 
modification of same gene. Panels represent numbers of compared studies or genes, Kendall’s Tau correlation coeffi-
cients, and P values (3- or 5-point scores).
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Supplemental Table 4. Listing of numbers of genes per class with scores for different groups. 
For description of groups, see Table 1.
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Supplemental Table 5. Overview of scored parameters of thrombus formation(classes I-III) and tail 
bleeding (class IV) per mouse gene. Also indicated are numbers of studies evaluated (N) and relevant phenotypic 
effects of modified mice. Abbreviations for tissues affected: A/m, all (mutation); B, blood; E, endothelial cells; H, he-
matopoietic cells; L, liver; M, monocytes; P, platelets + megakaryocytes; R, red blood cells; S, smooth muscle cells. For 
phenotyping: activ., activation; adh., adhesion; aggr., aggregation; CR, clot retraction; GP, glycoprotein; F, factor; MGK, 
megakaryocyte; RBC, red blood cell; secr., secretion; TG, thrombin generation; WBC, white blood cell. Green and red 
cells indicated antithrombotic and prothrombotic effects respectively (3- and 5-point scale), yellow is no effect, grey 
indicates the number of studixss
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Supplemental Figure 1. Numbers of analyzed and scored studies in classes I-III with main experimental 
variables. (A, B) Class I studies with separation according to vascular bed or type of injury. (C) Class II studies with 
separation for type of systemic intervention. (D) Class III studies with separation for thrombogenic surface.
Supplemental Figure 2. Score distribution (5-point) of genes in class I, separated according to injury type (FeCl3, 
laser, photochemical, ligation/compression).
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Supplemental Figure 3. Chromosomal location of mouse genes contributing to arterial thrombus formation and 
thromboembolism (classes I-III, inner ring, 5-point scores) or tail bleeding (class IV, outer ring, 3-point scores).
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Supplemental Figure 4. Over-representation analysis in Reactome for classes and study scores.
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Supplemental Figure 5. Network visualization and analysis of genes in thrombus formation. Protein-protein 
interactions from the Reactome database were used to build a network of interacting proteins in Cytoscape. (A) Network 
with visualized five-point scores (green is negative score, red is positive score). (B, C) Magnification of indicated parts. 
Gray nodes display novel genes (proteins) not in database. Note that the gene FYN has multiple edges to genes with 
known influences on thrombus formation (GP6, PIK3CA, FCGER). It thus may have a high probability of involvement in 
thrombus formation.
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